

# Citicoline: pharmacological and clinical review, 2016 update

Julio J. Secades

**Summary.** This review is based on the previous one published in 2010 –Secades JJ. *Citicoline: pharmacological and clinical review, 2010 update*. Rev Neurol 2011; 52 (Suppl 2): S1-62–, incorporating 183 new references, having all the information available to facilitate the access to the information in one document. This review is focused on the main indications of the drug, as acute stroke and its sequelae, including the cognitive impairment, and traumatic brain injury and its sequelae. There are retrieved the most important experimental and clinical data in both indications.

**Key words.** Alcoholism. Alzheimer disease. Amblyopia. Apoptosis. CDP-choline. Cerebral edema. Cerebral ischemia. Citicoline. Cognitive disorder. Drug addiction. Glaucoma. Head injury. Memory. Neuronal membrane. Neuroplasticity. Neuroprotection. Neurorepair. Neurotransmission. Parkinson disease. Phosphatidylcholine. Phospholipase. Remyelination. Senile dementia. Stroke. Structural phospholipids. Traumatic brain injury.

## Introduction

Phospholipids are essential constituents of cells, specifically cell membranes, and have a very high turnover rate, which involves a continuous synthesis of these compounds to ensure adequate function of cell membranes, and thus cells [1-3].

The chemical structure of a phospholipid shows esterification of a polyalcohol (glycerol or sphingosine) with two long-chain fatty acids and a molecule of phosphoric acid that is in turn esterified with nitrogenated bases (choline, ethanolamine), amino acids (serine), or inositol [3,4]. The main phospholipids in humans are phosphatidylcholine, phosphatidylethanolamine, phosphatidylinositol, and sphingomyelin [4]. Their main function of the phospholipids is to be part of cell membrane structures, and these compounds are indispensable to fulfil membrane functions, particularly maintenance of homeostasis and cell compartmentalization, as well as enzymatic activities associated to membrane systems, and coupling between receptor and intracellular signal [1]. Additional specific functions of the neuronal membrane include nerve impulse conduction and neurotransmission [1,5].

There are various conditions in which a phospholipids loss or decreased synthesis occurs, leading to an impairment in cell functions that may have a pathophysiological impact [1,6]. At Central Nervous System (CNS) levels, structural phospholipids of the neuronal membrane are essential for

adequate brain maturation [7-9], including astroglial cells [10]. Phosphatidylcholine has been proposed as an important molecule for neurite growth and neuronal regeneration [11]. Impaired cell membrane and phospholipid metabolism have been implicated in the pathophysiology of cerebral edema and traumatic brain injury (TBI) [12-21], as well as cerebral hypoxia [22,23] and cerebral ischemia [24-37]. Moreover, it has been shown that there are certain changes in neuronal membranes and metabolism of structural phospholipids associated to brain aging [38-40] and certain neurodegenerative diseases such as cognitive impairment, vascular dementia and senile dementia of the Alzheimer type [33,41-53], contributing in the neuroplasticity mechanisms [54], and in other conditions where changes in neurotransmission [55-58] and excitotoxic aggression [59,60] are also involved. Changes in phospholipid metabolism, particularly phosphatidylcholine, have been implicated as mechanisms triggering the apoptotic cascade in several conditions [57-66]. Because of these pathophysiological conditions, there is an agreement on the need for having drugs that may accelerate and/or increase synthesis of membrane structural phospholipids in such situations, that is, having a protective and a restorative or reparative activity on the nervous system [67-72].

Citicoline is the generic name of the pharmaceutical substance that chemically is cytidine-5'-diphosphocholine (CDP-choline), which is identi-

Medical Department. Ferrer. Barcelona, Spain.

**Corresponding author:**  
Julio J. Secades, M.D., Ph.D.  
Medical Department. Ferrer.  
Avda. Diagonal, 549. E-08029  
Barcelona (Spain).

**E-mail:**  
jsecades@ferrer.com

**Competing interests:**  
The author is employed in the  
Scientific Department of Ferrer.


**Accepted:**  
15.11.16.

**How to cite this article:**  
Secades JJ. Citicoline:  
pharmacological and clinical  
review, 2016 update. Rev Neurol  
2017; XX (Suppl X): XXX-XXX.


© 2017 Revista de Neurología

Versión española disponible  
en [www.neurologia.com](http://www.neurologia.com)

**Figure 1.** Chemical structure of CDP-choline (citicoline).



**Figure 2.** Relationship between citicoline and choline metabolism, cerebral phospholipids and acetylcholine.



cal to the natural intracellular precursor of phospholipid phosphatidylcholine [73]. CDP-choline is a mononucleotide consisting of ribose, cytosine, pyrophosphate, and choline whose chemical structure (Fig. 1) corresponds to 2-oxy-4-aminopyrimidine [74]. CDP-choline is involved as an essential intermediate in the synthesis of structural phospholipids of cell membranes [4,73-87], and formation of this compound from phosphorylcholine is the rate-limiting step of this biosynthetic pathway [77,88-99]. The CDP-choline cycle is integrated into a larger metabolic network and interruption of the CDP-choline cycle can affect the distribution of lipid-related metabolites in several other pathways [100]. As shown in figure 2, CDP-choline is also related to acetylcholine metabolism. Thus, administration of CDP-choline is an exogenous source of choline and cytidine. Choline participates in several relevant neurochemical processes. It is the precursor and metabolite of acetylcholine, plays a role in single-carbon metabolism and is an essential component of different membrane phospholipids [101]. The cytidine fraction, once transformed in uridine, is used for DNA and RNA synthesis as well as for the synthesis of membrane constituents and glycosylation, having also an important effect on purinergic receptors [102].

## Pharmacological actions

### Traumatic lesions and experimental cerebral edema

Horrocks and Dorman [103] have shown that citicoline and CDP-ethanolamine prevent degradation of choline and ethanolamine phospholipids during decapitation ischemia in rats, and induce a partial reversion of free fatty acid release during reperfusion after experimental global ischemia in gerbils. Citicoline and CDP-ethanolamine, when administered together, have a synergistic effect and stimulate resynthesis of choline, ethanolamine, and inositol phospholipids, markedly decreasing free arachidonic acid levels.

In an experimental rat model of acute induced ischemia, LePoncin-Lafitte et al. [104] assessed integrity of the blood-brain barrier (BBB) with labelled iodinated albumin, and brain metabolism using histoenzymological studies. In this experimental model, administration of citicoline was able to reduce vasogenic cerebral edema and to restore BBB integrity. Authors also found that the size of induced infarctions was smaller with citicoline, and

this compound decreased the activity of lactate dehydrogenase, succinyl dehydrogenase, monoamine oxidase, and acid phosphatase, emphasizing its protective role through a direct action at cell membrane level.

Mykita et al. [105] found in neuronal cultures that addition of citicoline after a hypocapnic lesion resulted in culture protection. Hypocapnia increases incorporation of labelled choline into phospholipids, while this process is slowed in the presence of citicoline. These authors concluded that citicoline is able to protect neurons under alkalosis conditions and may promote cell proliferation.

Yasuhara et al. [106,107], in an electrophysiological study in rabbits, showed that citicoline decreased in the threshold for the arousal reaction and the threshold for muscle discharge, and concluded that this is a valuable drug for treatment of brain lesions because of its effects on consciousness and on the motor activity of the pyramidal system and its afferent pathways.

Martí-Viaño et al. [108] compared the effects of pyriglutine, piracetam, centropheoxine, and citicoline in a study on antagonism of barbiturate coma in mice. No differences were seen in animals treated with pyriglutine, piracetam, or centropheoxine as compared to the control group, while with citicoline both coma duration and depth, as well as respiratory depression, were decreased as compared to all other groups. Arousal effects of citicoline were found to be due to increased cerebral blood flow (CBF), improved O<sub>2</sub> cerebral uptake and utilization of energy metabolism, and enhanced mitochondrial breathing.

Ogashiwa et al. [109], in an experimental model of head injury in monkeys, established a significant dose-effect relationship between citicoline dose and coma duration, that started to be significant at doses of 60 mg/kg ( $p < 0.05$ ). Watanabe et al. [110], studying the effects of several activators of brain metabolism, found that citicoline increased glucose incorporation and metabolism and decreased lactate accumulation in the brain, and also induced a slight increase of CBF.

Alberghina and Giuffrida [11], in a study on nerve tissue response to a contusion lesion, showed that a moderate increase occurred in the activity of cholinephosphotransferase and was associated to a greater increase in the activity of phospholipases A<sub>2</sub> and several lysosomal hydrolases. They also found an increased number and size of lysosomes during neuronal regeneration. Arrigoni et al. [111] have shown citicoline to be able to completely inhibit activation of phospholipases A<sub>2</sub> without alter-

ing cholinephosphotransferase activity. On the other hand, Freysz et al. [112] showed that, in addition to decreasing phospholipase A<sub>1</sub> and A<sub>2</sub> activity, citicoline decreases free fatty acid release under hypoxic conditions, thus adding a protecting effect to its activating capacity of phospholipid reconstruction. Massarelli et al. [113] also showed citicoline action upon phospholipases A<sub>1</sub>, and agreed with all other authors in their conclusions. Kitazaki et al. [114] also showed the inhibitory effect of citicoline upon membrane-associated phospholipases A<sub>2</sub> in rat brain cortex. Based on these characteristics, citicoline has been considered a non-specific inhibitor of phospholipase A<sub>2</sub> at intracellular level [115].

Algate et al. [116] tested the effects of citicoline in an experimental model of epidural compression in anesthetized cats. They noted that animals treated with citicoline had a greater resistance to the effects of mechanic brain compression as compared to animals in the control group. They also found that respiratory and cardiovascular changes were less intense in treated animals, and concluded that citicoline provides a significant protection against the lethality of epidural compression. These results agreed to those obtained by Hayaishi [117] and Kondo [118], who showed an improvement in the EEG tracing following administration of citicoline to cats undergoing experimental brain compression, and also in survival quality.

Tsuchida et al. [119] administered <sup>3</sup>H-citicoline by the intraperitoneal route to rats subjected to cerebral cryogenic lesion by dry ice application on the scalp, and confirmed the presence of the labelled drug in brain parenchyma, particularly in the white matter, and above all in damaged areas.

Boismare [12,120] conducted an experimental model of craniocervical trauma without direct blow ('whiplash') in order to assess the effects occurring upon central catecholamine levels, and found increased dopamine levels and decreased norepinephrine levels in the brain following trauma. This type of lesion causes postural dysregulation of brain supply and behavioural and learning disorders, that are related to accelerated degradation of cerebral norepinephrine. In animals treated with citicoline, trauma did not change the levels of these amines. The author stressed the protective role of citicoline, due to this stabilizing effect of catecholamine brain levels.

Clendenon et al. [121] showed that the decrease in Mg<sup>++</sup>-dependent ATPase activity in the mitochondrial and synaptosomal membrane occurring in traumatic lesions is prevented by citicoline administration.

Cohadon et al. [14,15,122], in a series of studies on a model of cryogenic cerebral edema in rabbits, showed that treatment with citicoline 20 mg/kg/d:

- Slowed the drop in enzymatic activity of mitochondrial ATPase.
- Restored Na<sup>+</sup>/K<sup>+</sup> ATPase activity.
- Restored oligomycin-sensitive ATPase activity.
- Accelerated cerebral edema reabsorption, with normal values achieved in the fourth day, while such levels were not reached until the tenth day with spontaneous resorption.

These authors stated that the beneficial activity of citicoline in cerebral edema occurred by two mechanisms: by restoring insertion of membrane enzymes and enhancing their activity, and by acting upon edema by reducing water imbibition of brain parenchyma.

Lafuente and Cervós-Navarro [123,124] conducted a microgravimetric study in experimental cerebral edema induced by ultraviolet radiation in cats to assess the effect of citicoline in this situation. The results suggested an action of citicoline decreasing the amount of edema, enhancing fluid reabsorption and accelerating fluid drainage to ventricles, i.e. increasing cerebral compliance. Authors concluded that CDPamines are helpful to control tissue lesions related to increased free fatty acids and to restore cell energy metabolism by restarting the Na<sup>+</sup>/K<sup>+</sup> pump.

Majem et al. [125] assessed the EEG changes occurring in rats when cryogenic edema is induced, and how such EEG changes were modified by citicoline administration. These authors noted a significant increase in the theta frequency band during the awakening state, with decreased delta and slow alpha bands and a lesser interindividual scatter of the overall frequency bands, which resulted in a greater electrogenic cerebral stability. They concluded that citicoline protected from the effects of cryogenic cerebral edema.

Roda [126], in an experimental model of cryogenic cerebral edema, measured extravasation of Evans blue through the BBB and fluorescein uptake by astrocytes and neurons, and found that citicoline administration significantly reduced both processes as compared to control animals, thus allowing to state that citicoline has a direct effect upon transmembrane transport of sodium, potassium, water, and proteins at both BBB endothelial cell level and astrocyte and neuron level. Though the exact mechanism of this action is not completely understood, its effect appears to occur at two levels: on the interface separating capillaries from the

neuroglia and on cell membranes. Citicoline reduces microvascular permeability during experimental endotoxemia [127] and in early burn edema in rats [128].

Dixon et al. [129] analyzed the effects of exogenous administration of citicoline on motor deficits, spatial memory capacity, and acetylcholine levels in dorsal hippocampus and neocortex in a model of traumatic brain lesion in rats, induced by a controlled lateral impact. Citicoline was administered by the intraperitoneal route at a dose of 100 mg/kg for 18 days from the first day following induction of the traumatic lesion. Another group of animals was treated with saline solution. Motor assessment was performed using a balance test for which animals had previously been trained, and cognitive assessment was made with a variant of the Morris maze test, that is sensitive to cholinergic function. Microdialysis methods were also used to analyze the effects upon acetylcholine release. In the motor function study, citicoline-treated animals showed on day 1 after the lesion a significantly longer balance period as compared to animals receiving saline (39.66 ± 3.2 seconds versus 30.26 ± 2.9 seconds; *p* < 0.01). In addition, animals treated with citicoline had significantly less cognitive deficits. In microdialysis studies, after a single administration of citicoline by the intraperitoneal route, a rapid increase in acetylcholine production was seen as compared to baseline, that was maintained for up to 3 hours, in both dorsal hippocampus (*p* < 0.014) and neocortex (*p* < 0.036), while no changes were noted in animals receiving saline. Authors concluded that post-traumatic deficits in spatial memory function are due, at least partly, to deficiency changes in cholinergic transmission, that are attenuated with citicoline administration.

Plataras et al. [130] analyzed the effects of different citicoline concentrations (0.1-1 mM) upon the activities of acetylcholinesterase, Na<sup>+</sup>/K<sup>+</sup>-ATPase, and Mg<sup>++</sup>-ATPase in total brain homogenates from rats and extracts of non-membrane bound pure enzymes. Following 1-3 h preincubation with citicoline, peak stimulations of 20-25% (*p* < 0.001) and 50-55% (*p* < 0.001) are seen for acetylcholinesterase and Na<sup>+</sup>/K<sup>+</sup>-ATPase respectively, while no significant effects are seen on Mg<sup>++</sup>-ATPase. Authors concluded that citicoline may stimulate cerebral acetylcholinesterase and Na<sup>+</sup>/K<sup>+</sup>-ATPase independently from acetylcholine and norepinephrine, which could partly account for the clinical effects of the drug.

Baskaya et al. [131] examined the effects of citicoline upon cerebral edema and rupture of the BBB

in a rat model of traumatic brain injury. Animals received citicoline (50, 100, 400 mg/kg) or saline by the intraperitoneal route twice following induction of the traumatic brain lesion. Induction of the traumatic lesion caused an increase in water content percentage and Evans blue extravasation (a marker of BBB rupture) at the damaged cortex and ipsilateral hippocampus. The 50 mg/kg dose of citicoline was not effective, while at 100 mg/kg a reduction was seen in Evans blue extravasation in both regions, although this dose only decreased cerebral edema in the damaged cortex. The 400 mg/kg dose of citicoline significantly reduced cerebral edema and the BBB rupture in both regions. Authors concluded that these results suggest citicoline to be an effective neuroprotective agent upon secondary lesions occurring in association to traumatic cerebral injury.

Dempsey and Rao [132], using an experimental model of controlled lateral impact in rats, have shown that intraperitoneal administration of citicoline 200-400 mg/kg following induction of the TBI prevents neuronal damage in hippocampus associated to the traumatic lesion, decreases cortical contusion volume, and improves neurological recovery.

It has been demonstrated a synergistic effect in the association of propofol with citicoline in an experimental model of TBI in rats [133], resulting in a higher reduction of the lipidic peroxidation when the drugs are administered together.

Jacotte-Simancas et al. [134] examined the effects of citicoline and of voluntary physical exercise in a running wheel (3 weeks), alone or in combination, on TBI-related short-term (3 h) and long-term (24 h) object recognition memory (ORM) deficits, and on neurogenesis and neuroprotection, using a rodent model of TBI (controlled cortical impact injury). Citicoline improved memory deficits at the two times tested, while physical exercise only in the long-term test. Some degree of neuroprotection of citicoline was suggested by reduced interhemispheric differences in the volume of the hippocampal formation. But, contrary to what was expected, the effects of citicoline and physical exercise did not sum up.

Qian et al. [135] demonstrate the protection of citicoline against white matter and grey matter damage due to closed head injury through suppressing oxidative stress and calpain overactivation, providing additional support to the application of citicoline for the treatment of traumatic brain injury.

Abdolmaleki et al. [136] evaluated the anticonvulsant effect of citicoline in the pentylentetrazole

seizure model. In this study it was showed that the acute administration of citicoline has anticonvulsant activity and sedative effect, suggesting a positive effect of citicoline on post-traumatic epileptogenesis.

Effect of citicoline upon traumatic spinal cord lesion was also studied, and it was shown that intraperitoneal (i.p.) administration of citicoline 300 mg/kg 5 minutes after lesion induction significantly reduced lipid peroxidation and improved motor function in treated animals [137], having the same efficacy than methylprednisolone in the behavioral and neuroanatomical recovery [138]. It has been demonstrated that the administration of repeated doses of citicoline prevents the tissue damage associated with the spinal cord shock in acute phase [139], and that the combination of ischemic post-conditioning with citicoline confers protection in a model of ischemic spinal cord lesion [140], through the inhibition of the caspases pathway and the increase of antiapoptotic proteins.

Also it has been observed some beneficial effects of citicoline in experimental models of partial optic nerve crush in the rat [141] and also there are some data suggesting that citicoline promotes nerve regeneration, and reduces postoperative scarring after peripheral nerve surgery [142]. Aslan et al. [143] demonstrated that CDP-choline improves the functional recovery and promotes the regeneration of injured sciatic nerves treated with immediate or delayed surgical repair in rats. The same team [144] demonstrated that intraperitoneal administration of CDP-choline improves nerve regeneration and functional recovery in a rat model of sciatic nerve injury, improving also nerve adherence and separability. Kaplan et al. [145] concluded that citicoline exhibits dose-dependent effects on axonal regeneration and recovery without scar formation in a rat model of peripheral nerve incision and primary anastomosis. In this context, CDP-choline modulates matrix metalloproteinase activity and promotes the expression of tissue inhibitor of metalloproteinases to stimulate axonal regeneration [146]. These data help to explain one mechanism by which CDP-choline provides neuroprotection in peripheral nerve injury. Emril et al. [147] demonstrated that in situ administration of 0.4 mL of 100  $\mu$ mol/L citicoline prevents the occurrence of neuropathic pain and induces motoric recovery 4 weeks after sciatic nerve injury. Savran et al. [148] demonstrated that citicoline may be effective for preventing postoperative epidural fibrosis in an experimental model. After a systematic review of the literature on rodent models, Wang et al. [149] con-

sider that citicoline is one of the most effective adjuvant treatments after surgery in peripheral nerve laceration.

Because of its biochemical, pharmacological, and pharmacokinetic characteristics, citicoline is a potentially useful drug for the treatment of traumatic cerebral injuries [150].

### Cerebral hypoxia and ischemia

In vitro studies using nerve tissues have shown anoxia to induce a decrease in the synthesis of structural phospholipids that is time-dependent, i.e. the longer the hypoxia the stronger the impact upon neuronal phospholipids metabolism [151]. Moreover, a decreased incorporation of marked precursors into phospholipids of neuronal subcellular fractions obtained from animals subjected to experimental hypoxia has also been shown [21]. It is also known that, when cerebral ischemia is experimentally induced, glycerophospholipids in cell membranes are broken down by the action of different phospholipases, producing free fatty acids and arachidonic acid derivatives. With prolonged ischemia, induced aggression upon membranes becomes more intense and membranes lose their functions.  $\text{Na}^+$  and  $\text{Ca}^{2+}$  accumulate inside the cell, triggering the ischemic cascade and invariably leading to cell death [6,28,32,36,115,152].

Under ischemia conditions, with the attendant neuronal distress, endogenous CDP-choline synthesis is compromised because the cell, under such conditions, lacks the high-energy phosphate compounds necessary for this biosynthetic route [32,153].

Because of the importance of restoring neuronal activity following cerebral ischemia [4] and based on the experimental data discussed, various authors have investigated the effects of citicoline administration in various experimental models of cerebral ischemia and/or hypoxia.

Boismare et al. [154] reported that treatment with citicoline 20 mg/kg by the i.p. route in rats induced, during acute hypoxia, a decrease in vegetative responses, protection from conditioned avoidance responses, and stabilization of dopamine and norepinephrine brain levels. This same group [155] found in dogs subjected to normobaric hypoxia increases in blood pressure, heart rate, cardiac output, and regional blood flows, while no changes occurred in total peripheral resistance. Administration of citicoline abolished these hemodynamic effects induced by acute hypoxia, suggesting that this action was correlated to a dopaminergic agonistic


effect of the drug. In cats subjected to short periods of cerebral ischemia, these authors [156] noted that a depression occurred in cortical evoked potentials. Such depression was attenuated by prior administration of citicoline by the intracarotid route. These authors think that the protective effects of citicoline are metabolic/biochemical rather than hemodynamic in origin, and do not rule out a direct action of the drug upon central dopaminergic structures.

Alberghina et al. [157] investigated the effect of citicoline upon incorporation of labelled precursors into cerebral phospholipids of guinea pigs subjected to hypoxia. A group of animals were given 100 mg/kg of citicoline by the i.p. route. Ten minutes later, the labelled precursors  $[2\text{-}^3\text{H}]\text{glycerol}$  and  $[1\text{-}^{14}\text{C}]\text{palmitate}$  were administered by the intraventricular route. Another group of animals received the precursors only, and acted as control group. Investigators noted that, as compared to the control group, citicoline-treated animals showed an increase in specific radioactivity of total lipids and phospholipids in purified mitochondria obtained from brain hemispheres, cerebellum, and brain stem. In a subsequent study, this same investigating team [158] showed citicoline to be able to counteract the effects of hypoxia upon incorporation of labelled precursors into RNA and proteins, particularly at nuclear and mitochondrial level.

Various experimental studies have shown citicoline to prevent fatty acid release during cerebral ischemia and hypoxia, and to increase synthesis of structural phospholipids [159-178]. Horrocks et al. [159,162,164], using an experimental model of global cerebral ischemia by decapitation, showed that administration of a mixture of citicoline and CDP-ethanolamine decreased free fatty acid release and increased synthesis of the corresponding glycerophospholipids, suggesting an involvement of choline and ethanolamine phosphotransferases.

Trovarelli et al. [160,161], using an experimental global ischemia model consisting of bilateral carotid ligation in gerbils, found that intraperitoneal citicoline administration partially prevents changes in lipid metabolism induced by cerebral ischemia, correcting the increase in free fatty acids, changes in neutral lipids such as diacylglycerol, and the decrease in phosphatidylcholine. Suno and Nagaoka [163] experimentally studied in rats the effects of citicoline administration upon free fatty acid release caused by total cerebral ischemia lasting 5 minutes. It was shown that the tested drug reduced the increase in free fatty acids, and that the intensity of this effect depended on the dose

**Figure 3.** Effect of citicoline on arachidonic acid release in ischaemic rat brains. Citicoline (200 and 1,000 mg i.p.) was administered 10 min before decapitation. Five minutes later, free fatty acids were extracted. Arachidonic acid levels were determined by gas chromatography. <sup>a</sup>  $p < 0.05$ ; <sup>b</sup>  $p < 0.001$  vs. untreated ischaemia.



used. Arachidonic acid contents in brains from control group animals subjected to ischemia was  $174 \pm 22$  mmol/g, as compared to  $119 \pm 8$  mmol/g and  $61 \pm 8$  mmol/g in animals receiving 200 and 1000 mg/kg i.p. of citicoline respectively (Fig. 3). Authors concluded that these results suggest that administration of citicoline may prevent ischemic cerebral damage. Agut and Ortiz [165] treated male rats weighing 190-200 g with 4 mg/kg of <sup>14</sup>C-methyl-citicoline (50  $\mu$ Ci) by the oral route. At 24 hours, brain radioactivity levels and the presence of labelled phospholipids were assessed under conditions of normoxia, hypoxia, and hypoxia following additional administration of 100 mg/kg of unlabelled citicoline. Investigators found a marked incorporation of radioactivity into the brains of normoxic and hypoxic animals, mostly associated to phosphatidylcholine. In addition, administration of unlabelled citicoline reduced the elevation in cerebral lysophosphatidylcholine caused by hypoxia. Rao et al. [169] showed that citicoline significantly decreased BBB dysfunction after ischemia with a 6-hour reperfusion in gerbils and, in the same model of transient cerebral ischemia, consid-

erably reduced the increase in arachidonic acid and leukotriene C<sub>4</sub> synthesis 24 hours after ischemia induction. They also showed that the cerebral edema volume was substantially lower at 3 days in animals treated with citicoline. Following 6 days of reperfusion, ischemia was seen to cause  $80 \pm 8\%$  neuronal death at the hippocampal CA<sub>1</sub> layer level, and citicoline provided a neuroprotection of  $65 \pm 6\%$ . In a subsequent study, these authors [151] showed citicoline to be able to significantly restore phosphatidylcholine, sphingomyelin, and cardiolipin levels after induction of transient cerebral ischemia in gerbils. For these authors, the main action mechanism of citicoline would be inhibition of stimulation of phospholipase A<sub>2</sub> activity in ischemia conditions, though they also stress its effects upon glutathione synthesis and glutathione reductase activity. Thus, the drug would prevent membrane destruction, decrease free radical generation, and preserve the natural defenses of the nervous system against oxidative damage [171-175]. More recently, this investigating team has also shown that citicoline enhances phosphatidylcholine synthesis, which is impaired under ischemia

conditions, attenuating the loss of CTP-phosphocholine cytidyltransferase activity [176,177]. Thus, the drug has effects preventing phospholipid degradation and its implications and promoting regeneration of cerebral phosphatidylcholine, effects that are seen to result in a decreased volume of the cerebral ischemic lesion [178].

Tornos et al. [179] conducted a pharmacological study on the protective effect of citicoline against toxicity in an experimental model of hypoxia induced by potassium cyanide. They found that treatment with oral citicoline for 4 days before hypoxia induction had a protective effect, demonstrated by a longer survival time in treated animals. These benefits of citicoline may also be ascribed to the activation of the cerebral energy metabolism [180] and the increased activity of mitochondrial cytochrome oxidase [181] induced by this drug.

Narumi and Nagaoka [182] investigated the effects of citicoline administration upon metabolism of cerebral monoamines in two rat models of global cerebral ischemia. In the first model they performed cerebral ischemia, using bilateral carotid occlusion, for 30 minutes in spontaneously hypertensive rats and noted that a significant decrease occurred in norepinephrine levels in the brain cortex. In this model, administration of 1000 mg/kg of citicoline decreased dopamine contents in striatum and diencephalon, normalizing the decrease in the dopamine metabolites/dopamine ratio induced by ischemia. In the second model, bilateral carotid occlusion was also performed 24 hours after electrocauterization of both vertebral arteries in Wistar rats. In this model, norepinephrine, dopamine, and serotonin levels decreased 70-80% in the brain cortex. Similar decreases were also seen in norepinephrine and serotonin levels in hippocampus, in dopamine levels in the nucleus accumbens, in dopamine and serotonin levels in striatum, and in norepinephrine levels in diencephalon and brain stem. Administration of citicoline at a dose of 500 mg/kg significantly enhanced the ischemia-induced decrease in striatal dopamine levels. These authors therefore suggest that citicoline appears to restore dopamine turnover in the striatum of rats subjected to experimental cerebral ischemia.

Nagai and Nagaoka [183] reported the results of a study investigating the effect of citicoline upon glucose uptake in different brain areas from rats with global cerebral ischemia induced by the occlusion of both carotid arteries for 30 minutes after electrocauterization of both vertebral arteries. Glucose uptake by the brain was measured four days after recirculation. Without citicoline admin-

istration, global cerebral uptake was found to be reduced to 81% of the normal value. With administration of citicoline at a dose of 250 mg/kg i.p. twice daily for 3 days after the start of recirculation, postischemic reduction of glucose uptake was significantly lower in the brain cortex. This suggests that citicoline improves energy metabolism in the brain under ischemic conditions.

Hurtado et al. [184] have shown that administration of citicoline significantly increased ATP brain levels in both healthy and ischemic animals, and that this increase in ATP was correlated to a positive effect on glutamate transporters, restoring their normal activity and therefore decreasing both brain parenchymal and circulating glutamate levels. This was correlated to a decreased cerebral infarction volume. The same authors demonstrated that citicoline redistributes the glutamate transporter EAAT2 to lipid raft microdomains and improves glutamate uptake and this effect is also found after experimental stroke, when citicoline is administered 4 h after the ischemic occlusion [185]. In another study [186], they found that a chronic treatment with citicoline, initiated 24 h after the insult, is able to increase the neuronal plasticity within noninjured and functionally connected brain regions as well as to promote functional recovery. To assess the functional recovery they have performed the staircase reaching test and the elevated body swing test (EBST), for studying sensorimotor integration and asymmetrical motor function respectively. The treatment with citicoline, initiated 24 h after the middle cerebral artery occlusion (MCAO) and maintained during 28 days, improved the functional outcome in both the staircase test (MCAO + CDP =  $87.0 \pm 6.6\%$  pellets eaten versus MCAO + SAL =  $40.0 \pm 4.5\%$ ;  $p < 0.05$ ) and the EBST (MCAO + CDP =  $70.0 \pm 6.8\%$  versus MCAO + SAL =  $88.0 \pm 5.4\%$ ; contralateral swing  $p < 0.05$ ). In addition, to study potential neuronal substrates of the improved function, we examined the dendritic morphology of layer V pyramidal cells in the undamaged motor cortex using a Golgi-Cox procedure. The animals treated with citicoline showed enhanced dendritic complexity and spine density compared with saline group (Fig. 4). Zhao et al. [187] also showed a positive effect of citicoline on spatial learning and memory of rats after focal cerebral ischemia.

Kakihana et al. [188] investigated distribution of labelled citicoline and its effects on acetylcholine synthesis from glucose in the brain cortex of rats subjected to 30 minutes of ischemia followed by reperfusion. Treatment with citicoline improved




glucose metabolism and significantly restored acetylcholine synthesis from glucose. For these authors, the results obtained suggest that citicoline improves brain energy metabolism in ischemia conditions. These same authors [189] subsequently evaluated the effects of citicoline on neurological sequelae and glucose metabolism in the brain in an experimental rat model of transient cerebral ischemia, showing that high-dose citicoline improved the neurological state of animals subjected to ischemia, which was correlated to an improved brain energy metabolism and to drug incorporation in the fraction of membrane phospholipids. These results agree with those obtained by Fukuda et al. [190] in a preliminary study.

Nagaoka [191] studied the effects of citicoline on stroke onset and mortality in spontaneously hypertensive rats subjected to cerebral ischemia. Ischemia was induced by occluding both common carotid arteries. Citicoline (200-1000 mg/kg i.p.), administered before ischemia induction, caused a dose-dependent delay in the onset of stroke and respiratory arrest. These effects were also seen in animals treated after ischemia induction. In addition, citicoline 500 mg/kg i.p. improved the neurological status in rats undergoing brain ischemia for 40 minutes and reperfusion. These results suggest that citicoline has a neuroprotective role against cerebral ischemia and reperfusion.


Saligaut and Boismare [192] studied the effects of citicoline, administered at a dose of 1000 mg/kg p.o., in Wistar rats undergoing acute hypobaric hypoxia (15 minutes at a simulated altitude of 7180 m), assessing a behavior-conditioning test, striatal dopamine uptake, and levels of this neurotransmitter and its metabolites in the striatum. In the behavior-conditioning test, citicoline was seen to protect against hypobaric hypoxia in a different way and to a greater extent than apomorphine. Biochemical studies showed a presynaptic effect, probably because of activation of tyrosine hydroxylase, inducing changes in dopamine uptake, as well as an improved dopamine release. Similar results on the effect of citicoline on tyrosine hydroxylase activity have been obtained by other teams [193].

LePoncin-Lafitte et al. [104] studied the effects of citicoline on various histological brain changes in an experimental model of multifocal cerebral ischemia in cats, in which ischemic lesion was caused by introducing in the internal carotid artery calibrated microspheres, that will produce cerebral microinfarctions, characterized by having a central necrosis area surrounded by a penumbra area, together with edema due to rupture of the

**Figure 4.** Effect of chronic treatment with CDP-choline on functional recovery, as determined as sensorimotor integration (a) and asymmetrical motor behaviour (b). CDP-choline (MCAO+CDP) or saline (MCAO+SAL) were administered 24 h after pMCAO and for 28 days following pMCAO. Sensorimotor integration and asymmetrical motor behaviour were studied by the staircase skilled reaching test and the elevated body swing test (EBST), respectively. Data are means  $\pm$  SEM,  $n = 16$ . <sup>a</sup> $p < 0.05$  vs. MCAO+SAL.



**Figure 5.** Effect of citicoline at a low dose (100 mg/kg) or high dose (500 mg/kg) on infarct volume. The values represent the mean  $\pm$  SD. The infarct volume was significantly smaller ( $p < 0.01$ ) in the high-dose citicoline group than in the control group.



blood-brain barrier. Citicoline administration considerably decreased the number of lesions, and also the amount of extravasated albumin, which confirms, for these authors, that citicoline exerts its neuroprotective role against ischemia by acting upon cell membranes. Araki et al. [194] also found some neuroprotective effect of citicoline in complete cerebral ischemia induced by decapitation and potassium cyanide poisoning in mice.

Aronowski et al. [195] evaluated the effects of chronic citicoline administration (500 mg/kg) upon recovery in spontaneously hypertensive rats undergoing occlusion of the middle cerebral artery for 30 to 120 minutes. Drug or saline were administered by the intraperitoneal route from 15 minutes after ischemia induction and were continued for 14 days. Morphological lesion and neurological disorders (motor and sensorimotor capacities) were analyzed by measuring the maximum morphological lesion volume, maximum neurological change, and ischemia duration causing half the maximum morphological lesion or maximum neurological change. Maximum morphological lesion volume was not affected by citicoline ( $101.6 \pm 11.4$


mm<sup>3</sup> for citicoline,  $103.3 \pm 13.6$  mm<sup>3</sup> for saline); however, citicoline significantly increased ischemia duration required to cause half the morphological lesion, that changed from  $38.3 \pm 5.9$  min to  $60.5 \pm 4.3$  min ( $p < 0.05$ ). Similarly, citicoline did not change the value of maximum neurological change ( $8.5 \pm 0.7$  for citicoline,  $10.1 \pm 4.0$  for control), but did significantly increase ischemia duration required to cause half the maximum neurological change from  $41.9 \pm 4.6$  min to  $72.9 \pm 24.5$  min ( $p < 0.05$ ). According to these authors, citicoline shows a greater efficacy in animals that experience a sub-maximal lesion, occurring in this model with 30-75 minutes of ischemia.

Schäbitz et al. [196] evaluated the effects of long-term treatment with citicoline in a model of transient focal ischemia (2 hours) in rats. Ten animals were randomly assigned to each of the groups: placebo (saline 0.3 mL/d/7 d), low dose (citicoline 100 mg/kg/d/7 d i.p.) and high dose (500 mg/kg/d/7 d i.p.). Treatment was started at the time of reperfusion, once the 2-hour ischemia period had ended. Daily neurological assessments were made (modified Zea Longa scale), and surviving animals were killed on day 7, after which cerebral edema and infarction volume were calculated. No differences were seen in neurological assessment of animals at study end, but a more favorable trend was noted in the citicoline high-dose group. Mean infarction volume (Fig. 5) was  $243.5 \pm 88.6$  mm<sup>3</sup> in the placebo group,  $200.2 \pm 19.9$  mm<sup>3</sup> in the low-dose group, and  $125.5 \pm 45.2$  mm<sup>3</sup> in the high-dose group. These differences were statistically significant ( $p < 0.01$ ). A dose-dependent decrease in cerebral edema volume was also seen, but did not reach statistical significance.

In a series of conducted studies, citicoline was shown to have a synergistic effect with other drugs in the treatment of cerebral ischemia, such as thrombolytic [197-199,201] and neuroprotective drugs [202-207]. Andersen et al. [197] conducted an experimental study in a rat model of carotid embolism to evaluate the effect of different doses of citicoline, administered alone or combined with recombinant tissue plasminogen activator (rTPA), on infarction size. Ninety Sprague-Dawley rats subjected to embolism in the carotid territory were randomized into 6 groups:

- Group 1: saline-treated animals.
- Group 2: citicoline 250 mg/kg.
- Group 3: citicoline 500 mg/kg.
- Group 4: rTPA 5 mg/kg.
- Group 5: rTPA 5 mg/kg + citicoline 250 mg/kg.
- Group 6: rTPA 5 mg/kg + citicoline 500 mg/kg.

**Figure 6.** Effect of the association of citicoline (CIT) and rtPA on infarct size in a model of embolic stroke in rats. C250: citicoline 250 mg/kg; C500: citicoline 500 mg/kg; rtPA: rtPA, 5 mg/kg.



Treatment with rTPA was given at a suboptimal dosage (5 mg/kg infused over 45 minutes, starting treatment 45 minutes after embolization). Citicoline was administered daily by the intraperitoneal route for 4 days. Brains from surviving animals were fixed at four days and infarction volume, calculated as percentage of the total volume of the hemisphere affected, was measured using a microscope. Mean infarction volume values suggested that high-dose citicoline and the combination of citicoline with rTPA decreased the size of ischemic lesion (Fig. 6). In the control group, mean infarction volume was 41.2% (5.9-87.0%). In groups treated with citicoline alone, values were 30.4% (1.0-70.0%, n.s.) in group 2, and 22.2% (0.7-76.6%,  $p < 0.05$ ) in group 3. With rTPA alone (group 4), mean volume was 24.5% (1.4-71.1%, n.s.), while with combined treatment, mean volumes were 13.5% (0.2-47.8%,  $p = 0.002$ ) in group 5 and 29.2% (0.11-72.1%, n.s.) in group 6. This study showed that high-dose citicoline and a combination of citicoline at lower doses with rTPA significantly reduced the size of brain infarctions. Díez-Tejedor et al. [198,199] reported similar results, stating that results of this association are improved when citicoline is admin-

istered immediately after rTPA administration. The same team [200] compared the effects of high doses of CDP-choline (1000 mg/kg) with rTPA (5 mg/kg) in an experimental animal model of embolic stroke. CDP-choline and rTPA produced a significant reduction in brain damage considering infarct volume, cell death, and inflammatory cytokines (tumour necrosis factor-alpha and interleukin 6) compared with the infarct group. Additionally, CDP-choline significantly decreased infarct volume, cell death, and interleukin 6 levels with respect to the rt-PA group. From these results, they concluded that high-dose CDP-choline may be an effective treatment for acute ischaemic stroke even in absence of thrombolysis. Shuaib et al. [201] investigated the neuroprotective effects of citicoline alone or combined with urokinase in a rat model of focal cerebral ischemia induced by embolization at the origin of the middle cerebral artery. Both drugs were administered 2 hours after ischemia induction. Animals were killed at 72 hours. In saline-treated animals, infarction volume was  $33.1 \pm 9.7\%$ . Citicoline-treated animals were divided into two groups, one of which was given a single dose of citicoline 300 mg/kg, while the other group received

a daily dose of 300 mg/kg for 3 days, both by the intraperitoneal route. A significant reduction in infarction volume was seen in both groups ( $20.9 \pm 9.7\%$  with single doses,  $p = 0.01$ ;  $18.9 \pm 11.4\%$  with multiple doses,  $p = 0.008$ ). Animals treated with urokinase alone, at doses of 5000 IU/kg, also had a smaller infarction volume ( $19.5 \pm 12.5\%$ ,  $p = 0.01$ ). However, the greatest volume reduction was achieved in the group of animals treated with the combination of citicoline and urokinase ( $13.6 \pm 9.1\%$ ,  $p = 0.0002$ ). These authors concluded that citicoline provides a significant neuroprotective effect that may be enhanced by association with a thrombolytic. Synergistic effects have also been shown with the association of citicoline with MK-801 or dizocilpine [202], basic fibroblast growth factor or bFGF [203], lamotrigine [204], nimodipine [205,206], and L-NAME [207] in models of cerebral ischemia. It has been demonstrated that citicoline with hypothermia is more effective than either used alone in ameliorating cerebral damage after transient focal ischemia [208]. Also it has been demonstrated that pre-conditioning with CDP-choline attenuates oxidative stress-induced cardiac myocyte death in a hypoxia/reperfusion model [209]. Also it is known that citicoline and mesenchymal stem cells administration show equal efficacy in the neurological recovery, the decrease of neuronal death and the increase of neuronal repair in a model of cerebral infarction in rats, but the combination does not increase the benefit [210], despite that CDP-choline treatment induces brain plasticity markers expression in experimental animal stroke [211]. Diederich et al. [212] designed a study to check whether citicoline also enhances neuroregeneration after experimental stroke. Animals were subjected to photothrombotic stroke and treated either with daily injections of citicoline (100 mg/kg) or vehicle for 10 consecutive days starting 24 hours after ischemia induction. Sensorimotor tests were performed after an adequate training period at days 1, 10, 21, and 28 after stroke. Then brains were removed and analyzed for infarct size, glial scar formation, neurogenesis, and ligand binding densities of excitatory and inhibitory neurotransmitter receptors. Animals treated with citicoline showed a significantly better neurological outcome at days 10, 21, and 28 after ischemia, which could not be attributed to differences in infarct volumes or glial scar formation. However, neurogenesis in the dentate gyrus, subventricular zone, and peri-infarct area was significantly increased by citicoline. Furthermore, enhanced neurological outcome after citicoline treat-

ment was associated with a shift toward excitation in the perilesional cortex. The present data demonstrate that, apart from the well-known neuroprotective effects in acute ischemic stroke, CDP-choline also possesses a substantial neuroregenerative potential. Also citicoline potentiates angiogenesis [213] and astroglial cell proliferation and differentiation [214], both mechanisms involved in neuroplasticity.

Fresta et al. conducted a series of experiments in models of transient cerebral ischemia in rats using liposomal citicoline, in which they showed a significantly increased survival in animals treated with this citicoline formulation [215-217], and more recently, that this same drug formulation significantly reduces the maturation phenomenon, that is, delayed cerebral neurodegenerative lesion, that occurs after an ischemic event, resulting in a significant improvement in brain functions [218]. These results agree with previously discussed results [179] showing that administration of liposomal citicoline is more effective as compared to non-liposomal citicoline [219-221]. Other ways to improve neuroprotective efficiency of citicoline are the stereotactic delivery [222] or simple diffusion delivery via brain interstitial route [223].

Citicoline has also been shown to have a neuroprotective effect against neurotoxic damage induced by kainic acid in retinal cells [224-227] and in *in vitro* models of retinal neurodegeneration [228].

Hamdorf and Cervós-Navarro [229] exposed 48 rats for 103 days to a decreasing amount of oxygen, *i.e.* they were exposed to chronic hypoxia. Citicoline showed a protective effect by increasing vigilance under moderate hypoxic conditions (15% O<sub>2</sub>). In a subsequent study, these same authors [230] analyzed the effects of citicoline in Wistar rats subjected to hypoxia for 5 months. Behavioral changes induced by hypoxia were attenuated in the group or animals treated with citicoline. Interestingly, therapeutic administration of citicoline was found to be more effective than prophylactic administration. In addition, under extreme hypoxia conditions, citicoline showed a protective effect by lengthening survival. Lee et al. [231] demonstrated that citicoline protects against cognitive impairment in a rat model of chronic cerebral hypoperfusion.

Other mechanisms proposed to explain the neuroprotective effects of citicoline are the restoration of the barrier function of endothelial cells compromised by hypoxia/aglycemia probably via up-regulating the expression of tight junction proteins [232], the inhibition of mitochondrial perme-

ability transition [233, 234], and providing neuronal membrane integrity and protection of membrane stability in cortical spreading depression [235]. Another mechanism investigated has been the participation of Sirtuin1 in the neuroprotective actions of CDP-choline [236]. Treatment with CDP-choline increased Sirtuin1 protein levels in brain concomitantly to neuroprotection. Treatment with sirtinol blocked the reduction in infarct volume caused by CDP-choline, whereas resveratrol elicited a strong synergistic neuroprotective effect with CDP-choline. CDP-choline failed to reduce infarct volume in *Sirt1<sup>-/-</sup>* mice. These results demonstrate a robust effect of CDP-choline like Sirtuin1 activator by up-regulating its expression. These findings suggest that therapeutic strategies to activate Sirtuin1 may be useful in the treatment of stroke.

On the other hand, Masi et al. [237] have shown citicoline to have a certain antiplatelet aggregant effect, that may provide an additional benefit for the treatment of cerebral vascular disease. Pinardi et al. [238] investigated in Sprague-Dawley rats the effects of citicoline infusion on relaxation induced by exogenous acetylcholine in the isolated external carotid vascular bed, having no cholinergic nerve supply, and the isolated internal carotid vascular bed that, by contrast, has an abundant cholinergic nerve supply. Changes in perfusion pressure were measured during a dose-response curve to acetylcholine and following infusion of 1 mg/min/30 min of citicoline. Authors noted that citicoline caused relaxation in both vascular beds, which would suggest the presence of muscarinic receptors. In the internal carotid vascular bed, citicoline infusion for 30 minutes significantly shifted to the left the dose-response curve to acetylcholine, enhancing relaxation. However, this did not occur in the external carotid bed. The effect of citicoline was masked when it was jointly infused with hemicholinium. According to these authors, results suggest that citicoline would act by increasing choline levels at cholinergic endings, increasing acetylcholine synthesis and/or release.

Clark et al. [239] examined whether citicoline was able to reduce ischemic damage and improve the functional neurological result in an intracerebral hemorrhage model in mice. They caused hemorrhage in 68 Swiss albino mice by injecting them collagenase at the caudate nucleus. Animals randomly received saline or citicoline 500 mg/kg i.p. before administration of collagenase and at 24 and 48 hours. Mice were assessed using a 28-item neurological scale and were killed at 54 weeks to assess

hematoma volume, total damage, and surrounding ischemic damage. As regards neurological course, citicoline-treated animals had a better score than placebo-treated animals ( $10.4 \pm 2.0$  versus  $12.1 \pm 2.4$ ;  $p < 0.01$ ). No differences were seen in hematoma volumes, but a significant reduction in the volume of the surrounding ischemic damage was noted in animals treated with citicoline, with values being  $13.8 \pm 5.8 \text{ mm}^3$  ( $10.8 \pm 4.3\%$  of hemisphere) and  $17.0 \pm 7.1 \text{ mm}^3$  ( $13.3 \pm 5.1\%$ ) for placebo, with  $p < 0.05$ . According to authors, these results support a potential role of citicoline for treatment of intracerebral hemorrhage.


Apoptotic mechanisms have been shown to play a primary role in the pathophysiology of cerebral ischemic damage both at experimental level [240-244] and in humans [245,246]. We therefore investigated [247] whether citicoline could influence apoptotic mechanisms following focal cerebral ischemia. A model of permanent distal occlusion of the middle cerebral artery was used in Sprague-Dawley rats. Animals were randomized into 4 groups:

- B + A: citicoline 500 mg/kg i.p. 24 and 1 hours before occlusion and 23 hours after occlusion.
- A: citicoline 500 mg/kg i.p. within 30 minutes and 23 hours following occlusion.
- C: saline solution i.p.
- D: sham-operated.

Animals were killed at 12 (7 animals per group) and 24 hours (7 animals per group) following occlusion. Immunohistochemistry for procaspases 1, 2, 3, 6, and 8 was performed using goat polyclonal antibodies and, using gel electrophoresis and Western blotting, specific substrates for caspase action were tested using poly-ADP-ribose polymerase (PARP) antibodies. Ischemia induced expression of all procaspases and PARP in both the infarction and the penumbra areas 12 and 24 hours following ischemia. Citicoline reduced expression of all procaspases at 12 and 24 hours following ischemia, except for procaspase 3 at 24 hours in group A and PARP expression (Fig. 7), and results were more clear in group B + A, suggesting a certain prophylactic role of citicoline, results that have been confirmed recently [248]. Citicoline has been shown to be able to inhibit certain intracellular signals involved in apoptotic processes [249] and to maintain these inhibitory effects in different experimental models to study apoptotic mechanisms [135,208,250-254].

Fiedorowicz et al. [255] found that citicoline can attenuate brain damage in a rat model of birth asphyxia.

**Figure 7.** Band densitometry analysis for PARP by western blotting in different groups of rats in the infarct zone and penumbra zone 12 and 24 h after ischaemia. <sup>a</sup> $p < 0.05$ ; <sup>b</sup> $p < 0.025$ ; <sup>c</sup> $p < 0.0001$ .



It has been demonstrated that meta-analysis provides an effective technique for the aggregation of data from experimental stroke studies. With this technique, Bustamante et al. confirm that citicoline reduces the infarct volume and improves outcome [256], pointing doses of 300-500 mg/kg as the optimal dose to be translated into a candidate neuroprotective drug for human stroke [257].

According to Drago et al. [258], citicoline is a drug of choice for treatment of cerebrovascular diseases, particularly in its chronic form, because its clinical use is justified by the pharmacological actions it exerts on the central nervous system. To sum up, citicoline (Fig. 8):

- Interferes positively with the brain energy metabolism.
- Stimulates central neurotransmission.
- Activates cell repair mechanisms
- Decreases ischemic lesion size.
- Inhibits apoptosis associated to ischemia.
- Has synergistic effects with thrombolytic and neuroprotective drugs.


These characteristics confer citicoline a suitable pharmacological profile for the treatment of cerebral ischemia [34,35,259-261]. Also it has been

postulated a role of citicoline in the treatment of complications of infectious diseases, such as cerebral malaria [262,263].

### Synaptic transmission, intracellular signalling systems and neurotransmitter levels

As previously discussed, citicoline exerts some of its effects through its action on the levels of certain neurotransmitters and on some intracellular signalling processes. This section will discuss these specific effects upon neurotransmission and on intracellular signalling processes. As will be seen below, most studies have focused on analyzing the effect of citicoline on central dopaminergic transmission and on nicotinic cholinergic neurotransmission.

Martinet et al. [264] conducted a study in which the effects of citicoline administration on norepinephrine, dopamine, and serotonin levels were assessed in different rat brain regions. For this, conversion of <sup>3</sup>H-tyrosine and <sup>3</sup>H-tryptophan, administered by the intravenous route, into <sup>3</sup>H-norepinephrine, <sup>3</sup>H-dopamine, and <sup>3</sup>H-serotonin was measured, comparing the results obtained with administration of saline to those obtained after


**Figure 8.** Ischaemic cascade. Darkest boxes show the processes where citicoline has demonstrated pharmacological effects.

administration of citicoline at different doses. Metabolism of each neurotransmitter was studied in the brain regions where it has functional activity. Thus, for catecholamines citicoline action was studied in the striate body, brain cortex, and mid-brain, while for serotonin the hypothalamus was also studied. The synthesis rate of dopamine, norepinephrine, and serotonin was expressed as a conversion index equal to the ratio between the amount of labelled neurotransmitter per gram of brain (cpm/g) and the tyrosine- or tryptophan-specific radioactivity (cpm/mmol) in brain. As shown in figure 9, citicoline significantly increased dopamine levels and synthesis rate in the striate body, and the effect exerted on tyrosine levels was very similar. Norepinephrine levels were increased in cortex, but showed no changes from control in the brain stem. As regards effects on serotonin, the drug was seen to cause decreases in the levels and synthesis rate of this neurotransmitter in the brain stem and hypothalamus, and no changes were seen in the cortex or striate. According to these authors,

increased dopamine synthesis could be attributed to an enhancing effect of citicoline upon tyrosine hydroxylase activity, the rate-limiting step in dopamine synthesis. This activation of tyrosine hydroxylase would lead to an inhibition of dopamine reuptake at the synapse, an action that has been shown in *ex vivo* studies [265,266]. By contrast, the increase seen in dopamine synthesis does not appear to be related to increased levels of tyrosine, since this completely saturates tyrosine hydroxylase under physiological conditions. The effects of citicoline upon striatal dopamine synthesis are particularly interesting because changes in dopamine synthesis by extrapyramidal dopaminergic neurons are in the origin of Parkinson disease.

Saligaut et al. [267] obtained results in agreement with the previous ones when studying dopamine reuptake in synaptosomes taken from the striate body of rats previously treated with citicoline. Following long-term treatment with this drug, a decreased dopamine reuptake by synaptosomes was seen, and authors related this fact to the in-

**Figure 9.** Influence of citicoline (30 mg/kg i.v.) on catecholamine synthesis at different time points after administration. The graphs show variations in catecholamine concentrations and rates of synthesis, in percentages with respect to the control, at different locations. ● Corpus striatum; ■ Cortex; ▲ Brainstem-mesencephalon; <sup>a</sup> $p < 0.1$ , <sup>b</sup> $p < 0.05$ ; <sup>c</sup> $p < 0.01$ .



crease in tyrosine hydroxylase activity, that would involve an increased dopamine synthesis. They think that a structural change in neuronal membranes, mainly of phospholipid levels, could be one of the factors responsible for the change in synaptosomal reuptake of the neurotransmitter induced by citicoline. Hypobaric hypoxia was also seen to antagonize the inhibitory effect of citicoline on dopamine reuptake by synaptosomes. This antagonism may be explained by the fact that hypoxia decreases activity of tyrosine hydroxylase, an enzyme that requires oxygen, thus counteracting enzyme activation exerted by citicoline. This leads to a decreased dopamine synthesis and a subsequent increase in dopamine reuptake. These same authors studied

citicoline action in the experimental oxotremorine-induced cholinergic syndrome in mice [268], and showed that citicoline pretreatment does not potentiate this syndrome, but inhibits salivation induced by oxotremorine. Levodopa antagonized brain symptoms such as tremor-akinesia induced by oxotremorine. However, this antagonism disappeared in animals under long-term oral treatment with citicoline, thus confirming the action of citicoline on dopaminergic pathways. Citicoline effects appear to be mediated by hypersensitivity of some dopaminergic receptors, rather than by a direct stimulating effect on striatal dopaminergic receptors. In another series of experiments, these authors examined the effects of citicoline on catecholamine metabolism in the striate and hypothalamus from rats subjected to acute hypobaric hypoxia [269]. The results show that citicoline partially counteracts the effects of hypoxia upon the release and metabolism of certain neurotransmitters. In another study, Saligaut et al. analyzed the effects of citicoline in rats with unilateral nigrostriatal lesion induced by 6-hydroxydopamine [270]. In damaged animals, amphetamine administration induced an ipsiversive circling behavior, while such circling behavior was contraversive with administration of levodopa and apomorphine. This appears to be mediated by the development in the damaged side of a supersensitivity of postsynaptic dopaminergic receptors. Subchronic treatment with citicoline did not induce behavioral effects. Citicoline did not change the stimulating effect of apomorphine, but potentiated the effects of levodopa and amphetamine. These data show that citicoline effects are mediated by a presynaptic mechanism. Although potentiation of levodopa may not be explained by an activation of tyrosine hydroxylase, this effect appears to be related to an improved release of dopamine synthesized from exogenous levodopa.

Cansev et al. [271] found that peripheral administration of citicoline increases plasma adrenaline and noradrenaline concentrations. Also CDP-choline modulates monoaminergic [272] and cholinergic [273] transporters in rat brain.

Agut et al. [274] indirectly studied the effect of citicoline upon dopamine synthesis in the striate body by measuring local levels of dopamine metabolites in animals in which blockade of dopaminergic receptors had been induced by administration of haloperidol. Pretreatment with citicoline 100 mg/kg/d/5 d significantly increased levels of homovanillic acid (HVA) and 3,4-dihydroxyphenylacetic acid (DOPAC) in the striate of treated animals as compared to the control group. Increase in



**Table I.** Decrease in temperature for each batch studied relative to time zero, expressed as the mean for  $n = 20$ .

Batch	Drugs	Time		
		+ 30 min	+ 60 min	+ 90 min
A	Water (10 mL/kg v.o.) Apomorphine (1 mg/kg s.c.) Haloperidol (0.5 mg/kg i.p.)	1.19 ± 0.23	0.61 ± 0.17	0.19 ± 0.15
B	Citicoline (0.1 g/kg v.o.) Apomorphine (1 mg/kg s.c.) Haloperidol (0.5 mg/kg i.p.)	1.39 ± 0.18 <sup>b</sup>	0.74 ± 0.17 <sup>a</sup>	0.38 ± 0.14 <sup>b</sup>
C	Water (10 mL/kg/5 d v.o.) Apomorphine (1 mg/kg s.c.) Haloperidol (0.5 mg/kg i.p.)	1.13 ± 0.22	0.63 ± 0.25	0.26 ± 0.12
D	Citicoline (0.1 g/kg/5 d v.o.) Apomorphine (1 mg/kg s.c.) Haloperidol (0.15 mg/kg i.p.)	1.11 ± 0.25	0.70 ± 0.19	0.41 ± 0.12 <sup>b</sup>

<sup>a</sup>  $p < 0.05$ ; <sup>b</sup>  $p < 0.01$  vs. controls.

levels of these metabolites was even stronger in a group of animals also receiving apomorphine. Results obtained in this study suggest that citicoline increases dopamine synthesis in the striate of rats in which activation of such synthesis has been experimentally induced by haloperidol administration. This same investigating team subsequently conducted a study to examine whether citicoline alone, without provoking an increased dopamine demand by dopaminergic receptors, caused an increased synthesis of this neurotransmitter, resulting in increased striatal levels of its main metabolites, HVA and DOPAC [275].

Action of citicoline upon the dopaminergic system has also been studied by investigating its pharmacological actions in experimental models used for that purpose, such as hypothermia induced by apomorphine, tardive dyskinesia induced by haloperidol, or acrylamide-induced lesion. Agut et al. [276] studied the effect of citicoline administration on hypothermia induced by apomorphine, considered to be the result of the agonist action of apomorphine on  $D_2$  receptors. Experimental animals received, in addition to apomorphine, haloperidol at a sufficient dose to partially block apomorphine-induced hypothermia in order to obtain a pharmacological system sensitive to citicoline action upon the dopaminergic system. A group of animals received a dose of citicoline 100 mg/kg p.o., and haloperidol 0.15 mg/kg was administered at 30 minutes

by the intraperitoneal route. Thirty minutes later, rectal temperature was measured and apomorphine 1 mg/kg was administered by the subcutaneous route. Rectal temperature was again measured at 30, 60, and 90 minutes. Another group of animals received water instead of citicoline using the same scheme. Effects of chronic administration of citicoline at a dose of 100 mg/kg/d p.o. for 5 days were also analyzed. The same protocol as for acute administration was followed on the last day. Table I shows the mean temperature decrease seen in each animal batch and at the different evaluation time points. Acute administration of citicoline causes hypothermia, that is significant for all control time points. Chronic administration only achieves a significant result at 90 minutes. Authors concluded that a 100 mg/kg dose of citicoline administered acutely by the oral route has a hypothermizing effect similar to the one reported for various dopaminergic agonists. On the other hand, they considered that the fact that chronic citicoline administration only caused a significant hypothermia in the last time point analyzed probably reflects that, with this form of administration, the tested product predominately acts upon phospholipids rather than acetylcholine synthesis. This second action pathway of citicoline would predominate with acute administration, as this would involve a relatively rapid utilization of the choline provided, that would be used for acetylcholine syn-

thesis, thereby increasing tyrosine hydroxylase activity through cholinergic interneurons. By contrast, chronic administration of citicoline would result in a progressively greater availability of cytidine, and would therefore divert cerebral choline toward the synthetic pathway of citicoline and phospholipids, which would indirectly result in a dopaminergic agonistic effect. These authors developed an experimental model of tardive dyskinesia induced by haloperidol (2 mg/kg/d/7 d) in rats in a study including chronic administration of haloperidol or water to a total of 120 animals [277], finding that the administration of citicoline plus apomorphine in rats treated with haloperidol induced a motor activity similar to the activity seen in the group receiving citicoline only. Data provided in this study show that, in a model of haloperidol-induced dopaminergic hypersensitivity, administration of oral citicoline induces hypermotility; this may induce a phenomenon of competition against other agonists, leading to a partial reduction of the effect of apomorphine in animals pretreated with citicoline. In the model of acrylamide-induced lesion, these same authors [278] showed that administration of low oral doses of citicoline, 50 mg/kg, is effective for correcting the neurological syndrome induced by acrylamide. Simultaneous administration of both substances, inducing an obvious weight loss in mice, has also been shown to cause an activation of the dopaminergic system, as seen in the results obtained with the apomorphine stereotype test.

Shibuya et al. [279] measured, using fluorometry, striatal dopamine levels after administration of citicoline in a single dose of 500 mg/kg i.p., and found that a significant ( $p < 0.05$ ) increase occurred in striatal dopamine levels one hour after injection. On the other hand, Stanzani [280] showed citicoline to have a neuroprotective effect in substantia nigra, noting how citicoline protects this area against lesion induced by (horseradish) peroxidases, achieving an increased number of surviving cells. Porceddu and Concas [281] also reported a trophic and/or stimulating effect of citicoline upon nigrostriatal dopaminergic neurons in a model of lesion induced by kainic acid. Also there are experimental studies showing the protective effect of citicoline in cultures of dopaminergic neurons exposed to 6-hydroxydopamine [282], MPP<sup>+</sup> [283,284], and glutamate [283]. Miwa et al. [285] suggested that citicoline may act as a dopamine reuptake inhibitor after administration of a single dose, and that this drug may change the activity of dopaminergic neurons through changes in

compositions of the neuronal membrane following repeated administration. In addition, these authors found citicoline to have certain muscarinic effects. In this regard, Giménez et al. [286] showed that chronic administration of citicoline to aged mice promotes partial recovery of the function of dopaminergic and muscarinic receptors, that normally decreases with aging, and think that this action may be explained based on mechanisms involving fluidity of neuronal membrane, in agreement with the results obtained by Petkov et al. [287]. This latter investigating team, when comparing the effects of citicoline to those of the nootropic drugs adafenoxate and meclofenoxate upon the levels of the cerebral biogenic monoamines norepinephrine, dopamine, and serotonin in the frontal cortex, striate, hippocampus, and hypothalamus of rats [288], found that adafenoxate increased norepinephrine levels in striate and decreased norepinephrine levels in hypothalamus, increased dopamine levels in the cortex and hypothalamus and decreased them in the striate, and increased serotonin levels in the cortex but decreased them in the hippocampus. Meclofenoxate induced decreases in norepinephrine levels in the cortex and hypothalamus, while it increased dopamine levels in hippocampus and hypothalamus, and serotonin levels in the cortex, striate, hippocampus, and hypothalamus. Administration of citicoline has also recently been shown to increase dopamine levels in the retina [289]. Mao et al. [290] showed that an intraperitoneal injection of citicoline could retard the myopic shift induced by form deprivation in guinea pigs, which was mediated by an increase in the retinal dopamine level. Citicoline increases norepinephrine levels in cortex and hypothalamus, dopamine levels in striate, and serotonin levels in cortex, striate, and hippocampus, having a slightly different profile as compared to nootropic drugs. As regards action of citicoline upon norepinephrine, a study by López G.-Coviella et al. [291] showed that administration of citicoline increased total urinary excretion of 3-methoxy-4-hydroxyphenylglycol, reflecting noradrenergic activity, in rats and humans, suggesting that citicoline increases norepinephrine release. Recently, citicoline has also been experimentally shown to be able to influence the relationship between excitatory (glutamate) and inhibitory (GABA) amino acids at the brain cortex of rats [292]. A series of experiments assessed the potential of citicoline to produce a central cholinergic activation. Intracerebroventricular administration of citicoline was shown to cause an increase in levels of vasopressin [293] and other pituitary hor-

mones [294], due mainly to central cholinergic activation. Same effect has been demonstrated after intravenous administration [295]. Citicoline has also been shown to have a pressor effect in cases of hypotensive animals [296], or even in cases of hypotension due to hemorrhagic shock [297,298]. Also a contribution of the central histaminergic system is involved in this effect of citicoline [299]. The central cholinergic activating effect exerted by citicoline was again emphasized, involving this effect to explain the cardiovascular [300-303] and metabolic effects [304-307] of the drug. Citicoline also modulates cerebral metabolism through glutamate-linked enzyme activities [308]. Ilcol et al. [309] observed that citicoline treatment alters serum lipid responses to endotoxin and prevents hepatorenal injury during endotoxemia through a nicotinic acetylcholine receptor mediated mechanism. CDP-choline attenuates scopolamine induced disruption of prepulse inhibition in rats thanks to the involvement of central nicotinic mechanisms [310]. Yilmaz et al. [311] showed that citicoline administration restores the abnormalities in the primary, secondary, and tertiary hemostasis and prevents the development of disseminated intravascular coagulation during experimental endotoxemia in dogs probably by increasing both neuronal and nonneuronal cholinergic activity.

Also citicoline has antinociceptive effects involving the cholinergic system [312-314], opioid and GABA receptors [315,316], the arginine-vasopressin system [317], and the Na<sup>+</sup>/K<sup>+</sup> ATPase activity [318].

Citicoline also modulates conditioned avoidance response and quetiapine-induced metabolic syndrome in rats [318]. Citicoline, administered prior to thiopental sodium anesthesia, can improve brain function by decreasing the duration of lack of response to corneal reflex and also increasing the effect on analgesia duration [319], and a significant increase in heart and respiration rate, an insignificant increase in SPO<sub>2</sub> and an insignificant decrease of rectal temperature in animals [320]. Citicoline also has a protective effect in models of epilepsy induced by xylocaine [321] and pentylene-tetrazol [322,323], but not when the epilepsy is induced by pilocarpine [324].

In reference to the intracellular signalling systems, it has been demonstrated an effect of citicoline on the following systems:

- Platelet-activating factor [325,326].
- MAP kinase [249].
- ERK1/2 [213,226].
- Rho/Rho-kinase [327].

- Calpain [135].
- Phospholipase-thromboxane [328].
- Phospholipase-prostaglandin [329].
- Proinflammatory cytokines [330-332].

To sum up, the effects of citicoline in the experimental models used to reveal pharmacological actions upon the dopaminergic system have been studied. Citicoline has been shown to act as a dopaminergic agonist, and has a particularly significant effect upon levels of dopamine and its metabolites in the corpus striatum. The results obtained suggest that, with citicoline administration, striatal dopamine synthesis is increased, probably through tyrosine hydroxylase activation. Increase in dopamine levels would partly result from inhibition of dopamine reuptake, possibly related to citicoline action upon phospholipids synthesis. In addition, citicoline also has some effects upon the other monoamines, serotonin and norepinephrine, muscarinic and nicotinic receptors, and glutamate, opioids and GABA, together to important modulating effects on several intracellular signalling processes.

### Learning performance, memory, and brain aging

It has been shown that hypobaric hypoxia decreases learning performance in rats undergoing sound avoidance conditioning, and that this effect may be antagonized by pretreatment with apomorphine or other dopaminergic agonists. These effects of hypoxia appear in relation to an inhibition of metabolism of cerebral catecholamines that would be ultimately responsible for an understimulation of central postsynaptic dopaminergic receptors. Based on these assumptions, Saligaut and Boismare [192] conducted a study on the effects of citicoline administration upon learning performance in rats subjected to hypobaric hypoxia. Under hypoxic conditions, citicoline was administered at 300 mg/kg/d for 12 days to a group of rats that underwent learning tests of a sound avoidance conditioning in the last 5 days of treatment. Effects seen in this group were compared to those seen in another group receiving apomorphine 0.5 mg/kg 30 minutes before each daily conditioning session and to those recorded in animals receiving both treatments. A group of animals acted as control and received an ascorbic acid solution under the same experimental conditions. Citicoline partially restored learning performance. The same effect, but to a lesser extent, was seen with administration of apomorphine and with combined administration

of both drugs. These results suggest that administration of citicoline counteracts, as with dopaminergic agonists, the effects of hypoxia. Previously we commented the protective effect of citicoline against the cognitive impairment induced by chronic cerebral hypoperfusion [231].

Drago et al. [333] administered citicoline 10-20 mg/kg/d i.p. for 20 days to 24-month-old Sprague-Dawley male rats from a strain showing cognitive and motor deficits. The drug was also given to rats with behavioral changes induced by a single injection of scopolamine, a cholinergic antagonist, by prenatal exposure to methylazoxymethanol, or by bilateral injections of kainic acid into the magnocellular basal nuclei. In all cases, citicoline improved learning and memory performance, evaluated using active and passive avoidance tests. In the old rat group, improved motor capacity and coordination was also seen. For these authors, these results suggest that citicoline affects the central mechanisms involved in cognitive behavior, probably through a cholinergic action.

In a model of scopolamine-induced memory impairment, Petkov et al. [334] showed citicoline to be able to prevent amnesia induced by scopolamine. Subsequently, Mosharraf and Petkov [335] showed that citicoline 100 mg/kg completely prevented amnesia induced by scopolamine, as did the association of citicoline 50 mg/kg and piracetam 500 mg/kg, also causing a significant increase in retention. Authors suggested that this effect is mediated by drug actions on neurotransmission. Takasaki et al. [336] suggest that CDP-choline has ameliorative effect on the impairment of spatial memory induced by scopolamine, reducing the neuronal death and improving the impaired cholinergic signal. Citicoline acts as a memory-enhancing drug, and this effect is particularly marked in animals with memory deficits [337]. On the other hand, Álvarez et al. [338] showed that citicoline antagonized amnesia induced by bromazepam in rats. Bruhwyler et al. [339] found that chronic administration of citicoline has facilitating effects on learning and memory processes in dogs, but does not affect the established capacities and does not show, in this model, any effect on the motor, neurovegetative, or motivational systems. According to these authors, this represents an argument in favor of the selectivity of drug action in memory processes. Citicoline has even been shown to have a protective effect against amnesic disorders in aged animals [340] and in animals in isolation conditions [341] when administered as a dietary supplement, as well as in spontaneously hypertensive rats [342].


There are multiple morphological, neurochemical, and physiological changes characterizing brain aging in mammals. General agreement exists between investigators on the existence of aged-related changes in certain neurochemical parameters, such as enzyme activity, receptor binding, and neurotransmission. Biochemical evidence is available of the existence of a component of cholinergic dysfunction and impaired cerebral phospholipids metabolism in the pathophysiology of brain aging [1,4,5]. De Medio et al. [343] investigated the effects of citicoline upon changes in lipid metabolism in the brain during aging. Thus, they measured *in vivo* lipid synthesis in different brain areas from 12-month-old male rats. For this, they administered, by injection in the lateral cerebral ventricle, a mixture of (2-<sup>3</sup>H)glycerol and (Me-<sup>14</sup>C) choline, as lipid precursors, and measured, 1 hour after isotope administration, incorporation of these precursors into the fractions of total lipids, water-soluble intermediates, and choline phospholipids. In another series of experiments, citicoline was injected intraventricularly to aged rats 10 minutes before killing, and the same radioactivity tests as described above were performed. Distribution of the radioactivity contained in citicoline in the brain 10 minutes following administration showed enrichment, in the studied areas, of nucleotides and related water-soluble compounds. Incorporation of labelled glycerol, that is greatly decreased in aged rats, increased in all areas. Incorporation of labelled choline also decreases with aging, and citicoline was able to increase such incorporation in the cortex. As a result, the <sup>3</sup>H/<sup>14</sup>C ratio was increased in total lipids and in phosphatidylcholine and choline plasmalogens following citicoline treatment. Following this line of research, López G.-Coviella et al. [344] studied the effects of oral citicoline on phospholipids content in mouse brain. These authors supplemented animal diet with citicoline 500 mg/kg/d for 27 months in 3-month-old mice, and for 90, 42, and 3 days in 12-month-old mice, after which phosphatidylcholine, phosphatidylethanolamine and phosphatidylserine levels, and contents of phosphatidylinositol plus phosphatidic acid were measured in brain cortex. After 27 months of treatment, phosphatidylcholine and phosphatidylethanolamine levels significantly increased by 19% and 20% respectively, while phosphatidylserine levels increased by 18%, but statistical significance was not reached (Fig. 10). Similar increases were noted when 12-month-old animals were treated for 3 months, but not with shorter treatment periods. These results suggest that

chronic administration of citicoline may have significant effects on phospholipid composition of the brain that may partly be responsible for the reported therapeutic efficacy of this drug. Wang and Lee [345] obtained similar results in their study. Platarras et al. [346] showed citicoline to be able to restore activity of hippocampal acetylcholinesterase and  $\text{Na}^+/\text{K}^+$  pumps, involving these mechanisms in the improvement of memory performance exerted by citicoline. Zhang et al. [347] suggest the citicoline could play a role in improving memory performance and exert protective effects against Alzheimer's disease by increasing expression or activity of  $\text{Na}^+/\text{K}^+$ -ATPase. Giménez et al. [348] showed that citicoline, administered for 2 months to aged rats, caused a significant activation of cytidine triphosphate:phosphocholine cytidyltransferase, which according to authors would explain the reparative effects of the drug on damaged membranes of aged animals. This same investigating team made a more extensive study of the effects of citicoline on the activity of this enzymatic system and showed that, in addition to its effect on phospholipid metabolism, citicoline also has a regulatory effect upon platelet activating factor levels in the brain [325,326]. All such effects occur with no changes in plasma levels of homocysteine, a known risk factor [349]. However, citicoline also offers beneficial actions on brain metabolism of nucleic acids and proteins [345,350-352], on dopaminergic, nicotinic and muscarinic receptors [299], and on neuroendocrine and neurosecretory changes [353-355] in experimental aging models, as well as a neuroprotective effect against neurotoxic aggressions [356-362], an immunomodulatory effect [363], and an antiapoptotic effect [364,365] in various models of neurodegeneration and cerebrovascular dementia. Because of such actions, various studies have shown the positive effects of citicoline on learning and memory in aged animals [339,366,367]. Based on these effects and the effects on neuroplasticity [368] and on proliferation and differentiation of astroglial cells [10,369] it has been postulated the use of citicoline in neurodegenerative diseases, but there are some exceptions, such the no protective effect of the drug in a model of Huntington's disease [370] and in a model of amyotrophic lateral sclerosis [371].

### Experimental withdrawal syndrome and intoxications

If citicoline 300 mg is injected by the intracarotid route to cats, effects similar to those seen with administration of 2 mg of morphine by the same

**Figure 10.** Effect of chronic administration of citicoline on the brain titres of phospholipids in 30-month-old mice fed a dietary supplement with citicoline (500 mg/kg/day) or placebo for 27 months. <sup>a</sup>  $p < 0.05$ ; <sup>b</sup>  $p < 0.01$ .



route are obtained. The animal shows symptoms of anger and alertness, and the tail is placed in a rigid and upright position. This finding led to think that both substances could have some parallel effects at neuroreceptors of endogenous opiates, and that administration of citicoline could be of value in the opiate withdrawal syndrome by slowing the effects of sudden drug discontinuation [372]. Tornos et al. [373] studied the effects of citicoline administration upon experimental withdrawal syndrome by analyzing various methods, such as the jumping test in mice and studies of the behavior and body temperature changes in rats. The withdrawal syndrome caused by administration of naloxone to morphine-dependent mice was assessed based on the number of jumps by the animals. A decrease in severity was seen in the group of animals treated with citicoline 2 g/kg p.o. as compared to the untreated animal group. This decreased severity of the withdrawal syndrome was demonstrated by a 39% decrease in the mean number of jumps by the animals within 10 minutes of administration of the opiate antagonist. Similarly, the behavioral study in morphine-dependent rats showed that adminis-

tration of an oral dose of citicoline 2 g/kg at the same time as naloxone was able to significantly decrease the severity of manifestations that characterize the withdrawal picture provoked. As regards hypothermia caused by naloxone administration in morphine-dependent rats, administration of a single oral dose of citicoline neutralizes such effect almost completely.

Characteristic findings of fetal alcohol syndrome include delayed maturation and late development of dendrites in neocortex, hippocampus, and cerebellum. Based on these data, Patt et al. [374] conducted a study to investigate the effects of citicoline on Purkinje cells from rats newborn from alcoholic dams, showing that this stabilizing agent of neuronal membranes decreases the harmful effect of alcohol on the central nervous system. Wang and Bieberich [375] demonstrated that prenatal alcohol exposure triggers ceramide-induced apoptosis in neural crest-derived tissues concurrent with defective cranial development and that treatment with CDP-choline may alleviate the tissue damage caused by alcohol. Petkov et al. [376] have also shown that citicoline decreases mnemonic deficits in rats pre and post-natally exposed to alcohol, which may be related with the beneficial effects upon acetylcholine synthesis and release shown using cerebral microdialysis in rats chronically exposed to alcohol [377, 378]. Citicoline has also shown a protective effect in nicotine intoxication [379] and in mercury intoxication [380].

## Toxicity

### Acute toxicity

Acute toxicity from single citicoline administration has been studied in various animal species and using different administration routes. The intravenous LD<sub>50</sub> in mice, rats, and rabbits is 4.6, 4.15, and 1.95 g/kg, respectively [381,382]. Oral LD<sub>50</sub> is 27.14 g/kg in mice and 18.5 g/kg in rats [383]. The intravenous LD<sub>50</sub> of citicoline is approximately 44 times higher than the LD<sub>50</sub> of choline hydrochloride at equivalent doses, and it has been shown that choline doses inducing cholinergic crises do not cause any toxicity sign when equivalent doses of citicoline are administered [384,385]. This suggests that administration of choline has metabolic implications clearly different from those of exogenous choline administration. The administration of 2000 mg/kg of citicoline p.o. during 14 days was well tolerated [386].

### Subacute toxicity

Intraperitoneal administration to rats of doses up to 2 g/kg/d of citicoline for 4.5 weeks did not result in clinical toxicity signs or significant changes in the hematological, biochemical, or histological parameters analyzed. A slight decrease in intake and weight gain was only seen from 2 weeks of the study [383]. Similar results were seen following subcutaneous administration to male rats of up to 1 g/kg for 4 weeks [382]. Oral administration of 1.5 g/kg/d to rats for 30 days did not cause weight, hematological, biochemical, or histological changes [387].

### Chronic toxicity

Chronic oral (1.5 g/kg/d for 6 months in dogs) and intraperitoneal (1 g/kg/d for 12 weeks in rats) toxicity studies did not reveal either significant abnormalities related to drug administration [382,388]. Intravenous administration of citicoline 300-500 mg/kg/d for 3 months in dogs only caused toxic signs immediately after injection, including vomiting and occasional diarrhea and sialorrhea [385]. In a 90-day study in rats, 100, 350, and 1000 mg/kg/day oral doses resulted in no mortality. In males, slight significant increases in serum creatinine (350 and 1000 mg/kg/day), and decreases in urine volume (all treated groups) were observed. In females, slight significant increases in total white blood cell and absolute lymphocyte counts (1000 mg/kg/day), and blood urea nitrogen (BUN) (100 and 350, but not 1000 mg/kg/day) were noted. A dose-related increase in renal tubular mineralization, without degenerative or inflammatory reaction, was found in females (all treated groups) and two males (1000 mg/kg/day). Renal mineralization in rats (especially females) is influenced by calcium:phosphorus ratios in the diet. A high level of citicoline consumption resulted in increased phosphorus intake in the rats, and likely explains this result [386].

### Teratogenicity

Citicoline was administered to albino rabbits at a dose of 800 mg/kg during the organogenesis phase, *i.e.* from days 7<sup>th</sup> to 18<sup>th</sup> of pregnancy. Animals were killed on day 29, and a detailed examination was made of fetuses and their mothers. No signs of maternal or embryofetal toxicity were seen. Effects on organogenesis were imperceptible, and only a slight delay in cranial osteogenesis was seen in 10% of treated fetuses [unpublished data].

## Pharmacokinetics

### Plasma level curves. Bioavailability

Labelled citicoline (methyl  $^{14}\text{C}$ ) was administered to rats at a dose of 4 mg/kg by jugular vein injection and by the oral route using a nasogastric tube [389]. The results obtained, expressed as percent radioactivity in 10 ml of blood for each administration route, are shown in Table III. From these data, the ratio between bioavailability of the oral and the intravenous administration route was estimated and found to be virtually one, which agrees with the fact, demonstrated in the same study, that no residual radioactivity is found in feces excreted in the 72 hours following oral administration.

López G.-Coviella et al. [390] studied the effects of citicoline on plasma levels of cytidine, choline, and citicoline in healthy volunteers receiving the substance by the oral or intravenous route and in rats treated by the intravenous route. Two hours following administration of a single oral dose of citicoline 2 g, choline plasma levels increased 48%, and cytidine plasma levels 136% (Fig. 11). In individuals receiving three 2 g doses at 2-hour intervals, choline plasma levels reached a peak, representing approximately 30% of baseline value, 4 hours after administration of the initial citicoline dose, while cytidine plasma levels increased up to 6 hours (Fig. 12) and were 5-fold higher than the baseline value ( $p < 0.001$ ). Citicoline administered by the intravenous route was rapidly hydrolyzed in both humans and rats [391]. In healthy individuals receiving a citicoline infusion of 3 g in 500 ml of physiological saline over 30 minutes, citicoline levels were virtually undetectable just after the end of the infusion period, when plasma levels of cytidine and choline reached a peak, though their concentrations remained significantly increased up to 6 hours after the start of infusion (Fig. 13). These observations show that citicoline, administered by both the oral and intravenous routes, is converted into two major circulating metabolites, cytidine and choline. However, plasma cytidine is converted in humans to uridine, its circulating form, that is transformed in the brain to uridine phosphate, that will in turn be converted to cytidine triphosphate at neuronal level [392].

### Tissue diffusion and distribution. Transport and metabolism

Tissue diffusion of citicoline and its components has been studied in rats intravenously adminis-


**Table II.** Blood kinetics of the total radioactivity of 4 mg/g methyl  $^{14}\text{C}$ -citicoline after oral or intravenous administration to male rats. The percentages of radioactivity (mean  $\pm$  SD) with respect to the total administered are shown.

Time	Oral route	Intravenous route
10 min	0.26 $\pm$ 0.12	3.05 $\pm$ 0.24
20 min	0.40 $\pm$ 0.02	2.59 $\pm$ 0.31
30 min	0.74 $\pm$ 0.01	1.47 $\pm$ 0.22
1 h	1.32 $\pm$ 0.40	1.40 $\pm$ 0.02
2 h	2.33 $\pm$ 0.63	2.84 $\pm$ 0.02
3 h	3.31 $\pm$ 0.86	2.50 $\pm$ 0.05
4 h	3.57 $\pm$ 0.88	2.77 $\pm$ 1.00
5 h	4.17 $\pm$ 0.83	3.37 $\pm$ 0.31
6 h	4.18 $\pm$ 0.03	3.68 $\pm$ 0.02
7 h	3.81 $\pm$ 0.73	–
24 h	2.48 $\pm$ 0.40	3.12 $\pm$ 0.19


tered (methyl  $^{14}\text{C}$ , 5- $^3\text{H}$ ) citicoline, labelled in the choline and the cytidine fraction [393,394]. In the same battery test, plasma radioactivity levels were measured for 30 minutes following administration. Renal and fecal excretion of labelled metabolites was also measured for 48 hours. As early as 2 minutes following injection, less than 10% of administered radioactivity was found in plasma. In addition, radioactivity excreted by the kidney during the first 48 hours only accounted for 2.5% of  $^{14}\text{C}$  and 6.5 % of  $^3\text{H}$  administered. In the same time interval, fecal excretion did not exceed 2% of the administered dose. These results suggest that citicoline rapidly diffuses to tissue following administration, and is actively used by tissues. Figure 14 shows the radioactivity levels found in liver, brain, and kidney at different time points following intravenous administration of dually labelled citicoline. There is a special interest in changes in brain levels. Radioactivity uptake by the brain gradually increases for the first 10 hours after drug administration, and the levels achieved remain unchanged at 48 hours.

In a group of animals, radioactivity levels of the labelled compounds were measured in the brain at 0.5, 1, 4, and 48 hours of administration of dually labelled citicoline. Radioactivity corresponding to

**Figure 11.** Plasma concentrations of choline and cytidine immediately after administration of a single oral dose of 2 g citicoline in humans.



**Figure 12.** Plasma concentrations of choline and cytidine immediately after administration of three consecutive oral doses (2 g) in humans.




$^3\text{H}$  in the brain was mainly concentrated in cytidine nucleotides at the beginning, but subsequently concentrated in nucleic acids. As regards compounds labelled with  $^{14}\text{C}$ , the highest levels initially corresponded to betaine, choline, and phosphorylcholine, while at 4 hours  $^{14}\text{C}$ -methionine and  $^{14}\text{C}$ -phospholipids accounted for 26.4% and 24.2% respectively of total cerebral radioactivity corresponding to  $^{14}\text{C}$ . At 48 hours, this radioactivity mainly concentrated in phospholipids and proteins. Thus, labelled phospholipids were seen to continuously increase in the 48 hours following administration of dually labelled citicoline. As shown in figure 15, such increase is fast in the first 5 hours, but then becomes slower.

In another test battery, the presence of the drug in various brain areas and its distribution in cerebral ultrastructures was measured following administration of (methyl  $^{14}\text{C}$ ) citicoline [395-399]. In a study performed with high-performance autoradiography in mouse brain 24 hours following administration of labelled citicoline [395], the radioactive marker was seen to be widely incorporated into the different cerebral areas studied, brain cortex, white matter, and central grey nuclei. It was found in both intra and extracellular spaces, with a particular presence in cell membranes. In the same experimental model, but 10 days following administration of the labelled drug [396], concentration of radioactivity in the more myelinated areas was seen, as well as a marked uptake by the cerebellar Purkinje cells. Using low-performance autoradiography, distribution of radioactivity of labelled citicoline in rat brain was analyzed 5 and 24 hours after drug administration [397]. At 24 hours, most radioactivity was detected at intracellular level. In another study, incorporation of radioactivity from (methyl  $^{14}\text{C}$ ) citicoline after oral administration to male Sprague-Dawley rats was analyzed in the different cerebral phospholipid fractions [398]. Of total radioactivity measured in brain, 62.8% was found to be part of brain phospholipids, particularly phosphatidylcholine and sphingomyelin, showing that citicoline administered by the oral route has an effect upon the synthesis of structural phospholipids of cell membranes. These results agree with those obtained by Aguilar et al. [399], who showed radioactivity from labelled citicoline to be associated to cytoplasmic and mitochondrial membranes in brain homogenate.

In conclusion, these studies showed that the citicoline administered is widely distributed in brain structures, with a rapid incorporation of the choline fraction into structural phospholipids, and



**Figure 13.** Concentrations of choline, cytidine and CDP-choline in human plasma after intravenous infusion of a solution of citicoline (3 g/500 mL physiological saline solution).



of the cytosine fraction into cytidine nucleotides and nucleic acids. Citicoline reaches the brain and incorporates actively into the cytoplasmic and mitochondrial cell membranes, being part of the structural phospholipid fraction [391,400,401].

### Elimination route and kinetics

When labelled citicoline is administered by either the oral or intravenous route, radioactivity is eliminated very slowly by the urinary or fecal route and in expired CO<sub>2</sub> [402].

Figure 16 shows total radioactivity excretion for the 5 days following oral administration of <sup>14</sup>C-citicoline to healthy volunteers. Table III gives the main data on the elimination kinetics of the product.

Two phases are differentiated in urinary elimination of the drug: a first phase, lasting approximately 36 hours, in which excretion rate decreases rapidly, and a second phase in which excretion rate decreases much more slowly. The same occurs with expired CO<sub>2</sub>, whose elimination rate decreases

rapidly for the first 15 hours, approximately, after which a slower decrease is seen.

### Clinical experience

#### Head injury and sequelae

The above reported experimental studies showed that administration of citicoline led to a significant regression of brain edema and improvements in the electroencephalographic tracing and impairment of consciousness, as well as in survival quality. The effect on consciousness level is attributable to the facilitating action of the electroencephalographic arousal reaction, induced by stimulation of the ascending reticular activating system at brain stem level.

Based on these experimental assumptions, many clinical trials have been conducted to verify if these effects have some implications for treatment of patients with traumatic brain injury (TBI).

**Table III.** Most significant parameters in the elimination kinetics of <sup>14</sup>C-citicoline after oral administration. Data show the means of six individuals.

Parameters	CO <sub>2</sub>	Urine	Faeces
Maximum rate of excretion (% dose/h)	1.22 ± 0.59	0.159 ± 0.084	0.021 ± 0.008
Time of maximum excretion (h)	1.60 ± 0.73	1.3 ± 0.8	56 ± 18
First phase of elimination			
Apparent half-life	2.58 ± 0.60	6.62 ± 1.28	–
Apparent rate of elimination (% dose/h)	0.279 ± 0.055	0.107 ± 0.017	–
Second phase of elimination			
Apparent half-life (h)	56.22 ± 33.39	71.08 ± 58.16	19.39 ± 6.63
Apparent rate of elimination (% dose/h)	0.030 ± 0.049	0.013 ± 0.006	0.039 ± 0.014

In 1967, Moriyama et al. [403] published their study on the effects of citicoline in 25 patients with head injury and depressed consciousness. The drug was shown to be effective, leading to recovery from neurological clinical symptoms and return to a conscious state, in 70% of cases, and was very well tolerated, causing no side effects.

Ayuso and Saiz [404] conducted a double-blind study on the value of citicoline in mnesic dysfunction induced by bilateral electroshock in a series of 22 patients admitted to hospital for an endogenous depression. The group receiving active drug had a lower reduction in memory performance after four electroshock sessions as compared to the control group, thus showing the value of citicoline for treatment of patients with memory disorders of an organic base.

De la Herrán et al. [405] compared the effects of citicoline administration in a series of 50 patients with an impaired level of consciousness, of a traumatic origin in 32 cases, to another series of patients with similar characteristics who were receiving standard treatment. 34% of patients recovered consciousness within 48 hours. After a few days, 66% of patients had recovered consciousness. These results were better than those achieved in the control group. With these results, authors showed that citicoline reactivates and accelerates normalization of the consciousness stated in patients with head injury.

Carcassonne and LeTourneau [406] conducted a double-blind study in a series of 43 children with a true consciousness disorder of a traumatic origin, after excluding severe cases and those requiring surgical treatment. After analyzing the results obtained, these authors arrived to the following conclusions:

- Citicoline is very well tolerated, both locally and systemically.
- Citicoline significantly accelerates recovery of a normal consciousness state.
- Citicoline accelerates disappearance of neuropsychological disorders and cerebral electrogenesis disorders.
- Citicoline confers a better quality to the course of patients.

Espagno et al. [407] compared the effects of citicoline versus placebo in a series of 46 patients who had sustained a head injury. For this, authors conducted a double-blind study in which 22 patients received citicoline 250 mg/d by the parenteral route for 20 days, while 24 patients were given placebo. The results obtained showed that, in mild coma, citicoline significantly accelerated ( $p < 0.05$ ) recovery of consciousness, while in more severe coma and at the administered dose, that is currently considered to be highly inadequate, citicoline improved prognosis, so that 75.2% of patients in the placebo group showed a late recovery (> 15 days) of consciousness and/or progressed to death. By contrast, in the group treated with the active product, recovery from coma beyond the 15th day occurred in 31% of cases, and incidence of prolonged coma and/or death was 12.5%. In conclusion, citicoline resulted in an earlier recovery of consciousness and an increased number of clinical and electroencephalographic improvements, and was also very well tolerated.


Richer and Cohadon [408] conducted a double-blind study in a group of 60 patients with coma of a traumatic origin who were distributed into two homogeneous groups, one of which was given the ac-

tive drug, and the other placebo. As regards coma duration, the number of patients who had recovered consciousness at 60 days was significantly greater ( $p < 0.01$ ) in the group treated with citicoline. After 90 days, a greater recovery ( $p < 0.04$ ) from the motor deficit was found in the citicoline-treated group. Gait recovery was also shown to be significantly accelerated in the active drug group. As a result, a greater social and occupational reinsertion was found at 60 days in the group treated with citicoline ( $p < 0.06$ ). This demonstrated the limiting effect of duration of posttraumatic coma of citicoline, as well as its participation in restoration of deficits related to the brain lesions associated to such coma. However, there were no changes in mortality associated to the treatments.


Lecuire and Duplay [409], in a double-blind trial, compared the effects of citicoline, at an intravenous dose of 750 mg/d, to those of meclofenoxate at 3 g/d i.v. in a group of 25 patients. An analysis of the results showed a significant improvement in the patient group treated with citicoline, particularly as regarded recovery of consciousness, electroencephalographic changes, and functional recovery. Mean coma duration was 10 days in the citicoline group, as compared to 20 days in the meclofenoxate group. At 10 days, electroencephalographic tracings had improved in 50% of citicoline-treated patients and in 18% of patients given meclofenoxate. Citicoline was therefore shown to be superior to meclofenoxate, and its main characteristic was accelerated recovery of the consciousness level, that is related to improvement in the electroencephalographic tracing. These same authors carried out an open label study in a series of 154 patients with head injury [410]. This study assessed the effects of citicoline treatment and found the drug to accelerate patient arousal and recovery from deficit syndromes, and to improve the quality of survival. Lecuire [411] subsequently performed a double-blind study comparing piracetam (6 g/d) versus citicoline (750 mg/d) in a group of 40 patients sustaining head injury and found a favorable course in 75% of patients in the citicoline group, as compared to 33% in the piracetam group.

Cohadon et al. [16,412] showed the clinical efficacy of citicoline in a double-blind study conducted on a series of 60 patients with severe head injury. A standard treatment was used in both groups, and surgery was performed when required. A group of patients was given citicoline 750 mg/d by the intravenous route for the first 6 days, and subsequently by the intramuscular route for an additional 20 days. The other group was administered placebo.


**Figure 14.** Concentrations of radioactivity in the liver (a), brain (b) and kidneys (c) of rats at different time points after injecting double-labelled citicoline at a dose of 2 mg/kg. All values represent the means obtained from 10 animals.



**Figure 15.** Evolution of  $^{14}\text{C}$ -phospholipid concentrations in rat brains after intravenous administration of double-labelled citicoline. The concentrations represent the means of three animals and are expressed as a percentage of the total radioactivity corresponding to  $^{14}\text{C}$  in the brain.



**Figure 16.** Total excretion of radioactivity (percentage of total administered) for 5 days after oral administration of  $^{14}\text{C}$ -Citicoline. The mean values of six individuals are shown.



Clinical evaluation was continued up to 6 months. At 15 days, response to painful stimuli was already superior in the group of citicoline-treated patients

( $p < 0.01$ ), in which an earlier recovery of consciousness was also seen (Fig. 17). Authors also noted a greater recovery from neurological deficits in the active group. After 120 days, autonomous ambulation was seen in 84% of patients in the citicoline group, as compared to 62.5% of patients in the placebo group. This difference was statistically significant from day 60 ( $p < 0.01$ ). Table IV shows the final outcome obtained in both groups, as assessed using the Glasgow Outcome Scale (GOS). The mortality rate was similar in both groups. Data reported in this study show that citicoline shortens the time elapsed to recovery of consciousness and accelerates recovery from neurological deficits in patients with severe head injury.

Deleuze et al. [413] reported that citicoline is able to decrease serum creatine phosphokinase (CPK) levels and lactate levels in cerebrospinal fluid (CSF), with a decrease in the lactate/pyruvate ratio, in patients with severe brain distress and coma. They also emphasized that the product was very well tolerated.

Ogashiwa et al. [109] conducted a clinical trial in 101 patients with disorders of consciousness from different causes (20% of traumatic origin), showing the effectiveness of citicoline for improving the General Recovery Rate, closely related to the Principal Component Analysis Score. Authors found citicoline to be more effective in items related to the executive factor than in those related to the verbal factor, and that the greatest effect was achieved in patients less than 60 years of age and with a stabilized period of impaired consciousness not longer than 3 weeks. They also emphasized the excellent tolerability of the product, and even administered it by the intrathecal route in some cases [414,415].

At the Department of Neurosurgery of the 'Ramón y Cajal' Special Center in Madrid, a series of 100 patients with head injury treated with citicoline until discharge were studied, and their results were compared to those of another series of 100 patients with similar characteristics, but who did not receive citicoline [416]. Treatment with citicoline was started at doses of 600-1200 mg/d by the parenteral route, switched to 300-900 mg/d by the oral route in the rehabilitation phase. The course was monitored by assessing mean coma duration, persistence of neurological and psychic symptoms, the WAIS test, and electrophysiological studies of muscle tension. Results achieved suggested that citicoline addition to the treatment regimen caused a decrease in duration of posttraumatic coma and rate of both neurological and psy-

chic sequelae, and achieved a better response in recovery from intellectual disorders and motor deficits.


Raggueneau and Jarrige [417], in a national survey conducted in France, recorded 921 cases of severe head injury, *i.e.* with an initial score in the Glasgow Coma Scale (GCS) of 8 or less. Of these, 219 patients had been treated with citicoline, which allowed for distribution into two groups to compare the results obtained. No significant differences were found in mortality, but differences were seen in the number of dependent states, and the greatest effect was found in patients with an initial GCS score of 6-7 (Fig. 18). Citicoline improved quality of survival, allowing for more frequent social and familiar reinsertion, as well as return to work or school. Mortality in head injuries essentially depends on initial lesions which, except for epidural hematoma, are beyond any real therapeutic resolution.

Calatayud et al. [418] reported the results of the influence of citicoline addition to the treatment of head injury. Two hundred and sixteen patients with an initial GCS score ranging from 5 and 10 were reported. Of these, 115 patients received treatment with citicoline. Mean citicoline dose administered was 4 g/d. Analysis of the results showed that citicoline:

- Decreased hospital stay ( $p < 0.05$ ) and duration of outpatient follow-up ( $p < 0.001$ ), with differences being more marked in the group of patients with an initial GCS score ranging from 5 and 7.
- Promoted the recovery of memory, motor disorders, higher neurological functions, and mood changes.
- Improved global functional outcome (Table V).

Lozano [419] reported the impact of citicoline therapy on the course of posttraumatic cerebral edema in a study conducted in 78 cases of head injury with an initial GCS score ranging from 5 and 7. In all cases, a computerized tomography of the head was performed at the start and end of the study to assess changes in the tomographic image of cerebral edema. Other parameters investigated included duration of hospital stay and the extent of autonomy at hospital discharge. Citicoline was administered to 39 patients for the first 2 weeks at a dose ranging from 3 and 6 g/d by intravenous infusion. After 14 days of treatment with citicoline, image of cerebral edema evolved as shown in figure 19. Cerebral edema had been reduced or normalized in a higher number of patients treated with

**Figure 17.** Normalisation of the state of consciousness in relation to time and treatment;  $p < 0.01$  at day 60.




**Table IV.** Final results according to treatment.

	Glasgow Outcome Scale				
	I	II	III	IV	V
Placebo group	12	5	4	3	6
Citicoline group	11	9	3	2	5

citicoline as compared to control patients, with differences being highly significant ( $p < 0.005$ ). No significant differences were seen between both groups in therapeutic requirements or treatments received. Mean hospital stay was  $28.718 \pm 21.6$  days for the group receiving active treatment and  $37.323 \pm 35.22$  days for the control group, with statistically significant differences ( $p < 0.001$ ). Differences in final outcomes assessed according to the GOS did not reach statistical significance due to the low number of cases and the special characteristics of this type of patients. However, a trend was seen to a more favorable resolution in the group of patients treated with citicoline (Table VI).

**Figure 18.** Effect of treatment with citicoline on final results. Results are expressed as percentages. <sup>a</sup>  $p < 0.001$  vs. patients not treated with citicoline.



**Table V.** Final result, evaluated with the Glasgow Outcome Scale (GOS), in relation to treatment ( $p < 0.05$ ).

	Citicoline	Control
GOS I	77	51
GOS II	19	31
GOS III	1	7
GOS IV	0	2
GOS V	18	10

**Table VI.** Final result, evaluated with the Glasgow Outcome Scale (GOS), in relation to treatment (n.s.).

	Citicoline	Control
GOS I	15	11
GOS II	8	8
GOS III	6	7
GOS IV	4	6
GOS V	6	7

Levin [420] conducted a study in 14 patients with postconcussional syndrome following a mild to moderate head injury. This syndrome is characterized by the occurrence of symptoms such as headache, dizziness, mnesic disorders, and sleep disturbances mainly. In this study, patients treated with citicoline for one month experienced an improvement in memory tests, particularly recognition tests, that was statistically significant as compared to placebo. Figure 20 shows changes in symptoms after one month of treatment. Greater improvements were achieved in patients treated with citicoline as compared to placebo patients, except for gastrointestinal discomfort. Dizziness was significantly more common in patients from the placebo group after one month of study. However, in a simple-blind study in patients with mild head injury [421], the authors were unable to evidence differences between citicoline and control with regards to the evolution of the postconcussional symptoms. Despite that, CDP-choline is considered a therapeutic option for postconcussional syndrome [422].

León-Carrión et al. [423-425] investigated in a series of studies the effects of citicoline on post-


traumatic memory disorders. In a group of 7 patients with severe memory deficits, these authors investigated the effects of administration of citicoline 1 g on cerebral blood flow (CBF), as measured by the <sup>133</sup>Xe inhalation technique. Two measurements were made, one at baseline and the other at 48 hours, under the same conditions, except that patients had taken the drug one hour before the test. All patients showed a significant hypoperfusion at the inferoposterior area of the left femoral lobe in the first measurement, that disappeared following citicoline administration. In a second study, 10 patients with severe memory deficits were randomized into two groups. Both patient groups were subjected to a short memory rehabilitation program. A group received citicoline 1 g/d p.o. for the 3 months the neuropsychological treatment program lasted, while the other group was given placebo. The results obtained are shown in Table VII. Neuropsychological rehabilitation associated to citicoline achieved improvements in all evaluated areas, reaching statistical significance in verbal fluency and the word recall Luria test. CDP-choline is considered as a valid therapeutic option for the

treatment of post-traumatic cognitive impairments [426], improving also the quality of survival [427].

A Cochrane review of citicoline for the treatment of head injury will be available [428]. In 2012, the COBRIT trial was published [429,430], registered as NCT00545662. The Citicoline Brain Injury Treatment Trial (COBRIT), a phase 3, double-blind randomized clinical trial conducted between July 20, 2007, and February 4, 2011, among 1213 patients with the objective to determine the ability of citicoline to positively affect functional and cognitive status in persons with complicated mild, moderate, and severe TBI. Patients were randomized to a 90 days regimen of daily enteral or oral citicoline (2000 mg) or placebo. The main outcome was the functional and cognitive status, assessed at 90 days using the TBI-Clinical Trials Network Core Battery. A global statistical test was used to analyze the 9 scales of the core battery. Secondary outcomes were functional and cognitive improvement, assessed at 30, 90, and 180 days, and examination of the long-term maintenance of treatment effects. The main outcome was the functional and cognitive status, assessed at 90 days using the. A global statistical test was used to analyze the 9 scales of the core battery. Secondary outcomes were functional and cognitive improvement, assessed at 30, 90, and 180 days, and examination of the long-term maintenance of treatment effects. Rates of favorable improvement for the Glasgow Outcome Scale-Extended were 35.4% in the citicoline group and 35.6% in the placebo group. For all other scales the rate of improvement ranged from 37.3% to 86.5% in the citicoline group and from 42.7% to 84.0% in the placebo group. The citicoline and placebo groups did not differ significantly at the 90-day evaluation: global odds ratio (OR): 0.98 (95% CI: 0.83-1.15); in addition, there was no significant treatment effect in the 2 severity subgroups: global OR, 1.14 (95% CI: 0.88-1.49) and 0.89 (95% CI: 0.72-1.49) for moderate/severe and complicated mild TBI, respectively). At the 180-day evaluation, the citicoline and placebo groups did not differ significantly with respect to the primary outcome: global OR, 0.87 (95% CI: 0.72-1.04). According with the results obtained, the authors concluded that, among patients with TBI, the use of citicoline compared with placebo for 90 days did not result in improvement in functional and cognitive status.


The COBRIT trial is the largest study performed with citicoline in this indication, but there are several methodological issues that question seriously the validity and applicability of the results obtained. This study was an independent study, fi-

**Figure 19.** Evolution of the tomographic image of cerebral oedema after 14 days of treatment ( $p < 0.005$ ).



nanced by the US National Institute of Health, with a limited budget. A first point to consider is the sample size calculation. The authors chose an OR of 1.4 as the effect of the treatment, when in the most recent publications; the size of the effect of citicoline has been 1.26 in acute ischemic stroke patients, a less heterogeneous pathology than TBI. It appears that the sample size was calculated based on the number of patients that could be afforded and then the OR of the treatment was established accordingly, rather than basing it on the effects of the drug. A more conservative and realistic OR of 1.2 or less would result in a sample size which was much higher but that would likely have been unaffordable for the authors. Another point to consider is that the authors mixed different populations, confusing mild, moderate and severe TBI. The pathophysiology, localization, and trajectory for recovery can be very different among these groups. One means of avoiding this would have been to use a randomized, matched sample design. This mixing of lesion severity is a clear source of heterogeneity and would have to be considered an important confounding factor in the analysis and interpretation of the data. Also the oro-enteral administration of citicoline used in this trial is com-

**Figure 20.** Evolution of post-concussional symptoms after one month of treatment with citicoline or placebo. The number of patients reporting each symptom is shown.



**Table VII.** Scores (mean ± SD) obtained by patients before and after treatment.

	Group A (placebo + rehabilitation)		Group B (citicoline + rehabilitation)	
	Before	After	Before	After
Attention	95.60 ± 5.73	97.60 ± 2.19	82.00 ± 33.79	90.80 ± 20.57
Alertness	88.40 ± 8.65	96.80 ± 1.79	89.60 ± 17.74	98.80 ± 1.79
Verbal fluency	22.40 ± 9.91	23.60 ± 11.01	24.80 ± 14.65	31.80 ± 9.36 <sup>a</sup>
Benton test	8.20 ± 3.63	9.40 ± 6.95	8.80 ± 5.45	7.20 ± 3.70
Luria test	62.80 ± 13.24	62.00 ± 11.58	63.20 ± 17.31	71.00 ± 12.98 <sup>a</sup>

<sup>a</sup>  $p < 0.05$  vs. before treatment.



pletely atypical, is not approved in any country, has not previously been scientifically tested and additionally is not appropriate for many of the patients enrolled in the study. But the most controversial point is the poor compliance of the treatment. A compliance of only 44.4% of patients having taken more than 75% of the medication expected is very low and needs to be explained. Not receiving the active treatment is not the same as receiving the placebo, in terms of the standard of care being received. This means that less than half of the patients received something close to a therapeutic dose of citicoline. Thus, the COBRIT trial is not the definitive study on citicoline, especially when the methodological confounds just described are taken into consideration.

Given the controversy after the publication of the COBRIT trial, a meta-analysis has been published [431] to assess the real efficacy of citicoline in the treatment of TBI patients. Systematic search of the relevant terms was performed on Medline, Embase, and Ferrer database (the company marketing the product in a number of countries) to identify all published, unconfounded, comparative clinical trials of citicoline in acute phase head injured patients. Studies were identified by searching electronic databases, scanning reference lists of articles, and consulting with experts in the field and at the pharmaceutical company (Ferrer). To be included in the meta-analysis, the trials must assess the effect of citicoline in the acute phase of TBI, be comparative studies and have independence outcomes, evaluated with the Glasgow Outcome Scale (GOS) or similar scales. All trials randomizing patients of any age or sex were included. No restrictions were applied in regard to doses, route of administration or duration of treatment. No restrictions regarding language, publication date or publication status was applied. The primary efficacy measure was patient independence at the end of a scheduled follow-up period, evaluated as a score GOS 4-5, reflecting an excellent outcome or with mild sequelae, that guarantee an independence status after the TBI. The systematic search detected 23 clinical trials, but only 12 were considered valid for the meta-analysis. The included studies involved 2706 patients with mild, moderate, or severe TBI treated in the acute phase with citicoline or not. The doses of citicoline ranged from 250 mg to 6 g per day, administered orally or parenterally. The duration of the treatment ranged from 7 to 90 days. According to the formal meta-analysis, based on random effect model (Fig. 21), the use of citicoline is associated with a significant increase in the

rates of independence with an OR of 1.815 (95% CI: 1.302-2.530), but a significant heterogeneity ( $I^2 = 54.6\%$ ;  $p = 0.001$ ) was detected, reflecting the time gap of 34 years between the studies included in the meta-analysis. The meta-analysis under the fixed-effects model obtains an OR of 1.451 (95% CI: 1.224-1.721), reinforcing the results obtained. Recently a new meta-analysis has been published [432] showing neutral effects of CDP-choline in the treatment of patients with TBI, but this meta-analysis is based only in studies published in English, and that is a well-known source of bias, enough to question the results obtained.

In the last years new studies published found a significant effect of citicoline in the recovery of patients with severe head injuries [433], especially in patients with diffuse axonal injuries [434-436].


As a final conclusion, it has been shown that patients who have sustained a head injury, particularly those with an initial GCS score of 5-7, benefit from the addition of citicoline into their therapeutic regimen because this drug accelerates cerebral oedema reabsorption and recovery of both consciousness and neurological disorders, resulting in a shorter hospital stay and improved quality of survival, with a bigger degree of Independence. These effects could be explained by the pharmacodynamics of the product and its pleiotropic effect on the mechanisms involved in the development of the traumatic brain injury [437,438].

### Acute cerebrovascular disease and sequelae

The neurobiological processes involved in the pathophysiology of the cerebral ischemia are extremely complex [439]. For this reason, some authors postulate the need to use multifunctional treatments for this disease [440-445], for intracerebral hemorrhages [446,447], and for the recovery phase [448,449]. As experimentally shown, citicoline is a drug having pleiotropic actions including activation of neuronal metabolism, stabilization of neuronal membranes and their function, and normalization of neurotransmission [15,34-36,167,259,260]. Various studies with citicoline conducted in the 60s suggested its efficacy to reduce neurological symptoms in patients with cerebral ischemia [450,451].

Hazama et al. [452] conducted a double-blind study to assess the effect of citicoline on functional recovery from hemiplegia in 165 patients with cerebrovascular disease. These authors showed that citicoline, at a dose of 1000 mg/d for 8 weeks, was superior to placebo, particularly for motor re-

**Figure 21.** Forest plot of the meta-analysis of the effects of citicoline on independence after traumatic brain injury, based on the random-effects model: odds ratio, 1.815 (95% CI: 1.302-2.530). Reprinted with permission from J.J. Secades. *Citicoline for the treatment of head injury: a systematic review and meta-analysis of controlled clinical trials.* *J Trauma Treat* 2014; 4: 227. doi:10.4172/2167-1222.1000227.



covery in the upper limbs, and concluded that citicoline promotes natural recovery from hemiplegia.

Goas et al. [453] conducted a double-blind study comparing citicoline (750 mg/d/10 d i.v.) versus placebo in 64 patients with cerebral infarction starting less than 48 hours before. Assessment at 3 months showed citicoline to be superior to placebo for improving motor deficit ( $p < 0.05$ ), hypertonia ( $p < 0.03$ ), gait recovery ( $p < 0.02$ ), changes over time in electroencephalographic tracing ( $p < 0.01$ ) and psychometric tests ( $p < 0.05$ ), achieving a higher number of independent states (51.6% with citicoline; 24.24% with placebo) (Fig. 22). In a study with the same characteristics, Boudouresques et


al. [454] achieved similar results. This study included 52 patients, of whom 27 patients received citicoline (750 mg/d/10 d i.v.) and 25, placebo. An assessment was made at 10 days, and showed that citicoline-treated patients had a better course as regarded consciousness disorders, with recovery of consciousness in 66.7% of cases as compared to 32.0% in the placebo group ( $p < 0.01$ ), and also deficit syndromes (82.6% and 54.5% of patients recovered with citicoline and placebo respectively;  $p < 0.04$ ) and electroencephalographic tracings (83.3% with citicoline versus 35.3% with placebo;  $p < 0.01$ ). In both studies, citicoline tolerability was rated as excellent by investigators.

Corso et al. [455], in a double-blind study of citicoline (1 g/d/30 d i.v.) versus placebo in a sample of 33 patients, noted that at the end of the study the deficit syndrome had improved in 76.5% of patients treated with citicoline ( $p < 0.01$  versus placebo), while an improved electroencephalographic tracing was seen in 70.6% of patients ( $p < 0.01$  versus placebo).

Tazaki et al. [456] performed a double-blind, prospective, multicentre, placebo-controlled study on the value of citicoline for the treatment of acute cerebral infarction. Sixty-three Japanese academic centers participated in this study, in which a total of 272 patients were enrolled following strict inclusion criteria. Patients were randomized to receive 1 g/d i.v. of citicoline or saline (placebo) for 14 days. At the end of treatment, citicoline was shown to significantly improve consciousness (51% versus 33% for placebo;  $p < 0.05$ ) and overall improvement (52% versus 26%;  $p < 0.01$ ) and overall usefulness rates (47% versus 24%;  $p < 0.001$ ). In addition, fewer complications occurred in the citicoline-treated patient group (1%) as compared to the placebo group (8.1%). These authors concluded that citicoline is an effective and safe drug for the treatment of acute cerebral infarction. These results agree to those reported by other authors [457-460].

Guillén et al. [461] reported a comparative, randomized study on the efficacy of citicoline for treating acute ischemic stroke as compared to conventional therapy, showing a significantly higher improvement in the citicoline group as compared to the control group. In the open label studies by Bruhwylter et al. [462] and Fridman et al. [463], results favoring citicoline were also achieved, with a significant clinical improvement of patients and an excellent safety profile of the drug. Alviarez and González [464] reported the beneficial effects with citicoline in a double-blind study conducted in Venezuela. León-Jiménez et al. [465] evaluated the correlation between citicoline exposure and functional outcome at discharge and at 30 and 90 days post-stroke, in a retrospective case-control design on systematic descriptive databases from three referral hospitals in Mexico. Clinical records of 173 consecutively registered patients were analyzed, 86 of whom were treated with citicoline within the first 48 h after acute ischemic stroke and the remaining 87 were untreated, randomly selected controls matched for age ( $\pm 5$  years), gender and NIHSS ( $\pm 1$  point) at hospital admission. Pretreatment conditions were similar between groups. Compared with controls, exposure to citicoline was associated with a significantly lower 30-day

**Figure 22.** Outcome in relation to treatment, highlighting the number of good results achieved with citicoline compared to the control group.



mean and median modified Rankin score (in both,  $p < 0.05$ ). After paired multivariate analyses (controlled for NIHSS, age, gender, hospital arrival in  $< 24$  h, thrombolysis and comorbidities) citicoline was independently associated with a lower 90-day mortality risk ( $p = 0.047$ ) and with fewer in-hospital complications (mainly infections and sepsis,  $p = 0.001$ ). In this observational study, citicoline use was associated with a better functional status and lower rates of short-term mortality, possibly due to fewer in-hospital systemic complications.

In the second half of the 90s, study of oral citicoline for the treatment of acute ischemic stroke was started in the United States. The first clinical trial was a randomized, dose-response study [466]. This double-blind, randomized, multicentre study compared 3 citicoline doses (500, 1000, and 2000 mg by the oral route) to placebo to document drug safety, find the optimum dose, and collect data on the efficacy of citicoline for the treatment of acute ischemic stroke. A total of 259 patients with ischemic stroke in the territory of the middle cerebral artery were recruited within 24 hours of the start of symptoms. Patients were randomized into four

groups: administration of placebo or 500, 1000, or 2000 mg/d of oral citicoline for 6 weeks. Patient recovery at the end of the 6-week treatment period and after a subsequent follow-up period of 6 additional weeks was assessed. The main efficacy endpoint was Barthel Index (BI) at 12 weeks. Secondary endpoints included the modified Rankin Scale (mRS), the National Institutes of Health Stroke Scale (NIHSS), the Mini-Mental Status Examination (MMSE), hospital stay duration, and mortality. A significant difference favoring citicoline was found between the groups in functional status (BI, mRS), neurological assessment (NIHSS), and cognitive function (MMSE). In a regression analysis of BI including as covariate baseline NIHSS score, a significant effect of citicoline treatment was found at 12 weeks ( $p < 0.05$ ). The proportions of patients who achieved a BI score ranging from 85 and 100 were 39.1% for placebo, 61.3% for the 500 mg dose, 39.4% for the 1000 mg dose, and 52.3% for the 2000 mg dose. Odds ratios for an improved outcome were 2.0 for the 500 mg dose and 2.1 for the 2000 mg dose. The lack of efficacy seen in the 1000 mg group could be due to the greater overweight of patients included in this group and their poorer neurological status at baseline. Mean score in the mRS was 3.1 with placebo, 2.5 with citicoline 500 mg, 3.1 with 1000 mg, and 2.6 with 2000 mg, with a significant difference being found between the 500 mg and placebo groups ( $p < 0.03$ ). No citicoline-related serious adverse events or deaths were seen. According to these results, oral citicoline treatment achieves a better functional outcome, and 500 mg is the most effective dose of citicoline.

A second multicentre, double-blind, placebo-controlled, randomized study [467] recruited 394 patients with acute ischemic stroke arising in the middle cerebral artery less than 24 hours before and with a NIHSS score of 5 or higher. Patients were assigned oral administration of placebo ( $n = 127$ ) or citicoline 500 mg/d ( $n = 267$ ). Treatment was continued for 6 weeks, and follow-up was subsequently conducted for 6 additional weeks. Mean entry time was 12 hours after the stroke, and mean patient age was 71 years in the placebo group and 71 years in the citicoline group. While the mean baseline NIHSS score was similar in both groups, a greater proportion of patients had a baseline NIHSS  $< 8$  (34% versus 22%;  $p < 0.01$ ). The planned primary endpoint (logistic regression for 5 BI categories) did not meet the proportional odd assumption and was therefore not reliable. No significant between-group differences were seen in any of the planned secondary variables, including a BI of 95

or higher at 12 weeks (placebo 40%, citicoline 40%) or mortality rate (placebo 18%, citicoline 17%). However, a post hoc subgroup analysis showed that in patients with moderate to severe stroke, defined by a baseline NIHSS score of 8 or higher, treatment with citicoline conferred a greater chance of achieving a complete recovery, defined as a BI  $\geq 95$  at 12 weeks (21% placebo, 33% citicoline;  $p = 0.05$ ), while no differences were found in patients with mild stroke, i.e. with a baseline NIHSS score  $< 8$ . No serious adverse events attributable to the drug were detected, which attests to its safety. Based on these data, citicoline may be considered a safe drug that may induce favorable effects in patients with moderate to severe acute ischemic stroke.

The last clinical study conducted in the US was the ECCO 2000 study [468]. This study, having similar characteristics to the previous ones, enrolled 899 patients with moderate to severe acute ischemic stroke (baseline NIHSS score = 8) arising in the middle cerebral artery within the past 24 hours. Patients were randomized to receive citicoline 2000 mg/d ( $n = 453$ ) or placebo ( $n = 446$ ) by the oral route for 6 weeks, with a subsequent follow-up for 6 additional weeks. The primary study endpoint was the proportion of patients having a reduction by 7 or more points in the NIHSS scale at 12 weeks. At the end of the study, 51% of patients in the placebo group and 52% of those in the citicoline group had achieved the reduction by 7 or more points in the NIHSS scale, with no significant between-group differences. By contrast, there was a trend favoring citicoline in achievement of a complete neurological recovery, defined by a score in the NIHSS scale of 1 or less (40% with citicoline versus 35% with placebo;  $p = 0.056$ ), and in complete functional recovery, defined by a BI score of 95 or higher (40% with citicoline versus 35% with placebo;  $p = 0.108$ ). With regard to mRS, 20% of patients in the placebo group achieved a complete recovery (mRS  $\leq 1$ ), as compared to 26% of patients in the citicoline group, the difference being statistically significant ( $p = 0.025$ ). There were no differences between treatments in mortality or incidence of serious adverse events, but a significant decrease was seen in stroke worsening (3% with citicoline versus 6% with placebo;  $p = 0.02$ ). On the other hand, occurrence of new stroke was decreased in patients treated with citicoline (2.9% with placebo versus 1.8% with citicoline, i.e. a 62.1% risk reduction). A post hoc analysis assessed the effect of citicoline in a multiple outcome global assessment, using the method of Generalized Estimating Equations (GEE) defined by Tilley et al. [469], considering the proportion of pa-

tients who had a complete recovery in all 3 scales used, i.e. achieved scores of 0-1 in the NIHSS scale, 0-1 in mRS, and  $\geq 95$  in BI at 12 weeks. Citicoline was shown to be significantly superior to placebo, achieving this complete recovery in 19% of the cases, as compared to 14% in the placebo group (OR: 1.32; 95% CI: 1.03-1.69;  $p = 0.03$ ).

Citicoline effects on reduction of cerebral infarction volume were investigated in parallel. The first analysis conducted was a pilot study to assess citicoline effects on lesion volume measured by diffusion-weighted magnetic resonance imaging (MRI) in patients with acute cerebral infarction [470]. This study recruited 12 patients from the first clinical study on citicoline in the USA [466]. Lesion growth was seen in 3 of the 4 patients treated with placebo, while a decrease in lesion volume was noted in 7 of the 8 patients treated with citicoline ( $p < 0.01$ , with baseline NIHSS score as covariate). A second, double-blind study designed for this purpose, i.e. to measure changes in lesion volume using diffusion-weighted techniques, recruited 100 patients who were randomized to receive citicoline 500 mg/d or placebo by the oral route for 6 weeks [471]. These patients should be enrolled within 24 hours of symptom start, and have a baseline NIHSS score of 5 points or more and a lesion volume in cerebral grey matter of 1-120 cm<sup>3</sup> in diffusion-weighted MRI. Neuroimaging techniques (diffusion-weighted MRI, T<sub>2</sub>-weighted MRI, perfusion-weighted MRI, and MRI angiography) were performed at baseline and on weeks 1 and 12. Main endpoint was progression of ischemic lesion from baseline to final assessment at 12 weeks as measured by MRI. The primary analysis planned could be performed in 41 patients treated with citicoline and 40 patients treated with placebo, and no significant differences were found. From baseline to 12 weeks, ischemic lesion volume expanded by  $180 \pm 107\%$  in the placebo group and  $34 \pm 19\%$  in the citicoline group. A secondary analysis showed that, from week 1 to week 12, lesion volume decreased by  $6.9 \pm 2.8$  cm<sup>3</sup> in the placebo group and by  $17.2 \pm 2.6$  cm<sup>3</sup> with citicoline ( $p < 0.01$ ). A significant finding in this study was the great correlation existing, regardless of treatment, between lesion volume reduction and clinical improvement, supporting the idea of using this methodology for assessing stroke treatments. In the ECCO 2000 study [468], a substudy was conducted to assess the effects of citicoline on lesion volume [472]. This substudy had three objectives. The first objective was to assess the effects of the drug on chronic lesion volume, as measured using MRI T<sub>2</sub> sequences in

the whole patient sample, although this assessment could only be made in 676 patients. The second objective was to analyze citicoline effects on change in lesion volume, using diffusion-weighted MRI performed at baseline and week 12. One hundred and eighty-one patients were recruited for this second objective, of whom only 134 patients were evaluable. The third objective was methodological in nature, that is, an attempt was made to correlate clinical changes to volume changes and to check if lesion volume reduction was associated to clinical improvement. No significant differences were found in assessment of chronic lesion volume (median of 25.0 cm<sup>3</sup> for citicoline; median of 31.3 cm<sup>3</sup> for placebo). The diffusion-weighted study showed that in the placebo group ( $n = 71$ ) lesion the increased  $30.1 \pm 20.5\%$ , with a median of  $-8.7\%$ , while the change occurring in the citicoline group ( $n = 63$ ) was  $1.3 \pm 14.3\%$ , with a median of  $-22.9\%$ , a non-significant difference ( $p = 0.077$ ). However, when the logarithm of change was analyzed and the baseline NIHSS score was introduced as covariate, the difference was significant ( $p = 0.02$ ). In this diffusion-weighted substudy, 54% of patients in the placebo group and 67% of citicoline-treated patients were shown to have a decreased lesion volume compared to baseline, though the difference was not significant ( $p = 0.122$ ). If patients having at baseline a cortical lesion with a volume ranging from 1-120 cm<sup>3</sup> were analyzed, a lesion increase by  $40.5 \pm 28.7\%$  was seen in patients treated with placebo ( $n = 47$ ), with a median of 4.5%, while in patients receiving treatment with citicoline ( $n = 43$ ) the lesion increased by  $7.3 \pm 19.9\%$ , with a median of  $-23.9\%$ . The difference between the groups was statistically significant ( $p = 0.006$ , median comparison). In this patient subgroup with initial cortical lesions with a volume of 1-120 cm<sup>3</sup>, a decrease in lesion volume occurred in 47% of patients in the placebo group and in 70% of patients in the citicoline group. The difference was significant, with a value of  $p = 0.028$ . The decrease in volume was also seen to be significantly correlated to the clinical improvement of patients.

Although the results obtained in studies conducted in the USA with oral citicoline for treatment of acute ischemic stroke were not conclusive for citicoline efficacy, it may be seen that, in addition to drug safety, there is a certain trend to an improved prognosis of treated patients. Since there was currently no neuroprotective drug that has been shown to be effective for the treatment of this severe condition [473], it was decided to conduct a meta-analysis of the results obtained with oral citi-

**Table VIII.** Results obtained after three months on individual scales.

	Studies (n)	Patients (n)	Peto odds ratio (95% CI)	p
NIHSS $\leq$ 1	4	1,372	1.34 (1.05-1.71)	0.020
mRS $\leq$ 1	4	1,351	1.45 (1.11-1.90)	0.007
BI $\geq$ 95	4	1,372	1.28 (1.03-1.59)	0.003

95% CI: 95% confidence interval; NIHSS: National Institutes of Health Stroke Scale; mRS: modified Rankin Scale; BI: Barthel index.

coline in the treatment of acute ischemic stroke to examine the effects of the drug on neurological and functional recovery of patients [474]. For this, following the methods of the Cochrane Library [475] and the guidelines of the International Conference on Harmonization [476], a comprehensive literature search was made in both Medline and our own literature database. This search found that only 4 double-blind, randomized clinical studies had been conducted with oral citicoline for the treatment of acute ischemic stroke, namely the 4 trials performed in the US [466-468,471]. The total sample comprised 1652 patients, 686 patients in the placebo group and 966 patients in the citicoline group (381 with 500 mg/d, 66 with 1000 mg/d, and 519 with 2000 mg/d). The first analysis was performed irrespective of the dose and in the total patient sample. As regards complete neurological recovery (NIHSS  $\leq$  1) at 3 months, the odds ratio was 1.22 (95% CI :0.98-1.52), not reaching statistical significance ( $p = 0.07$ ); by contrast, significant differences favoring citicoline were obtained in an analysis of patients who achieved a virtually complete recovery in activities of daily living (BI  $\geq$  95) at 3 months (OR: 1.26; 95% CI: 1.02-1.55;  $p = 0.01$ ) and functional recovery at 3 months, defined as a score of 1 or less in the mRS (OR: 1.36; 95% CI: 1.06-1.74;  $p = 0.01$ ). Since the experience gathered in the above clinical studies suggests that the drug is more effective in patients with moderate to severe acute ischemic stroke (baseline NIHSS  $\geq$  8), databases from the original studies were obtained, and patients who met this criterion and had an optimum functional status before the stroke (mRS  $\leq$  1) were selected. Of the whole sample, 1372 patients met these criteria and therefore underwent the same assessment. In this case, the meta-analysis found statistically significant differences for all variables analyzed (Table VIII).

To continue with analysis of these data, it was decided to perform a pooling data analysis [477], using individual data from each patient. This additional analysis included the sample of 1372 patients who met the established criteria of severity (baseline NIHSS  $\geq$  8), prior functional status (mRS  $\leq$  1), therapeutic window not longer than 24 hours, and consistent neuroimage. The efficacy endpoint selected was total recovery at 3 months in the three scales analyzed (mRS  $\leq$  1 + NIHSS  $\leq$  1 + BI  $\geq$  95), using the previously described GEE analysis [469]. Among the 1372 patients, 583 received placebo and 789 citicoline (264 patients 500 mg, 40 patients 1000 mg, and 485 patients 2000 mg). Total recovery at 3 months was achieved in 25.2% of patients treated with citicoline and 20.2% of patients in the placebo group (OR: 1.33; 95% CI: 1.10-1.62;  $p = 0.003$ ), and the dose shown to be most effective was 2000 mg. This dose resulted in complete recovery at 3 months in 27.9% of patients who received it (OR: 1.38; 95% CI: 1.10-1.72;  $p = 0.004$ ) (Fig. 23). In addition, citicoline safety was similar to placebo.

The preliminary results of a Cochrane review on the effects of choline precursors, including citicoline, in the treatment of acute and subacute stroke were reported in 2002 [478]. This meta-analysis collected data from 8 double-blind studies conducted with citicoline at doses ranging from 500 and 2000 mg daily, administered by both the oral and intravenous routes. Despite study heterogeneity, citicoline treatment was associated to decreases in late mortality and disability rates: citicoline 611/1119 (64.6%) versus placebo 561/844 (54.4%) (OR: 0.64; 95% CI: 0.53-0.77;  $p < 0.00001$ ). In order to decrease heterogeneity, analysis was restricted to the 4 studies with a greater sample size ( $n > 100$ ), and the positive effect seen persisted: citicoline 574/1048 (54.58%) versus placebo 500/773 (64.7%) (OR: 0.70; 95% CI: 0.58-0.85;  $p < 0.0003$ ). In the safety analysis, no differences were found between citicoline and placebo in the mortality rate. Authors concluded that the formal meta-analysis of citicoline studies in acute and subacute stroke suggests a beneficial and substantial effect of the drug, with absolute reductions by 10-12% in the long-term disability and mortality rate, i.e. the number of patients with a score of 3 or higher in the modified Rankin scale is significantly decreased. These results agree with those previously reported for the pooled data analysis [477].


A pooled data analysis evaluating the effect of citicoline on increase of cerebral infarction size is also available [479]. Data used in this analysis come from two studies in which neuroimaging data had

been obtained using MRI techniques [468,471]. The primary endpoint in this analysis was percent change in infarction size from the start to the end of the study at 3 months. Data were available for 111 patients receiving placebo, 41 patients treated with citicoline 500 mg/d/6 weeks, and 62 patients treated with citicoline 2000 mg/d/6 weeks. Patients receiving placebo experienced a mean increase by  $84.7 \pm 41.2\%$ , while a dose-dependent effect was seen associated to citicoline: mean increase by  $34.0 \pm 18.5\%$  with citicoline 500 mg and by  $1.8 \pm 14.5\%$  with citicoline 2000 mg.

These benefits shown in these systematic reviews were also associated to a reduction in the costs of integral treatment of patients with acute ischemic stroke [480], with average cost savings between €101.2 and €126.4 per patient treated, then in patients with acute ischemic stroke, treatment with placebo was more expensive and less effective in the scenarios of inpatient care and inpatient plus outpatient care after discharge from the hospital. Same results on cost-efficacy of citicoline have been obtained in Russia [481,482].

Sobrino et al. [483] investigate if an administration of citicoline, started in the acute phase of stroke, could increase the endothelial progenitor cell (EPC) concentration in patients with ischemic stroke. Forty eight patients with a first-ever non-lacunar ischemic stroke were prospectively included in the study within 12 hours of symptoms onset. Patients received treatment ( $n = 26$ ) or non-treatment ( $n = 22$ ) with oral citicoline (2000 mg/day/6 week). EPC colonies were quantified as early outgrowth colony forming unit-endothelial cell (CFU-EC) at admission (previous to citicoline treatment) and day 7. The EPC increment during the first week was defined as the difference in the number of CFU-EC between day 7 and admission. CFU-EC were similar at baseline between patients treated and non-treated with citicoline ( $7.7 \pm 6.1$  versus  $9.1 \pm 7.3$  CFU-EC;  $p = 0.819$ ). However, patients treated with citicoline and recombinant tissue-plasminogen activator (rt-PA) had a higher EPC increment compared to patients treated only with citicoline or non-treated ( $35.4 \pm 15.9$  versus  $8.4 \pm 8.1$  versus  $0.9 \pm 10.2$  CFU-EC;  $p < 0.0001$ ). In a logistic model, citicoline treatment (OR; 17.6; 95% CI: 2.3-137.5;  $p = 0.006$ ) and co-treatment with citicoline and rt-PA (OR: 108.5; 95% CI: 2.9-1094.2;  $p = 0.001$ ) were independently associated with an EPC increment  $\geq 4$  CFU-EC. The authors concluded that the administration of citicoline and the co-administration of citicoline and rt-PA increase EPC concentration in acute ischemic stroke. However, the molecular

**Figure 23.** Estimated probabilities (GEE analysis) of overall recovery three months after onset of symptoms. Overall recovery is defined as a consistent and persuasive difference in the proportion of patients who achieve scores of NIHSS  $\leq 1$ , BI  $\geq 95$  and mRS  $\leq 1$  at the same time.



mechanism by which citicoline increases the concentration of EPCs remains to be clarified.

Regarding safety, a drug surveillance study involving 4191 acute stroke patients treated with citicoline has been finished in South Korea [484]. The aim of this study was to determine the efficacy and safety of oral citicoline in Korean patients with acute ischemic stroke. Oral citicoline (500-4000 mg/day) was administered within less than 24 h after acute ischemic stroke in 3,736 patients (early group) and later than 24 h after acute ischemic stroke in 455 patients (late group) for at least 6 weeks. For efficacy assessment, primary outcomes were patients' scores obtained with a short form of the National Institutes of Health Stroke Scale (s-NIHSS), a short form of the Barthel Index of activities of daily living (s-BI) and a modified Rankin Scale (mRS) at enrolment, after 6 weeks and at the end of therapy for those patients with extended treatment. All adverse reactions were monitored during the study period for safety assessment. All measured outcomes, including s-NIHSS, s-BI and mRS, were improved after 6 weeks of therapy ( $p < 0.05$ ). Further improvement was observed in 125 patients who continued citicoline therapy for more

than 12 weeks when compared with those who ended therapy at week 6. Improvements were more significant in the higher dose group ( $\geq 2000$  mg/day) ( $p < 0.001$ ). s-BI scores showed no differences between the early and late groups at the end of therapy. Citicoline safety was excellent; 37 side effects were observed in 31 patients (0.73%). The most frequent findings were nervous system-related symptoms (8 of 37, 21.62%), followed by gastrointestinal symptoms (5 of 37, 13.5%). Oral citicoline improved neurological, functional and global outcomes in patients with acute ischemic stroke without significant safety concerns.

A pilot study has been published on the safety and efficacy of citicoline for the treatment of primary intracerebral hemorrhage [485]. This study recruited 38 patients aged 40 to 85 years, who should be previously independent and be enrolled within 6 hours of the onset of symptoms caused by primary intracerebral hemorrhage, as diagnosed by neuroimaging tests (CT or MRI). Patients should have a baseline severity as determined by a score higher than 8 in the Glasgow Coma Scale and higher than 7 in the NIH stroke scale. Patients were randomized to 1 g/12 h of citicoline or placebo by the i.v. or oral route for 2 weeks. The primary study objective was to assess treatment safety based on the occurrence of adverse events. The efficacy endpoint selected was the proportion of patients who had a score of 0-2 in the modified Rankin scale at 3 months. Nineteen patients were included in each of the groups, that were perfectly matched as regarded baseline characteristics. Adverse event rate did not differ between the groups (4 cases each). With regard to efficacy, a patient from the placebo group was rated as independent (mRS < 3), as compared to 5 patients from the citicoline group (OR: 5.38; 95% CI: 0.55-52; n.s.). As a conclusion, it may be stated that citicoline appears to be a safe drug in patients with primary intracerebral hemorrhage, which may allow citicoline to be given to patients with clinical signs suggesting stroke before neuroimaging tests are performed, at an earlier time than usual. As regards efficacy, highly promising data have been obtained, but should be confirmed in a larger study. Also, recently Eribal and Chua [486] communicated the results of the RICH trial performed in the Philippines. This study was conceived to investigate the role of neuroprotectants, particularly citicoline, in intracerebral supratentorial hemorrhage which to date, still has paucity of data on proven effective therapy. This was a randomized double-blind, placebo-controlled, multicentre, parallel group study on pa-

tients with first ever supratentorial intracerebral hemorrhage given either 4 gram citicoline or placebo for 14 days from index stroke. A total of 182 patients were enrolled into the study. The mean age of both groups were similar:  $56.90 \pm 11.45$  citicoline and  $57.61 \pm 11.83$  for placebo. Comorbidities were similar except for the significantly higher number of diabetes patients in citicoline group. Results showed there were more patients with favorable Barthel Index scores (2.2 versus 0, 9.2 versus 8.5, and 50.8 versus 31.9) in the citicoline group than in the placebo group respectively. However the difference was only clinically significant after day 90. Patients had favorable MRS score (7.9 versus 13.4, 18.2 versus 20.3, and 46.1 versus 33.8) in the citicoline that in the placebo group only on the day 90. This was however not statistically significant. The NIHSS did not differ in both groups with scores of 76.3 versus 75.6, 93.9 versus 91.9, and 96.8 versus 94.3 respectively. Mortality was slightly higher in the citicoline group (11 patients) than in the placebo group (10 patients) but this was not statistically significant. The incidence of adverse in both groups was not different statistically. For the authors, citicoline is effective in improving the BI, and mRS scores on the attainment of functional independence beginning on the 90th day post stroke compared to placebo. Iranmanesh and Vakilian demonstrated the efficiency of citicoline in increasing muscular strength of patients with nontraumatic cerebral hemorrhage in a double-blind randomized clinical trial [487]. Thus, citicoline could play a role in the pharmacological treatment of patients with intracerebral hemorrhages [488,489], and also in subarachnoid hemorrhage [490].


In a new study-based meta-analysis, including all the double-blind studies performed with citicoline in acute stroke patients, Saver [491,492] suggest again the beneficial effect of citicoline on the long-term death and disability in this kind of patients (Fig. 24).

Several publications from different countries about the use of citicoline in the treatment of acute stroke have been published in the last years [493-503], and, in some cases, assessing the major efficacy when associated with other neuroprotective drugs [504].

From 2006 to 2012, a large trial was conducted in Europe with the objective to corroborate the data obtained with citicoline, but under the current circumstances. This was the International citicoline Trial on acUte Ischemic Stroke, the ICTUS trial [505-508]. It was a randomised, placebo-controlled, sequential trial in patients with moderate-



**Figure 24.** Death or dependency at long-term follow-up. Forest plot meta-analysis of the effect of citicoline vs. control in trials enrolling patients with ischaemic stroke, intracerebral haemorrhage and stroke without imaging confirmation of subtype. C010: citicoline 010 trial; CI: confidence interval; CSSG: Citicoline Stroke Study Group; df: degree of freedom; Fixed: fixed-effects model; M-H: Mantel-Haenszel estimate. Reprinted with permission from J.L. Saver. *Citicoline: update on a promising and widely available agent for neuroprotection and neurorepair.* Rev Neurol Dis 2008; 5: 167-77.



to-severe acute ischaemic stroke admitted at university hospitals in Germany, Portugal, and Spain. Using a centralised minimisation process, patients were randomly assigned in a 1:1 ratio to receive citicoline or placebo within 24 h after the onset of symptoms (1000 mg every 12 h intravenously during the first 3 days and orally thereafter for a total of 6 weeks (2 × 500 mg oral tablets given every 12 h). All study participants were masked. The primary outcome was recovery at 90 days measured by a global test combining three measures of success: NIHSS ≤ 1, mRS ≤ 1, and BI ≥ 95 [507]. Safety endpoints included symptomatic intracranial haemorrhage in patients treated with recombinant tissue plasminogen activator, neurological deterioration, and mortality. This trial was registered, NCT00331890. 2298 patients were enrolled into the study. 37 centres in Spain, 11 in Portugal, and 11 in Germany recruited patients. Of the 2298 patients who gave informed consent and underwent randomisation, 1148 were assigned to citicoline and 1150 to placebo. The trial was stopped for fu-

tility at the third interim analysis on the basis of complete data from 2078 patients. The final randomised analysis was based on data for 2298 patients: 1148 in citicoline group and 1150 in placebo group. Global recovery was similar in both groups (OR: 1.03; 95% CI: 0.86-1.25;  $p = 0.364$ ). No significant differences were reported in the safety variables nor in the rate of adverse events. Thus, under the circumstances of the ICTUS trial, citicoline is not efficacious in the treatment of moderate-to-severe acute ischaemic stroke. But when the results of the ICTUS trial were placed in the context with the previous data, the interpretation of the study was that on top of the best treatment possible, citicoline does not show any clinical improvement but, as shown in the updated fixed-effects meta-analysis included in the original paper, the effect of the drug remains significant (OR: 1.14; 95% CI: 1.00-1.30). Heterogeneity coming from the older studies suggests that the beneficial effect of citicoline over time was diluted in parallel with the improvement of the standard of care of acute ischaemic stroke.

One of the points to consider interpreting the results of this study is that more than 46% of patients were treated with rTPA. Clinical guidelines for the treatment of ischaemic stroke should be updated in light of the salutary results of ICTUS [509].

A new updated meta-analysis [510] was done with to assess whether starting citicoline treatment within 14 days after stroke onset improves the outcome (measured as a mRS of 0-2 or equivalent) in patients with acute ischemic stroke, as compared with placebo. Additionally, to explore if the effect of citicoline has decreased along with improvements in the standard of care. A systematic search of the adequate terms was performed on Medline, PubMed, Embase, Cochrane Specialised Register of Clinical Trials, Clinicaltrials.gov, Internet Stroke Center and Ferrer database to identify all published, unconfounded, randomized, double-blind and placebo-controlled clinical trials of citicoline initiated within the first 24 h and up to 14 days of onset in acute ischemic stroke patients. Ten randomized clinical trials ( $n = 4436$ , but only 4420 were valid for analysis) met the inclusion and quality criteria. The studies used citicoline with doses ranging from 500 to 2000 mg administered by oral and/or intravenous route. Heterogeneity among studies was observed, reflecting the time gap of 32 years between the studies included in the meta-analysis. The administration of citicoline was associated with a higher rate of independence (Fig. 25), using as a measure the mRS of 0-2, independently of the method of evaluation used (OR: 1.56; 95% CI: 1.12-2.16 under random effects; OR: 1.20; 95% CI: 1.06-1.36 under fixed effects). The results obtained with the subgroup of patients not treated with rtPA (OR: 1.63; 95% CI: 1.18-2.24 under random effects; OR: 1.42; 95% CI: 1.22-1.66 under fixed effects), and the results of patients not treated with rtPA and receiving the highest dose of citicoline (2g/d/6 weeks) started in the first 24 h after onset (OR: 1.27; 95% CI: 1.05-1.53) demonstrated that the effect of citicoline is diluted when paralleled with improved standards of care. In conclusion, this systematic review shows the benefits of citicoline in the treatment of acute ischemic stroke, increasing the rate of independence. This effect is stronger in the case of patients not treated with rtPA. However, another meta-analysis based only on studies in chinese and english, that is with an important bias, citicoline cannot reduce long-term mortality and dependence rate in the treatment of acute stroke [511].

In the sequelar phase, some studies have been shown that citicoline potentiates the effects of mo-

tor rehabilitation [452,487,512,513]. In a published meta-analysis [514], it was shown how citicoline is able to increase the efficacy of motor rehabilitation in upper limbs in hemiplegic patients after ischemic stroke. Citicoline could play a relevant role in neurorehabilitation [515].


In conclusion, it may be stated that it has been adequately shown that patients with acute stroke, as well as with sequelae, may benefit from citicoline treatment by achieving a better functional and neurological recovery, and that this is a safe and well tolerated treatment, as recognized by various authors [516-529] and some agencies [530,531].

### Cognitive disorders

Various experimental investigations on the so-called brain aging have led in recent years to give an increasing importance to changes in neuronal metabolism as a factor involved in the pathophysiology of this process. In the senile brain there is a general decrease in enzyme activities related to energy metabolism, and also more specific biochemical changes affecting lipid and nucleic acid metabolism. It has also been shown that specific changes in certain neurotransmitters (dopamine, acetylcholine) and hormones (growth hormone, prolactin) are associated in both aging processes and certain presenile and senile diseases [532], and more recently there are several publications showing an increasing evidence of vascular risk factors as key mechanisms in the development of cognitive impairment and dementia [533-535].

As shown in the various experimental studies analyzed, citicoline increases phospholipid synthesis and glucose uptake in the brain in conditions in which these processes are decreased. Citicoline also influences metabolism of neurotransmitters, and has been shown to increase dopamine synthesis in certain brain regions. Based on these facts, many clinical trials have been conducted to assess the efficacy of citicoline in the treatment of cognitive disorders associated to brain aging, chronic cerebral vascular disease, and dementia [536]. Using magnetic resonance spectroscopy techniques, citicoline has been shown to stimulate phosphatidylcholine synthesis in the brain [537-540] and improves the energetic cerebral metabolism of elderly subjects [541], which is related to an improvement in their cognitive capacities [542], particularly memory [543-545] and reaction time [546]. In healthy volunteers, the administration of citicoline has been associated with improvement in attention

**Figure 25.** Effect estimates and 95% confidence intervals (95% CI) of the intervention with citicoline on the rates of independence (mRS score of 0-2 or equivalent) in comparison with the placebo in patients with acute ischemic stroke. Reprinted with permission from J.J. Secades, et al. *Citicoline for acute ischemic stroke: a systematic review and formal meta-analysis of randomized, double-blind, and placebo-controlled trials.* J Stroke Cerebrovasc Dis 2016; 25: 1984-96.



[547,548], memory [549,550] and in some neuro-physiological parameters [551-554].

In one of the early studies conducted in this field, Madariaga et al. [555] showed that, in a group of female senile patients, treatment with citicoline induced improvements in memory, cooperation, and capacity of relationship to the environment. Fassio et al. [556] discussed the value of citicoline in psychogeriatrics, and also stressed that use of citicoline as background treatment allows for reducing dosage of psychoactive drugs routinely used in psychogeriatrics. Many studies have shown the value of citicoline for the treatment of the so-called senile cerebral involution, decreasing its characteristics symptoms [557-566]. Lingetti et al. [557], in an open-label, controlled study conducted on a group of 30 patients with senile involutive brain disease, achieved symptomatic improvements in 83.3% of cases and emphasized the absence of treatment-related side effects. Stramba-Badiale and

Scillieri [558] were able to show a significant improvement in scores of the Fishback Mental Status Questionnaire in a group of 24 elderly subjects after 20 days of treatment with citicoline 500 mg/d i.m. Bonavita et al. [559] emphasized the efficacy of citicoline for promoting changes in some neuropsychiatric symptoms, such as memory and attention, in senile patients without causing side effects. Lozano et al. [560] reviewed a series of 2067 elderly patients treated with citicoline at doses of 300-600 mg/d for 2 months. Table IX gives the results obtained based on remission and improvement of certain neuropsychic symptoms. Palleschi and Capobianco [561] showed significant improvements in scores of the SCAG and Mini Mental State Examination scales in patients with pathological brain aging following citicoline treatment. In a multicentre study in which 502 senile patients participated, Schergna and Lupo [562] showed citicoline to induce significant improvements in atten-

**Table IX.** Percentage remission and symptomatic improvement ( $p < 0.001$  for each symptom in relation to the onset of treatment).

	Patients (n)	Remission (%)	Improvement (%)
State of mood	1521	38.2%	40.9%
Emotivity	1559	36.9%	39.7%
Restlessness	1504	41.3%	34.1%
Own initiative	1378	35.8%	32.9%
Short-term memory	1614	26.0%	45.5%
Interest in the environment	1410	38.3%	34.5%
Appearance	1132	40.0%	26.9%
Vertigo	1463	59.4%	31.3%
Mobility	1234	35.2%	30.5%
Headache	1425	57.7%	31.2%

tion, behavior, relational life, and independence. No side effects occurred associated to this treatment. Suryani et al. [563] showed citicoline to be effective for the treatment of memory deficits in the elderly, achieving significant and progressive improvements in all parameters analyzed (Table X). Citicoline has been able to improve scores of senile patients in various scales, such as the Plutchik scale [564], Trail Making Test, Randt Memory Test, and Toulouse-Piéron Attention Test [565,566].

Administration of citicoline to healthy adult individuals was shown to act upon the anterior pituitary gland, inducing an increased growth hormone secretion and a decreased prolactin secretion thanks to the activation of the dopaminergic system induced [567, 568]. Ceda et al. [569] showed that citicoline is able to increase growth hormone secretion, both basal and stimulated by the growth hormone-releasing hormone, in elderly patients. This secretion is impaired in such individuals and, to a greater extent, in patients with degenerative brain diseases.

One of the main causes of cognitive impairment in the elderly is chronic cerebral vascular disease, also called cerebral insufficiency, whose maximum degree of clinical expression is vascular dementia. A multicentre, randomized, double-blind study versus placebo assessed the efficacy of citicoline for the treatment of patients with chronic vascular disease [570]. In this study, 33 patients received treatment

with citicoline 1 g/d or saline as an intravenous infusion for 28 days. At the end of the treatment period, significant improvements were noted in the citicoline-treated group in the Bender-Gestalt test, Hamilton scale for depression, Parkside scale, neurological assessment scale, and attention test. Falchi Delitalia et al. [571] and Moglia et al. [572] noted that the clinical improvement seen was associated to an improved EEG tracing in these patients. Merchan et al. [573] showed a gradual improvement in symptoms associated to cerebrovascular insufficiency in a group of 40 elderly patients treated with citicoline at a dose of 1 g/d i.m. for 60 days.

Agnoli et al. [574] conducted a double-blind study in 100 patients with chronic cerebral vascular disease, in whom effectiveness of administration of citicoline 1 g/d/28 d i.v. compared to placebo was assessed. After the treatment period, the group of citicoline-treated patients showed statistically significant improvements in the scores obtained in the Hamilton scale for depression and in the modified Parkside behavior rating scale, as well as in the psychometric and observational tests used. It was concluded that citicoline improved perceptual-motor capacity and attention in these patients, in addition to having a stabilizing effect on behavior. Sinforani et al. [575], Motta et al. [576], and Rossi and Zanardi [577] achieved very similar results in their respective studies. The best clinical and behavioral results were seen in patients with a diffuse cerebral vascular disease [578-583].

Eberhardt and Derr [584] conducted a double-blind, crossover study to assess the efficacy and tolerability of citicoline in patients with senile cerebral insufficiency. This study enrolled 111 patients with a mean age of  $74.6 \pm 6.9$  years and a clinical diagnosis of senile cerebral insufficiency. After a placebo washout period, 2 homogeneous groups were formed, one of which received treatment with citicoline 600 mg/d p.o. for 5 weeks and placebo for 5 additional weeks, with a placebo washout period between both treatments. The reverse administration order was used in the other group. Controls were performed at 2, 7, 9, and 12 weeks. Citicoline significantly improved the clinical status in all six tests used (number recall, labyrinth, number connection, neuropsychological assessment scale or NAS, geriatric observation scale or NAB, and SCAG) as initial treatment, and provided a statistically significant additional improvement as second treatment after placebo, that achieved some degree of improvement in 5 of the 6 tests. Between-subject comparisons also showed a superior efficacy of citicoline. Table XI shows the

**Table X.** Scores for the repetition of digits, an adaptation by Wechsler of the Stanford-Benét logical history test, the Bali image memorisation test and memory deficits and physical disorders reported by patients before and after treatment with citicoline. Values are expressed as means  $\pm$  SD.

	Baseline (n = 10)	After treatment		
		1 week (n = 10)	2 weeks (n = 10)	3 weeks (n = 6)
Direct repetition of digits	14.6 $\pm$ 4.6	19.6 $\pm$ 5.6 <sup>b</sup>	20.2 $\pm$ 4.5 <sup>b</sup>	22.8 $\pm$ 6.0 <sup>b</sup>
Reverse repetition of digits	5.60 $\pm$ 4.1	7.30 $\pm$ 3.4 <sup>b</sup>	11.3 $\pm$ 7.1 <sup>b</sup>	12.1 $\pm$ 7.7 <sup>b</sup>
Logic history test	6.10 $\pm$ 4.4	9.60 $\pm$ 3.8 <sup>b</sup>	12.7 $\pm$ 3.7 <sup>b</sup>	13.6 $\pm$ 4.8 <sup>b</sup>
Bali images test	5.20 $\pm$ 3.2	9.30 $\pm$ 3.5 <sup>b</sup>	11.7 $\pm$ 3.4 <sup>b</sup>	12.0 $\pm$ 2.4 <sup>b</sup>
Memory deficits	2.5 $\pm$ 0.9	1.00 $\pm$ 0.9 <sup>a</sup>	0.30 $\pm$ 0.4 <sup>b</sup>	0.30 $\pm$ 0.5 <sup>b</sup>
Physical disorders	2.3 $\pm$ 0.9	1.00 $\pm$ 0.8 <sup>a</sup>	0.20 $\pm$ 0.6 <sup>b</sup>	0.10 $\pm$ 0.4 <sup>b</sup>

<sup>a</sup>  $p < 0.05$ ; <sup>b</sup>  $p < 0.01$ , vs. baseline values.

proportions of patients who improved in each treatment phase in both groups. No treatment-associated severe side effects were seen. Authors concluded that these results support the efficacy of citicoline for the treatment of senile cerebral insufficiency and its excellent tolerability in geriatric patients. Such benefits would be due to the capacity of citicoline to inhibit degradation of phospholipids in neuronal membranes, increase choline plasma levels, and activate the synthesis of structural phospholipids and the synthesis and release of catecholamines. Citicoline effects on test improvement were also shown to persist after switching to placebo, suggesting that they are related to the neuronal metabolic process tending to restore and maintain neuron function.

Chandra [585] reported the results of a double-blind study on the treatment of multi-infarction dementia with citicoline. The study enrolled 146 patients who were randomized into two groups, one of which received treatment with citicoline, 750 mg/d i.v., and the other saline for 2 months, though follow-up was prolonged up to 10 months. At the end of the treatment period, citicoline-treated patients showed significant improvements in the MMSE scores. By contrast, such scores slightly worsened in the placebo group. After 10 months, citicoline-treated patients had a sustained improvement, while patients in the placebo group continued to worsen.

Piccoli et al. [586] reported the results of a double-blind study conducted in 92 patients with

chronic cerebral vascular disease treated with citicoline (1000 mg/d i.m.) or placebo in 2 treatment cycles of 4 weeks each separated by a one week interval. Forty-six patients were randomized to each group, and both groups were fully matched as regarded cognitive impairment. Psychometric assessment was performed using the Toulouse-Piéron test (attention to non-verbal stimuli), Randt memory test, and SCAG scale (a measure of behavior and emotional control). A between-group comparison revealed significant improvements in the citicoline group in attention tests, with a decreased number of wrong answers in the Toulouse-Piéron test ( $p < 0.05$ ), in mnemonic capacities according to the general information subtest of the Randt memory tests ( $p < 0.05$ ), and in the affective disorder score in the SCAG scale ( $p < 0.02$ ). In addition to being clinically effective, citicoline was shown to be a very safe drug, as no adverse effects associated to treatment were detected.

Capurso et al. [587] assessed the efficacy of citicoline for the treatment of chronic cerebrovascular disease in a multicentre, double-blind, placebo-controlled study. Cognitive and behavioral functions were assessed using psychometric scales and tests in 31 patients, who were randomized to receive citicoline (17 cases) or placebo (16 cases). After a 2-week washout period, 3 treatment periods, each lasting 28 days, were started. Patients were given 1 g/d of citicoline or placebo by the intramuscular route. A 1-week washout period was left between each treatment cycle. Various cognitive func-

**Table XI.** Percentage of patients who improved in each group in relation to treatment initiation with citicoline or placebo.

	Group I		Group II	
	Citicoline	Placebo	Placebo	Citicoline
Numerical counting	47	31	21	52
Labyrinth	73	69	71	83
Numerical connection	67	76	67	87
NAS	57	41	44	69
NAB	63	57	48	67
SCAG	80	73	65	83

NAS: Neuropsychological Self-Assessment Scale; NAB: Gerontopsychological Observation Scale; SCAG: Sandoz Clinical Assessment Geriatric Scale.

tions improved in the group of citicoline-treated patients, particularly short and long-term memory. The Randt Memory Test showed a constant improvement in several subtests, and cognitive and attention efficiency also significantly improved. The GBS scale, assessing behavioral indices, also showed improvements associated to citicoline treatment. Authors concluded that patients treated with citicoline showed a significant improvement in cognitive functions, while placebo-treated patients showed no favourable trends. On the other hand, good tolerability of the drug was also reported.

However, in patients with vascular dementia according to current diagnostic criteria, Cohen et al. [588] were not able to show any beneficial effect of citicoline in their pilot study.

Using positron emission tomography, Tanaka et al. [589] correlated cognitive improvement to a significant increase in cerebral blood flow in patients with vascular dementia who received treatment with citicoline (1 g/d/1 week i.v.).


Lozano [590] reported the results of a study conducted by the Iberian-American Group for the study of Alzheimer disease and Longevity (GIAL), aimed at assessing the status and course, after one year, of a group of patients with dementia-like psychic and organic impairment following diagnosis and classification of its cause as degenerative, vascular or mixed, and treatment with oral citicoline. Citicoline 600 mg/d p.o. was administered for one year to 314 patients with a mean age of  $75.02 \pm 7.72$  years to assess the course of their dementia during

that time. Dementia was rated as degenerative in 41.1% of cases, while vascular dementia accounted for 39.5% of cases and mixed dementia for 11.4%. The MMSE and BI were used for assessment, and controls were performed at months 1, 3, and 12. MMSE scores were seen to significantly improve in vascular and mixed dementia and to remain stable, with a certain trend to improve, in degenerative dementia. Scores in the BI showed statistically significant improvements in each of the controls and for each type of dementia. These results suggest that citicoline has a beneficial effect of long-term course of dementia and is also a safe treatment.

Corona et al. [591] pointed that citicoline benefits in the treatment of patients with dementia would be partly due to the ability of the drug to improve activity of the noradrenergic, dopaminergic, and serotonergic systems, as shown by them in a study assessing changes over time in CSF and urinary levels of metabolites from the monoamines involved in these systems during treatment of patients with senile dementia of the Alzheimer type.

Cacabelos et al. [592] conducted a study to assess the therapeutic effects of citicoline in dementia patients. This study recruited 40 patients, who were distributed into 4 groups: 10 healthy elderly subjects, 10 patients with early onset Alzheimer disease, 10 patients with late onset Alzheimer disease, and 10 patients with multi-infarction dementia. These patients received treatment with citicoline at a dose of 1 g/d p.o. for 3 months. After this treatment period, all groups experienced a significant improvement in MMSE scores (Fig. 26) and a significant antidepressant effect, as assessed by the Hamilton scale for depression (Fig. 27). Patients with early onset Alzheimer disease were also found to have significantly higher interleukin 1 $\beta$  (IL-1 $\beta$ ) plasma levels at baseline as compared to all other groups, revealing the participation of a neuroimmune change in the pathophysiology of Alzheimer disease. After citicoline treatment, IL-1 $\beta$  plasma levels were normalized, which suggests that this drug has a certain immunomodulatory action. In a subsequent phase of their study, this same investigating group showed that, in patients with Alzheimer disease, citicoline not only improved cognitive function, but also cerebrovascular function, as assessed using transcranial Doppler ultrasonography [593]. The neuroimmune effect of the drug was demonstrated by the findings that citicoline therapy decreased histamine plasma levels that are abnormally elevated in patients with Alzheimer disease [594] and increases plasma levels of tumor necrosis factor alpha or TNF $\alpha$  [595].

**Figure 26.** Effects of citicoline on cognitive function assessed using the MMSE in healthy older subjects (control), patients with early-onset Alzheimer's disease (EOAD) or late-onset Alzheimer's disease (LOAD) and patients with multi-infarct dementia (MID). <sup>a</sup> $p < 0.02$ ; <sup>b</sup> $p < 0.01$ .




This same investigating group recently published the results of a double-blind, randomized, placebo-controlled, pilot study where citicoline (1 g/d/12 weeks p.o.) or placebo was administered to 30 patients with mild to moderate senile dementia of the Alzheimer type [596]. As compared to the 17 patients treated with placebo, patients receiving citicoline who had a positive APOE  $\epsilon 4$  genotype showed a significant improvement in their cognitive capacity as assessed with the ADAS scale ( $p < 0.05$ ). As previously seen, citicoline was also shown to increase cerebral blood flow and improve bioelectric activity in the brain.

Soto et al. [597] showed the value of the therapeutic association of citicoline, piracetam, and a dihydropyridine calcium channel blocker, either nicardipine or nimodipine, for the treatment of senile dementia of the Alzheimer type. Cacabelos et al. [598] also advocated a multifactorial treatment, that would include citicoline, for Alzheimer disease in genotyped patients. Zhuravin et al. [599]

demonstrated that the activities of blood serum acetylcholinesterase, butyrylcholinesterase and neprilysin reflect the level of cognitive dysfunction in patients with Alzheimer's disease and can be used as prognostic biomarkers of the level of dementia progression, and that the treatment with citicoline can modify positively these levels.

In a systematic review published by the Cochrane Library, Fioravanti and Yanagi [600] examined the effects of citicoline in the treatment of cognitive, emotional, and behavioral deficits associated to chronic brain disorders in the elderly. Fourteen studies were included in this review. Some of the included studies did not present numerical data suitable for analysis. Description of participants varied over the years and by type of disorders and severity, and ranged from aged individuals with subjective memory disorders to patients with vascular cognitive impairment (mild to moderate), vascular dementia or senile dementia (mild to moderate). Seven of the included studies

**Figure 27.** Antidepressive effects of citicoline in healthy older subjects (control) and in patients with Alzheimer's disease or multi-infarct dementia (MID), evaluated with the Hamilton Depression Scale. EOAD: early-onset Alzheimer's disease; LOAD: late-onset Alzheimer's disease. <sup>a</sup> $p < 0.02$ ; <sup>b</sup> $p < 0.01$ ; <sup>c</sup> $p < 0.05$ .



observed the subjects for a period between 20 to 30 days, one study was of 6 weeks duration, four studies used periods extending over 2 and 3 months, one study observed continuous administration over 3 months and one study was prolonged, with 12 months of observation. The studies were heterogeneous in dose, modalities of administration, inclusion criteria for subjects, and outcome measures. Results were reported for the domains of attention, memory testing, behavioural rating scales, global clinical impression and tolerability. Reaction time was used as a measure of attention, and the results were obtained from seven of the included studies with a total of 790 subjects, 384 in the citicoline group and 406 in the placebo group. Using the standardised mean difference (SMD) and fixed-effect model, the summary effect size is  $-0.09$  ( $-0.23$  to  $0.05$ ), then there was evidence of little effect of CDP-choline on attention. The meta-analysis of the memory tests from ten studies included a total of 924 subjects, 456 in the citicoline group

and 468 in the placebo group. The effect size on memory was  $0.38$  ( $0.11$ - $0.65$ ) which was statistically significant. Using the six studies which reported memory test results in 675 participants with cognitive deficits associated with cerebrovascular disorders, the meta-analysis of memory function revealed homogeneous results and there was evidence of a statistically significant positive effect on memory (SMD =  $0.22$ ;  $0.07$ - $0.37$ ). Behaviour was measured using five different scales in eight studies with 844 subjects, 412 in the citicoline group and 432 in the placebo group. There was evidence of a positive effect of citicoline on behaviour (SMD =  $-0.60$ ;  $-1.05$  to  $-0.15$ ) using the random-effects model. The evidence of benefit from global impression was stronger; using a fixed-effect model, the Peto OR for improvement in the subjects treated with citicoline as opposed to the subjects treated with placebo was  $8.89$  (95% CI:  $5.19$ - $15.22$ ). Relevant was the finding that citicoline tended to be associated with fewer adverse effects than pla-




cebo, but this was not statistically significant. According to the authors, further research with citicoline should focus on longer term studies in subjects who have been diagnosed with currently accepted standardised criteria, especially vascular mild cognitive impairment or vascular dementia.

Deutsch et al. [601,602] are studying the association citicoline plus galantamine in schizophrenia. Also recently some positive effects of citicoline in the prevention of postoperative cognitive dysfunction during total intravenous anesthesia have been reported [603-605]. In a recent study, Li et al. [606] demonstrated the effect of citicoline as adjuvant therapy on mild cognitive impairment in Parkinson's disease. Putignano et al. published the VITA study [607], a retrospective and observational study was performed to assess the efficacy of citicoline in elderly patients suffering from stupor related to complex geriatric syndrome, showing that there was an improvement in key measures of performance after the treatment. The same team published the *Studio di Intervento nel Decadimento Vascolare Lieve* study (IDEALE) [608]. The IDEALE study was an open multicentre Italian study, the aim of which was to assess the effectiveness and safety of oral citicoline in elderly people with mild vascular cognitive impairment. The study was performed in 349 patients. The active or citicoline group was composed of 265 patients and included 122 men and 143 women of mean age  $79.9 \pm 7.8$  years selected from six Italian regions. Inclusion criteria were age  $\geq 65$  years, MMSE  $\geq 21$ , subjective memory complaints but no evidence of deficits on MMSE, and evidence of vascular lesions on neuro-radiology. Those with probable Alzheimer's disease were excluded. The control group consisted of 84 patients, including 36 men and 48 women of mean age  $78.9 \pm 7.01$  (range: 67-90) years. Patients included in the study underwent brain computed tomography or magnetic resonance imaging, and plasma dosage of vitamin B<sub>12</sub>, folate, and thyroid hormones. Functional dependence was investigated by scores on the Activities of Daily Living (ADL) and Instrumental Activities of Daily Living (IADL) scales, mood was assessed by the Geriatric Depression Scale (GDS), and behavioral disorders using the Neuropsychiatric Inventory scale. Comorbidity was assessed using the Cumulative Illness Rating Scale. An assessment was made at baseline (T0), after 3 months (T1), and after 9 months (T2, ie, 6 months after T1). The main outcomes were an improvement in MMSE, ADL, and IADL scores in the study group compared with the control group. Side effects were also investigated. The study group

was administered oral citicoline 500 mg twice a day throughout the study. MMSE scores remained unchanged over time ( $22.4 \pm 4$  at T0;  $22.7 \pm 4$  at T1;  $22.9 \pm 4$  at T2), whereas a significant difference was found between the study and control groups, both in T1 and in T2 (Fig. 28). No differences were found in ADL and IADL scores between the two groups. A slight but not statistically significant difference was found in GDS score between the study and control groups ( $p = 0.06$ ). No adverse events were recorded. In this study, citicoline was effective and well tolerated in patients with mild vascular cognitive impairment. Recently the same team published the CITIRIVAD Study [609], with the aim to show the effectiveness of oral citicoline plus rivastigmine in patients with Alzheimer's disease and mixed dementia. The results show the effectiveness and safety of combined administration versus rivastigmine alone, mainly in slowing disease progression and consequently in disease management, both in Alzheimer's disease and in mixed dementia.

Cognitive disorders are common stroke sequelae and can impair functional recovery [610]. Ischemic stroke is a significant risk factor for vascular cognitive impairment and vascular dementia [611]. In this context, Álvarez-Sabín et al. performed a study to assess the safety of long-term administration and its possible efficacy of citicoline in preventing poststroke cognitive decline in patients with first-ever ischemic stroke [612], following an open-label, randomized, and parallel design to compare citicoline versus usual treatment. All subjects were selected 6 weeks after suffering a qualifying stroke and randomized by age, gender, education and stroke type into parallel arms of citicoline (1 g/day) for 12 months versus no citicoline (control group). Medical management was similar otherwise. All patients underwent neuropsychological evaluation at 1 month, 6 months and 1 year after stroke. Tests results were combined to give indexes of 6 neurocognitive domains: attention and executive function, memory, language, spatial perception, motor speed and temporal orientation. Using adjusted logistic regression models the association between citicoline treatment and cognitive decline for each neurocognitive domain at 6 and 12 months was determined. 347 subjects were recruited –mean age 67.2 years, 186 male (56.6%), mean education 5.7 years–; 172 (49.6%) received citicoline for 12 months (no significant differences from controls  $n = 175$ ). Demographic data, risk factors, initial stroke severity (NIHSS), clinical and etiological classification were similar in both groups. Only 37 subjects (10.7%) discontinued treatment


**Figure 28.** Comparison of corrected Minimental State Examination levels between citicoline group and controls.

(10.5% citicoline versus 10.9% control) at 6 months; 30 (8.6%) due to death (16 (9.3%) citicoline versus 14 (8.0%) control ( $p = 0.740$ ), 7 lost to follow-up or incorrect treatment, and 4 (2.3%) had adverse events from citicoline without discontinuation. 199 patients underwent neuropsychological evaluation at 1 year. Cognitive functions improved 6 and 12 months after stroke in the entire group but in comparison with controls, citicoline-treated patients showed better outcome in attention-executive functions (OR: 1.721; 95% CI: 1.065-2.781;  $p = 0.027$  at 6 months; OR: 2.379; 95% CI: 1.269-4.462;  $p = 0.007$  at 12 months) and temporal orientation (OR: 1.780; 95% CI: 1.020-3.104;  $p = 0.042$  at 6 months; OR: 2.155; 95% CI: 1.017-4.566;  $p = 0.045$  at 12 months) during the follow-up. Moreover, citicoline group showed a better functional outcome (mRS  $\leq 2$ ) at 12 months (57.3 versus 48.7%) without statistically significant differences ( $p = 0.186$ ). The authors concluded that citicoline treatment for 12 months in patients with first-ever ischemic stroke is safe and probably effective in improving post-stroke cognitive decline. Citicoline appears to be a

promising agent to improve recovery after stroke. Recently, the authors published the follow-up of this study after 2 years of treatment with citicoline [613], adding an evaluation of the quality of life, using the EuroQoL-5D questionnaire, to the cognitive assessment. 163 patients were followed during 2 years. The mean age was 67.5 years-old, and 50.9% were women. Age and absence of citicoline treatment were independent predictors of both utility and poor quality of life. Patients with cognitive impairment had a poorer quality of life at 2 years (0.55 versus 0.66 in utility;  $p = 0.015$ ). Citicoline treatment improved significantly cognitive status during follow-up ( $p = 0.005$ ), showing a gradual improvement across the time (Fig. 29). Other authors communicated beneficial effects of citicoline in the treatment of post-stroke cognitive disturbances [614,615].

The drug may be more effective for mild cognitive disorders [616-618] and cases related with vascular pathologies [619-621]. In addition, citicoline has been shown to have beneficial effects on neurophysiological and neuroimmune changes.

**Figure 29.** Global cognitive impairment during follow-up. Patients treated with citicoline show a significant improvement in cognitive status during follow-up ( $p = 0.005$ ). After the first year, only citicoline-treated patients continue to improve cognitive status. Reprinted from J. Álvarez-Sabín, et al. *Long-term treatment with citicoline prevents cognitive decline and predicts a better quality of life after a first ischemic stroke*. *Int J Mol Sci* 2016; 17: 390.



### Other clinical experiences

#### *Parkinson disease*

While levodopa continues to be the central therapeutic agent in Parkinson disease, it has well-known limitations, the main of which is a progressive loss of efficacy, that is often already evident at 3-5 years of treatment. It seems therefore warranted to use other drugs that, associated to levodopa, allow for decreasing its dosage or may even be administered as the only medication in the early stages of the disease. In this regard, use of citicoline has been tested because of its previously analyzed capacity to increase dopamine availability in the striatum and to act as a dopaminergic agonist. Citicoline has been shown to be effective in various experimental models, and its use in Parkinson disease is therefore accepted [622].

Ruggieri et al. [623], in a double-blind, crossover study conducted on 28 parkinsonian patients comparing citicoline 600 mg/d/10 d i.v. to placebo, showed citicoline to be an effective treatment for these patients, achieving improvements in the assessment of bradykinesia, rigidity, and tremor, and also in the scores of the Webster scale and the Northwestern University Disability Scale (NUDS). These same investigators later obtained very similar results in an extension of the above [624]. They subsequently tested the effects of citicoline in two groups of patients with Parkinson disease [625]. The first group included 28 patients who had not previously received treatment, while the second group included 30 patients who were already receiving treatment with levodopa and carbidopa since at least 2 months before, and in whom dosage had been stabilized at the minimum effective level.

The same methods as in previous studies by these investigators were used, that is, a double-blind, crossover study comparative to placebo. Treatment was administered for 20 days at a dose of 500 mg/d by the parenteral route. Clinical assessments were performed on days 10 and 20, coinciding with change in treatment, according to the study design. Treatment with citicoline provided statistically significant improvements in Webster scale, NUDS, and assessment of bradykinesia in both patient groups. Rigidity also improved in both groups, although this improvement only reached statistical significance in the previously treated group of patients. Tremor also improved in both groups, but the desired statistical significance was not reached.

Eberhardt et al. [626-628] have shown that association of citicoline to levodopa treatment allows for reducing levodopa dose by 50%, thus minimizing the side effects associated to levodopa therapy. Thus, for this group of investigators, citicoline represents a useful alternative in patients requiring a reduction in levodopa doses and, moreover, addition of citicoline to a treatment with levodopa may relieve decompensation states in the course of parkinsonism [629].

Loeb et al. [630] conducted a multicentre, double-blind study with citicoline for the treatment of parkinsonian patients. In this study, 65 patients were randomized to a group to which citicoline 1 g/d i.v. was added or to a placebo group. Treatment lasted 21 days. All patients continued their underlying treatment with levodopa plus mianserin or benserazide for at least 8 weeks. Authors found significant differences between citicoline and placebo at the controls performed after 14 and 21 days of treatment in all parameters assessed by the Webster and NUDS scales. They also noted that patients treated with citicoline experienced a significant worsening 45 days after the medication was discontinued, thus showing the efficacy of citicoline as adjuvant treatment to levodopa in patients with Parkinson disease.

Acosta et al. [631] treated with citicoline 61 parkinsonian patients, of whom 48 patients were already receiving treatment with levodopa. Each patient received two treatment courses. In the first 10-day phase, citicoline 500 mg daily were administered by the intramuscular route. This was followed in a second phase by oral treatment at the same dose for 14 weeks. Patients treated with levodopa continued taking this medication at the same dose in a first period, after which an attempt was made to decrease it. Parkinsonian symptoms were assessed using the Webster scale. Among pa-

tients receiving levodopa, 36% improved when citicoline was added, with the greater percent improvements being obtained in bradykinesia, rigidity, posture, gait, and limb sway. In patients who had been treated with levodopa for less than 2 years, percent improvements amounted to 42.12%, as compared to 19.08% of improvements in patients with more than 2 years of levodopa therapy. Levodopa doses could be decreased by 20% to 100% in 35.3% of patients with less the 2 years of treatment. In patients with more than 2 years of levodopa treatment, levodopa dose could be reduced by 25-33% in 10% of the cases. Authors concluded that citicoline treatment allows for delaying the start of levodopa therapy in the early disease stages, and for decreasing or maintaining levodopa dosage in already treated subjects.

Cubells and Hernando [632] tested citicoline in 30 parkinsonian patients who were already being treated with levodopa. The dose administered was 500 mg/d by the intramuscular route for 2 months, and was reduced to a third at the end of the first month of treatment. Changes in parkinsonian symptoms, according to the Yahr scale, showed after the first month of treatment a moderate improvement in facial expression and digital skills, and an obvious improvement in postural stability, motor changes and bradykinesia. A greater stabilization of therapeutic response was also seen, with a decreased incidence of 'wearing-off' and 'on-off' phenomena, although dyskinesia increased. When levodopa dose was decreased during the second study month, clinical improvement was maintained and incidence of dyskinesia was decreased. Measurements of various electrophysiological parameters using an original technique by the authors revealed recovery from hyporeflexia and hypotonia after one month of treatment with citicoline, and also a major improvement in active muscle contraction, decreased muscle fatigue, and an obvious recovery of contractile speed, a parameter that was greatly decreased before treatment with citicoline was started. Authors stated that the increase in levodopa plasma levels was so significant that it could not be interpreted as due only to an increased release of dopamine stored in presynaptic vesicles. They therefore assumed that citicoline exerts an action upon the synthetic mechanism of dopamine, acting through the tyrosine hydroxylase enzymatic system. In addition, the increase in dopamine receptors quantified in lymphocytes suggests, according to authors, a promoting role of citicoline upon the availability of postsynaptic dopamine receptors.

Martí-Massó and Urtasun [633] examined the effects of citicoline in 20 parkinsonian patients treated with levodopa for more than 2 years. These patients were administered citicoline 1 g/d/15 d i.m., and then continued with half the dose for 15 additional days. A progressive symptom improvement was achieved. Thus, 4.16% and 7.26% overall improvements were achieved in the Columbia University scale at 15 days and at the end of treatment respectively. Partial improvements achieved in ambulation, turning time in bed, and writing time should be particularly noted. In assessment conducted by relatives, improvements achieved in agility, ambulation, and general patient status deserved special mention.

García-Mas et al. [634] conducted a study with quantified electroencephalography (qEEG) using fast Fourier transforms in two groups of patients with idiopathic Parkinson disease, one of which showed cortical cognitive impairment. Study of specific qEEG indices allowed for establishing some parameters differentiating patients with and without cortical impairment. Specifically, differences were found in global potencies of delta and alpha rhythms, the alpha/theta index, posterior activities, anteriorization index of delta and alpha rhythms and finally, spatialization index of alpha rhythm. Administration of citicoline 2 g i.v. in these patients achieves a global increase in potencies corresponding to posterior rhythms, particularly alpha rhythm, that is a marker of cognitive activity in dementia processes. As shown previously, citicoline is an adjuvant therapy on mild cognitive impairment in Parkinson's disease [606]. By other hand, citicoline significantly improved essential tremor [635].

Based on the reported and discussed studies, it may be stated that citicoline represents an effective treatment for Parkinson disease in both untreated patients and patients already treated with levodopa, in whom it also allows for reducing levodopa dose. In patients with Parkinson disease and cognitive impairment, administration of citicoline induces a trend to normalization of deficits and the main electrophysiological parameters altered.

#### ***Alcoholism and drug addiction***

Clinical experience with citicoline in alcoholism and drug addictions is not very extensive, but there is some evidence of its efficacy in these applications.

Chinchilla et al. [636] conducted a randomized, double-blind study on the effects of citicoline in 20 patients with alcohol withdrawal syndrome. At the

end of the study, i.e. at 2 months, a significant improvement in attention-concentration and time and space orientation in the group of patients receiving citicoline suggesting, according to the authors, that the drug may be useful for the treatment of chronic alcoholism.

Renshaw et al. [637-639] published a double-blind pilot study of patients addicted to cocaine, showing that after 14 days of treatment with 500 mg/12 h of citicoline, or placebo, the patients in the citicoline group experienced a reduction in craving for cocaine. Consequently, citicoline appears to be a promising therapy for this type of affliction, that not perturb sleep/wake cycles [640]. But Licata et al. [641] reported that citicoline is not an effective treatment reducing craving for heavy cocaine users. Also have been reported positive effects in patients with mood disorders related with the use of cocaine [642,643], antidepressant properties in methamphetamine dependence [644], and a role facilitating the treatment of marijuana use disorders by improving the cognitive skills necessary to fully engage in comprehensive treatment programs [645]. There is a clear implication of the cerebral metabolism in the drug addiction pathophysiology [646,647]. The recent application of brain imaging to study drug addictions has offered new insights into the fundamental factors that contribute to their use and abuse [648]. And also there is some data suggesting a potential usefulness of citicoline in modulating appetite [649]. Despite the limited research on the efficacy of citicoline for addictive disorders, the available literature suggests promising results [650].

#### ***Amblyopia and glaucoma***

There is clinical evidence that citicoline improves visual acuity in patients with amblyopia [651-661], visual function in patients with glaucoma [662-672], and in patients with non-arteritic ischemic optic neuropathy [673].

#### ***Other uses***

There are positive results reported for citicoline in the treatment of facial neuritis [674], X-chromosome-linked ichthyosis [675], Delayed-onset encephalopathy caused by carbon monoxide poisoning [676], epilepsy [677], and vertigo [678]. Recently, a new mechanism to enhance central nervous system remyelination via the choline pathway has been described. Due to its regenerative action combined with an excellent safety profile, CDP-choline could become a promising substance for patients with multiple sclerosis as an add-on therapy [679-682].

### ***Pediatric use***

The experience in children is limited; therefore it may only be administered when the expected therapeutically benefit is higher than any possible risk.

There are some studies published in pediatric populations with citicoline in traumatic brain injuries [406], organic brain syndromes [683-685], neonatal hypoxic-ischaemic encephalopathy [686,687], visual impairment [688], neurophysiologic abnormalities in developmental dysphasias [689] and learning disturbances [690,691]. No safety concerns related with the use of citicoline were reported in these studies.

### **Safety**

Dinsdale et al. [692] administered citicoline or placebo to 12 healthy volunteers in two oral regimens repeated at short-term intervals (600 mg/day and 1 g/day), every day for 5 days. The only adverse effects that appeared were self-limiting headaches in four and five subjects with high and low doses, respectively and in one subject who was given placebo. The results of hematological and clinical analyses did not show any abnormality associated to citicoline administration. No clinically significant ECG and EEG abnormalities were registered. Empirical neurological tests, tendon reflexes, blood pressure and heart rate were not affected by any dose of the drug or placebo.

In addition to an excellent tolerability in healthy individuals, as demonstrated in the above study, all of the authors of clinical trials using citicoline that have been reviewed in this present article, agree in rating the safety of this drug as excellent without serious side effects being reported. In some cases, the appearance of digestive intolerance has been reported and occasional excitability or restlessness in the first days of treatment. For instance, Lozano [693] monitored a study of the efficacy and safety of citicoline in 2,817 patients of all ages, with a predominance of patients between 60 and 80 years, who had different neurological processes, mostly cognitive disorders of diverse origin. The duration of citicoline Treatment ranged from 15 to 60 days and the mean dose administered was 600 mg/day orally. Only 5.01% of the patients had collateral effects associated with citicoline treatment, most often digestive intolerance (3.6%). In no case was it necessary to interrupt treatment for side effects attributable to citicoline use.

In the pooled analysis of citicoline in the treatment of acute ischemic stroke [477], in the safety analysis, there were few adverse events that were

reported in more than the 5 %. These adverse events are listed in Table XII.

In the South Korean drug surveillance study [484], the safety of the product was considered as excellent, with only 37 side effects in 31 cases among the 4191 patients treated, that is a rate of side effects of 0.73%.

Also, in the Cochrane Library review [600], it was demonstrated a lower rate on the incidence of adverse events related with citicoline in comparison with placebo.

In conclusion, the tolerability of citicoline is excellent and the side effects attributable to this drug are infrequent. In any case, side effects are never severe and consist, mainly, in gastrointestinal discomfort and restlessness.

### **Conclusions**

Cytidine 5'-diphosphocholine, CDP-choline, or citicoline is an essential intermediate in the biosynthetic pathway of structural phospholipids in cell membranes, particularly phosphatidylcholine. Following administration by both the oral and parenteral routes, citicoline releases its two main components, cytidine and choline. Absorption by the oral route is virtually complete, and bioavailability by the oral route is therefore approximately the same as by the intravenous route. Once absorbed, citicoline is widely distributed throughout the body, crosses the blood-brain barrier and reaches the central nervous system (CNS), where it is incorporated into the membrane and microsomal phospholipid fraction. Citicoline activates biosynthesis of structural phospholipids of neuronal membranes, increases brain metabolism, and acts upon the levels of different neurotransmitters. Thus, citicoline has been experimentally shown to increase norepinephrine and dopamine levels in the CNS. Owing to these pharmacological mechanisms, citicoline has a neuroprotective effect in hypoxic and ischemic conditions, and also improves learning and memory performance in animal models of brain aging. In addition, citicoline has been shown to restore the activity of mitochondrial ATPase and membrane Na<sup>+</sup>/K<sup>+</sup>ATPase, to inhibit activation of phospholipase A<sub>2</sub>, and to accelerate reabsorption of cerebral edema in various experimental models. Citicoline is a safe drug, as shown by the toxicological tests conducted, that has no significant systemic cholinergic effects and is a well-tolerated product. These pharmacological characteristics and the action mechanisms of citicoline sug-

**Table XII.** Safety analysis in the pooling data analysis of acute ischaemic stroke patients treated with citicoline. The table shows adverse events that were reported in more than 5% of cases. n.s.: no significant.

	Placebo		Citicoline		<i>p</i>
	<i>n</i>	%	<i>n</i>	%	
<b>Adverse events with incidence &gt; 5% in the citicoline group</b>					
Anxiety	58	9.95	108	13.69	0.036
Leg oedema	38	6.52	77	9.76	0.032
<b>Adverse events with incidence &gt; 5%</b>					
Accidental injury	86	14.75	135	17.11	n.s.
Agitation	78	13.38	113	14.32	n.s.
Constipation	228	39.11	286	36.25	n.s.
Coughing	81	13.89	105	13.31	n.s.
Diarrhoea	81	13.89	117	14.83	n.s.
Dizziness	46	7.89	72	9.13	n.s.
ECG abnormality	57	9.78	74	9.38	n.s.
Fever	182	31.22	241	30.54	n.s.
Auricular fibrillation	65	11.15	92	11.66	n.s.
Headache	186	31.90	261	33.08	n.s.
Haematuria	53	9.09	91	11.53	n.s.
Hypertension	88	15.09	131	16.60	n.s.
Hypokalemia	71	12.18	119	15.08	n.s.
Hypotension	55	9.43	90	11.41	n.s.
Urinary tract infection	235	40.31	298	37.77	n.s.
Insomnia	103	17.67	145	18.38	n.s.
Joint pain	48	8.23	78	9.89	n.s.
Nausea	111	19.04	157	19.90	n.s.
Pain	180	30.87	227	28.77	n.s.
Back pain	45	7.72	74	9.38	n.s.
Chest pain	55	9.43	82	10.39	n.s.
Rash	79	13.55	112	14.20	n.s.
Restlessness	49	8.40	74	9.38	n.s.
Shoulder pain	75	12.86	105	13.31	n.s.
Vomiting	89	15.27	111	14.07	n.s.
<b>Adverse events with incidence &gt; 5% in the placebo group</b>					
Depression	160	27.44	178	22.56	0.038
Falling down	109	18.70	99	12.55	0.002
Urinary incontinence	82	14.07	83	10.52	0.047

gest that this product may be indicated for treatment of cerebral vascular disease, head injury of varying severity, and cognitive disorders of different causes. In studies conducted in the treatment of patients with head injury, citicoline was able to accelerate recovery from post-traumatic coma and improve gait, achieving an improved final functional outcome and shortening hospital stay in these patients. Citicoline also improved the mnemonic and cognitive disorders seen after head injury of minor severity that constitute the so-called post-concussional syndrome. In the treatment of patients with acute ischemic cerebral vascular disease, citicoline accelerates recovery of consciousness and motor deficit, achieves a better final outcome, and facilitates rehabilitation of these patients. The other major indication of citicoline is for the treatment of senile cognitive impairment, either secondary to degenerative diseases (e.g. Alzheimer disease) or to chronic cerebral vascular disease. In patients with vascular cognitive impairment, citicoline improves scores in cognitive rating scales, while in patients with senile dementia of the Alzheimer type it stops the course of disease, and neuroendocrine, neuroimmunomodulatory, and neurophysiological benefits have been reported. Moreover, citicoline has also been shown to be effective as adjuvant therapy in Parkinson disease. No serious side effects have occurred in any series of patients treated with citicoline, which attests to the safety of treatment with citicoline [694,695].

## References

- Lozano R. La membrana neuronal: implicaciones terapéuticas. *Boletín de Neurología* 1993; 2: 3-8.
- McMurray WC, Magee WL. Phospholipid metabolism. *Ann Rev Biochem* 1972; 41: 129-61.
- Nilsson B. CDP-choline: a short review. In Tognon G, Garattini S, eds. *Drug treatment and prevention in cerebrovascular disorders*. Amsterdam: Elsevier/North Holland Biomedical Press; 1979. p. 273-7.
- Kennedy EP, Weiss SB. The function of cytidine coenzymes in the biosynthesis of phospholipides. *J Biol Chem* 1956; 222: 193-214.
- Agut J. Neurotransmisores y membrana neuronal. *Rev Esp Geriatr Gerontol* 1989; 24 (Supl 1): 16-21.
- Farooqui AA, Horrocks LA, Farooqui T. Glycerophospholipids in brain: their metabolism, incorporation to membranes, functions, and involvement in neurological disorders. *Chem Phys Lipids* 2000; 106: 1-29.
- González-Padrónes T, Rodríguez-Fernández C. Los fosfolípidos como índice de maduración cerebral. *Rev Clin Esp* 1982; 167: 99-101.
- Martínez M, Conde, C, Ballabriga A. Some chemical aspects of human brain development. II. Phosphoglyceride fatty acids. *Pediatr Res* 1974; 8: 93-102.
- Padmini S, Srinivasa Rao P. UDP galactose: ceramide galactosyltransferase, CDP choline: 1,2-diacyl-sn-glycerol phosphocholine transferase and microsomal reductases in major regions of the developing rat brain in nutritional stress. *J Neurosci Res* 1989; 23: 310-5.
- Bramanti V, Bronzi D, Tomassoni D, Li Volti G, Cannavò G, Raciti G, et al. Effect of choline-containing phospholipids on transglutaminase activity in primary astroglial cell cultures. *Clin Exp Hypertens* 2008; 30: 798-807.
- Paoletti L, Domizi P, Marcucci H, Montaner A, Krapf D, Salvador G, et al. Lysophosphatidylcholine drives neuroblast cell fate. *Mol Neurobiol* 2015; Nov 14. [Epub ahead of print].
- Alberghina M, Giuffrida-Stella AM. Changes of phospholipid-metabolizing and lysosomal enzymes in hypoglossal nucleus and ventral horn motoneurons during regeneration of craniospinal nerves. *J Neurochem* 1988; 51: 15-20.
- Boismare F. Souffrance cérébrale: comportement et neurotransmetteurs sur des modèles expérimentaux. *Symposium Internacional Souffrance Cérébrale et Précurseurs des Phospholipides*. Paris, Jan 18, 1980.
- Cardenas DD. Cognition-enhancing drugs. *J Head Trauma Rehabil* 1993; 8: 112-4.
- Cohadon F, Rigoulet M, Guérin B, Vandendriessche M. Edème cérébral vasogénique. Altérations des ATPases membranaires. Restauration par un précurseur des phospholipides. *Nouv Presse Med* 1979; 8: 1589-91.
- Cohadon F, Rigoulet M, Guérin B, Vandendriessche M. L'activité membranaire dans la souffrance cérébrale. Altérations des ATPases membranaires dans l'edème cérébral vasogénique. Restauration par un précurseur des phospholipides. *Symposium Internacional Souffrance Cérébrale et Précurseurs des Phospholipides*. Paris, Jan 18, 1980.
- Cohadon F. Physiopathologie des edèmes cérébraux. *Rev Neurol (Paris)* 1987; 143: 3-20.
- Hayaishi O, Ozawa K, Araki C, Ishii S, Kondo Y. Biochemical studies of head injury and brain edema. *Jpn J Med Prog* 1961; 48: 519-39.
- Rigoulet M, Guérin B, Cohadon F, Vandendriessche M. Unilateral brain injury in the rabbit; reversible and irreversible damage of the membranar ATPases. *J Neurochem* 1979; 32: 535-41.
- Secades JJ, Lozano R. Traumatismos craneoencefálicos: revisión fisiopatológica y terapéutica. *Aportaciones de la citicolina*. Amsterdam: Excerpta Medica; 1991.
- Homayoun P, Parkins NE, Soblosky J, Carey ME, Rodríguez de Turco EB, Bazan NG. Cortical impact injury in rats promotes a rapid and sustained increase in polyunsaturated free fatty acids and diacylglycerols. *Neurochem Res* 2000; 25: 269-76.
- Alberghina M, Giuffrida AM. Effect of hypoxia on the incorporation of [2-<sup>3</sup>H] glycerol and [1-<sup>14</sup>C]-palmitate into lipids of various brain regions. *J Neurosci Res* 1981; 6: 403-19.
- Dvorkin VY. Turnover of individual phospholipid fractions in the rat during hypoxia. *Nature* 1966; 212: 1239-40.
- Decombe R, Bentue-Ferrer D, Reymann JM, Allain H. L'edème dans l'infarctus cérébral. Aspects physiopathologiques et perspectives thérapeutiques. *Angéiologie* 1990; 42: 45-51.
- Goldberg WJ, Dorman RV, Horrocks LA. Effects of ischemia and diglycerides on ethanolamine and choline phosphotransferase activities from rat brain. *Neurochem Pathol* 1983; 1: 225-34.
- Goldberg WJ, Dorman RV, Dabrowiecki Z, Horrocks LA. The effects of ischemia and CDPamines on Na<sup>+</sup>,K<sup>+</sup>-ATPase and acetylcholinesterase activities in rat brain. *Neurochem Pathol* 1985; 3: 237-48.
- Goto Y, Okamoto S, Yonekawa Y, Taki W, Kikuchi H, Handa H, et al. Degradation of phospholipid molecular species during experimental cerebral ischemia in rats. *Stroke* 1988; 19: 728-35.
- Hirashima Y, Moto A, Endo S, Takaku A. Activities of enzymes metabolizing phospholipids in rat cerebral ischemia. *Mol Chem Neuropathol* 1989; 10: 87-100.



29. Horrocks LA, Dorman RV, Porcellati G. Fatty acids and phospholipids in brain during ischemia. In Bes A, Braquet P, Paoletti R, Siesjö BK, eds. *Cerebral ischemia*. Amsterdam: Elsevier Science Publishers; 1984. p. 211-22.
30. Nilsson BI. Pathophysiological and clinical problems in the treatment of acute stroke. In Zappia V, Kennedy EP, Nilsson BI, Galletti P, eds. *Novel biochemical, pharmacological and clinical aspects of cytidinediphosphocholine*. Amsterdam: Elsevier Science Publishing; 1985. p. 287-97.
31. Rehcróna S, Siesjö BK, Smith DS. Reversible ischemia of the brain: biochemical factors influencing restitution. *Acta Physiol Scand* 1980; Suppl 492: 135-40.
32. Scheinberg P. The biologic basis for the treatment of acute stroke. *Neurology* 1991; 41: 1867-73.
33. Klein J. Membrane breakdown in acute and chronic neurodegeneration: focus on choline-containing phospholipids. *J Neural Transm* 2000; 107: 1027-63.
34. Pettegrew JW, Panchalingam K, Whithers G, McKeag D, Strychor S. Changes in brain energy and phospholipid metabolism during development and aging in the Fischer 344 rat. *J Neuropathol Exp Neurol* 1990; 49: 237-49.
35. Adibhatla RM, Hatcher JF. Role of lipids in brain injury and diseases. *Future Lipidol* 2007; 2: 403-22.
36. Adibhatla RM, Hatcher JF, Dempsey RJ. Lipids and lipidomics in brain injury and diseases. *AAPS J* 2006; 8: e314-21.
37. Adibhatla RM, Hatcher JF. Lipid oxidation and peroxidation in CNS health and disease: from molecular mechanisms to therapeutic opportunities. *Antioxid Redox Signal* 2010; 12: 125-69.
38. Reis DJ, Ross RA, Joh TH. Changes in the activity and amounts of enzymes synthesizing catecholamines and acetylcholine in brain, adrenal medulla, and sympathetic ganglia of aged rat and mouse. *Brain Res* 1977; 136: 465-74.
39. Samorajski T, Rolsten C. Age and regional differences in the chemical composition of brains of mice, monkeys and humans. *Prog Brain Res* 1973; 40: 253-65.
40. Cohen BM, Renshaw PF, Stoll AL, Wurtman RJ, Yurgelun-Todd D, Babb SM. Decreased brain choline uptake in older adults. An in vivo proton magnetic resonance spectroscopy study. *JAMA* 1995; 274: 902-7.
41. Holbrock PG, Wurtman RJ. Calcium-dependent incorporation of choline into phosphatidylcholine (PC) by base-exchange in rat brain membranes occurs preferentially with phospholipid substrates containing docosahexaenoic acid (22:6(n-3)). *Biochim Biophys Acta* 1990; 1046: 185-8.
42. Agut J. Metabolismo fosfolipídico en la fisiopatología de la enfermedad de Alzheimer. In Acarín N, Alom J, eds. *Marcadores biológicos y perspectivas terapéuticas en la enfermedad de Alzheimer*. Barcelona: Editorial MCR; 1989. p. 77-88.
43. Blusztajn JK, Wurtman RJ. Choline and cholinergic neurons. *Science* 1983; 221: 614-20.
44. Blusztajn JK, Liscovitch M, Richardson UI. Synthesis of acetylcholine from choline derived from phosphatidylcholine in a human neuronal cell line. *Proc Natl Acad Sci U S A* 1987; 84: 5475-7.
45. Ginsberg L, Atack JR, Rapoport SI, Gershfeld NL. Regional specificity of membrane instability in Alzheimer's disease brain. *Brain Res* 1993; 615: 355-7.
46. Kalaria KN. The immunopathology of Alzheimer's disease and some related disorders. *Brain Pathol* 1993; 3: 333-47.
47. Knusel B, Jenden DJ, Lauretz SD, Booth RA, Rice KM, Roch M, et al. Global in vivo replacement of choline by N-aminodeanol. Testing hypothesis about progressive degenerative dementia. I. Dynamics of choline replacement. *Pharmacol Biochem Behav* 1990; 37: 799-809.
48. Lee HC, Fellenz-Maloney MP, Liscovitch M, Blusztajn JK. Phospholipase D-catalyzed hydrolysis of phosphatidylcholine provides the choline precursor for acetylcholine synthesis in a human neuronal cell line. *Proc Natl Acad Sci U S A* 1993; 90: 10086-90.
49. Nitsch RM, Blusztajn JK, Pittas AG, Slack BE, Growdon JH, Wurtman RJ. Evidence for a membrane defect in Alzheimer disease brain. *Proc Natl Acad Sci U S A* 1992; 89: 1671-5.
50. Wurtman RJ, Coviella ILG. CDP-cholina, neurotransmisores y metabolismo de fosfolípidos. *Med Clin (Barc)* 1986; 87 (Supl 1): 3-4.
51. Wurtman RJ, Blusztajn JK, Ulus IH, Coviella ILG, Buyukuyal RL, Growdon JH, et al. Choline metabolism in cholinergic neurons: Implications for the pathogenesis of neurodegenerative diseases. *Adv Neurol* 1990; 51: 117-25.
52. Wurtman RJ. Choline metabolism as a basis for the selective vulnerability of cholinergic neurons. *Trends Neurol Sci* 1992; 15: 117-22.
53. Farber SA, Slack BE, DeMicheli E, Wurtman RJ. Choline metabolism, membrane phospholipids, and Alzheimer's disease. In Giacobini E, Becker R, eds. *Alzheimer disease: therapeutic strategies*. Boston: Birkhäuser; 1994. p. 247-51.
54. Cansev M, Wurtman RJ, Sakamoto T, Ulus IH. Oral administration of circulating precursors for membrane phosphatides can promote the synthesis of new brain synapses. *Alzheimers Dement* 2008; 4 (Suppl 1): S153-68.
55. Giesing M, Gerken U, Kastrup H. Phospholipid-induced changes of  $\gamma$ -aminobutyric acid in cortex grey matter in culture. *J Neurochem* 1985; 44: 740-51.
56. Roufogalis BD, Thornton M, Wade DN. Nucleotide requirement of dopamine sensitive adenylate cyclase in synaptosomal membranes from the striatum of rat brain. *J Neurochem* 1976; 27: 1533-5.
57. Challis RAJ, Mistry R, Gray DW, Nahorski SR. Modulation of muscarinic cholinergic-stimulated inositol 1,4,5-trisphosphate accumulation by N-methyl-D-aspartate in neonatal rat cerebral cortex. *Neuropharmacology* 1994; 33: 15-25.
58. Lynch MA, Voss KL. Arachidonic acid increases inositol phospholipid metabolism and glutamate release in synaptosomes prepared from hippocampal tissue. *J Neurochem* 1990; 55: 215-21.
59. Albright CD, Liu R, Bethea TC, Da Costa KA, Salganik RI, Zeisel SH. Choline deficiency induces apoptosis in SV40-immortalized CWSV-1 rat hepatocytes in culture. *FASEB J* 1996; 10: 510-6.
60. Cui Z, Houweling M, Chen MH, Record M, Chap H, Vance DE, et al. A genetic defect in phosphatidylcholine biosynthesis triggers apoptosis in Chinese hamster ovary cells. *J Biol Chem* 1996; 271: 14668-71.
61. Baburina I, Jackowski S. Apoptosis triggered by 1-O-octadecyl-2-O-methyl-rac-glycerol-3-phosphocholine is prevented by increased expression of CTP:phosphocholine cytidyltransferase. *J Biol Chem* 1998; 273: 2169-73.
62. Anthony ML, Zhao M, Brindle KM. Inhibition of phosphatidylcholine biosynthesis following induction of apoptosis in HL-60 cells. *J Biol Chem* 1999; 274: 19686-92.
63. Howe AG, Remberg V, McMaster CR. Cessation of growth to prevent cell death due to inhibition of phosphatidylcholine synthesis is impaired at 37 degrees C in *Saccharomyces cerevisiae*. *J Biol Chem* 2002; 277: 44100-7.
64. Lagace TA, Ridgway ND. Induction of apoptosis by lipophilic activators of CTP:phosphocholine cytidyltransferase (CCT)alpha. *Biochem J* 2005; 392 (Pt 3): 449-56.
65. Joo JH, Jetten AM. Molecular mechanisms involved in farnesol-induced apoptosis. *Cancer Lett* 2010; 287: 123-35.
66. Morton CC, Aitchison AJ, Gehrig K, Ridgway ND. A mechanism for suppression of the CDP-choline pathway during apoptosis. *J Lipid Res* 2013; 54: 3373-84.
67. Cramer SC, Finkelstein SP. Reparative approaches: growth factors and other pharmacological treatments. In Miller LP, ed. *Stroke therapy: basic, preclinical, and clinical directions*. New York: Wiley-Liss; 1999. p. 321-36.
68. Zweifler RM. Membrane stabilizer: citicoline. *Curr Med Res Opin* 2002; 18 (Suppl 2): S14-7.
69. McDaniel MA, Maier SF, Einstein GO. 'Brain-specific' nutrients: a memory cure? *Nutrition* 2003; 19: 957-75.

70. Mamoun CB, Prigge ST, Vial H. Targeting the lipid metabolic pathways for the treatment of malaria. *Drug Dev Res* 2010; 71: 44-55.
71. Candelario-Jalil E. Injury and repair mechanisms in ischemic stroke: considerations for the development of novel neurotherapeutics. *Curr Opin Investig Drugs* 2009; 10: 644-54.
72. Saver JL. Targeting the brain: neuroprotection and neurorestoration in ischemic stroke. *Pharmacotherapy* 2010; 30: S62-9.
73. Grieb P. Neuroprotective properties of citicoline: facts, doubts and unresolved issues. *CNS Drugs* 2014; 28: 185-93.
74. De la Morena E, Goldberg DM, Werner M. Citidindifosfato de colina y biosíntesis de fosfolípidos. In De la Morena E, ed. *Citicolina: bioquímica, neurofarmacología y clínica*. Barcelona: Salvat; 1985. p. 25-38.
75. Chida N, Shimizu Y. Biosynthesis of myelin lipids of cultured nervous tissues. Incorporation of choline and CDPcholine into myelin phospholipids. *Tohoku J Exp Med* 1973; 111: 41-9.
76. Marggraf WD, Anderer FA. Alternative pathways in the biosynthesis of sphingomyelin and the role of phosphatidylcholine, CDPcholine and phosphorylcholine as precursors. *Hoppe-Seyler's Z Physiol Chem* 1974; 355: 803-10.
77. Vance DE, Pelech SL. Cellular translocation of CTP: phosphocholine cytidyltransferase regulates the synthesis of CDPcholine. In Zappia V, Kennedy EP, Nilsson BI, Galletti P, eds. *Novel biochemical, pharmacological and clinical aspects of cytidinediphosphocholine*. Amsterdam: Elsevier Science Publishing; 1985. p. 15-24.
78. Goracci G, Francescangeli E, Mozzi R, Porcellati S, Porcellati G. Regulation of phospholipid metabolism by nucleotides in brain and transport of CDPcholine into brain. In Zappia V, Kennedy EP, Nilsson BI, Galletti P, eds. *Novel biochemical, pharmacological and clinical aspects of cytidinediphosphocholine*. Amsterdam: Elsevier Science Publishing; 1985. p. 105-16.
79. George TP, Cook HW, Byers DM, Palmer FBSC, Spence MW. Channeling of intermediates in CDP-choline pathway of phosphatidylcholine biosynthesis in cultured glioma cells is dependent on intracellular Ca<sup>2+</sup>. *J Biol Chem* 1991; 266: 12419-23.
80. Murphy EJ, Horrocks LA. CDPcholine, CDPethanolamine, lipid metabolism and disorders of the Central Nervous System. In Massarelli R, Horrocks LA, Kanfer JN, Löffelholz K, eds. *Phospholipids and signal transmission*. Berlin: Springer-Verlag; 1993. p. 353-72.
81. Tronchère H, Record M, Tercé F, Chap H. Phosphatidylcholine cycle and regulation of phosphatidylcholine biosynthesis by enzyme translocation. *Biochim Biophys Acta* 1994; 1212: 137-51.
82. Weiss GB. Metabolism and actions of CDP-choline as an endogenous compound and administered exogenously as citicoline. *Life Sci* 1995; 56: 637-60.
83. Jackowski S, Wang J, Baburina I. Activity of the phosphatidylcholine biosynthetic pathway modulates the distribution of fatty acids into glycerolipids in proliferating cells. *Biochim Biophys Acta* 2000; 1483: 301-15.
84. Dowd SR, Bier ME, Patton-Vogt JL. Turnover of phosphatidylcholine in *Saccharomyces cerevisiae*. The role of the CDP-choline pathway. *J Biol Chem* 2001; 276: 3756-63.
85. Henneberry AL, Wright MM, McMaster CR. The major sites of cellular phospholipid synthesis and molecular determinants of fatty acid and lipid head group specificity. *Mol Biol Cell* 2002; 13: 3148-61.
86. Hunt AN, Clark GT, Neale JR, Postle AD. A comparison of the molecular specificities of whole cell and endonuclear phosphatidylcholine synthesis. *FEBS Lett* 2002; 530: 89-93.
87. Gibellini F, Smith TK. The Kennedy pathway –de novo synthesis of phosphatidylethanolamine and phosphatidylcholine. *IUBMB Life* 2010; 62: 414-28.
88. Kulinski A, Vance DE, Vance JE. A choline-deficient diet in mice inhibits neither the CDP-choline pathway for phosphatidylcholine synthesis in hepatocytes nor apolipoprotein B secretion. *J Biol Chem* 2004; 279: 23916-24.
89. Li Z, Vance DE. Phosphatidylcholine and choline homeostasis. *J Lipid Res* 2008; 49: 1187-94.
90. Arienti G, Corazzi L, Mastrofini P, Montanini I, Trillini B, Porcellati G. Involvement of CDP-choline in phospholipid metabolism of brain tissue in vitro. *Ital J Biochem* 1979; 28: 39-45.
91. Jané F. Algunos aspectos de la farmacología de la citicolina. In De la Morena E, ed. *Citicolina: bioquímica, neurofarmacología y clínica*. Barcelona: Salvat; 1985. p. 49-62.
92. Clement JM, Kent C. CTP:phosphocholine cytidyltransferase: insights into regulatory mechanisms and novel functions. *Biochem Biophys Res Commun* 1999; 257: 643-50.
93. Wong JT, Chan M, Lee D, Jiang JY, Skrzypczak M, Choy PC. Phosphatidylcholine metabolism in human endothelial cells: modulation by phosphocholine. *Mol Cell Biochem* 2000; 207: 95-100.
94. Lykidis A, Jackson P, Jackowski S. Lipid activation of CTP:phosphocholine cytidyltransferase alpha: characterization and identification of a second activation domain. *Biochemistry* 2001; 40: 494-503.
95. Fernández-Tome MC, Speziale EH, Sterin-Speziale NB. Phospholipase C inhibitors and prostaglandins differentially regulate phosphatidylcholine synthesis in rat renal papilla. Evidence of compartmental regulation of CTP:phosphocholine cytidyltransferase and CDP-choline:1,2-diacylglycerol cholinephosphotransferase. *Biochim Biophys Acta* 2002; 1583: 185-94.
96. Lagace TA, Ridgway ND. The rate-limiting enzyme in phosphatidylcholine synthesis regulates proliferation of the nucleoplasmic reticulum. *Mol Biol Cell* 2005; 16: 1120-30.
97. Satoh N, Harada A, Yokoyama K, Karasawa K, Inoue K, Setaka M. Regulation of activities of cytidine 5'-diphosphocholine: 1-O-alkyl-2-acetyl-sn-glycerol cholinephosphotransferase, an enzyme responsible for de novo synthesis of platelet-activating factor, by membrane phospholipids. *J Health Sci* 2003; 49: 13-21.
98. Richardson UI, Watkins CJ, Pierre C, Ulms IH, Wurtman RJ. Stimulation of CDP-choline synthesis by uridine or cytidine in PC12 rat pheochromocytoma cells. *Brain Res* 2003; 971: 161-7.
99. Zaccheo O, Dinsdale D, Meacock PA, Glynn P. Neuropathy target esterase and its yeast homologue degrade phosphatidylcholine to glycerophosphocholine in living cells. *J Biol Chem* 2004; 279: 24024-33.
100. Fagone P, Jackowski S. Phosphatidylcholine and the CDP-choline cycle. *Biochim Biophys Acta* 2013; 1831: 523-32.
101. Tayebati SK, Amenta F. Choline-containing phospholipids: relevance to brain functional pathways. *Clin Chem Lab Med* 2013; 51: 513-21.
102. Dobolyi A, Juhász G, Kovács Z, Kardos J. Uridine function in the central nervous system. *Curr Top Med Chem* 2011; 11: 1058-67.
103. Horrocks LA, Dorman RV. Prevention by CDP-choline and CDP-ethanolamine of lipid changes during brain ischemia. In Zappia V, Kennedy EP, Nilsson BI, Galletti P, eds. *Novel biochemical, pharmacological and clinical aspects of cytidinediphosphocholine*. Amsterdam: Elsevier Science Publishing; 1985. p. 205-15.
104. LePoncin-Lafitte M, Duterte D, Lageron A, Rapin JR. CDP-choline et accident cérébral expérimental d'origine vasculaire. *Agressologie* 1986; 27: 413-6.
105. Mykita S, Golly F, Dreyfus H, Freysz L, Massarelli R. Effect of CDP-choline on hypocapnic neurons in culture. *J Neurochem* 1986; 47: 223-31.
106. Yasuhara M, Naito H. Characteristic actions of CDP-choline on the central nervous system. *Cur Ther Res Clin Exp* 1974; 16: 346-74.

107. Yasuhara M, Naito H, Tachibana Y, Yasuhara A. An electrophysiological study on the effects of CDP-choline in the central nervous system. In Zappia V, Kennedy EP, Nilsson BI, Galletti P, eds. *Novel biochemical, pharmacological and clinical aspects of cytidinediphosphocholine*. Amsterdam: Elsevier Science Publishing; 1985. p. 259-74.
108. Martí-Viaño JL, Selles J, Orts A, Marco J, Vega F, Esplugues J. Antagonismo del coma barbitúrico mediante productos alertizantes. Estudio experimental. *Rev Esp Anest Reanim* 1978; 25: 21-8.
109. Ogashiwa M, Sano K, Manaka S, Kitamura K, Kagawa M, Takeuchi K. Effectiveness of CDP-choline on disturbance of consciousness (DOC): 1. An experimental study of concussive head injury in mice. 2. A controlled trial in patients with DOC. In Zappia V, Kennedy EP, Nilsson BI, Galletti P, eds. *Novel biochemical, pharmacological and clinical aspects of cytidinediphosphocholine*. Amsterdam: Elsevier Science Publishing; 1985. p. 317-27.
110. Watanabe S, Kono S, Nakashima Y, Mitsunobu K, Otsuki S. Effects of various cerebral metabolic activators on glucose metabolism of brain. *Folia Psychiatr Neurol Jpn* 1975; 29: 67-76.
111. Arrigoni E, Averet N, Cohadon F. Effects of CDP-choline on phospholipase A<sub>2</sub> and cholinephosphotransferase activities following a cryogenic brain injury in the rabbit. *Biochem Pharmacol* 1987; 36: 3697-700.
112. Freysz L, Golly F, Mykita S, Avola R, Dreyfus H, Massarelli R. Metabolism of neuronal cell culture: Modifications induced by CDP-choline. In Zappia V, Kennedy EP, Nilsson BI, Galletti P, eds. *Novel biochemical, pharmacological and clinical aspects of cytidinediphosphocholine*. Amsterdam: Elsevier Science Publishing; 1985. p. 117-25.
113. Massarelli R, Mozzi R, Golly F, Hattori H, Dainous F, Kanfer JN, et al. Synthesis de novo of choline, production of choline from phospholipids, and effects of CDP-choline on nerve cell survival. *Fidia Res Ser* 1986; 4: 273-81.
114. Kitazaki T, Ohta Y, Tsuda M. Inhibition of membrane-associated phospholipase A<sub>2</sub> by CDP-choline. *Jpn Pharmacol Ther* 1985; 13: 159-64.
115. Farooqui AA, Litsky ML, Farooqui T, Horrocks LA. Inhibitors of intracellular phospholipase A<sub>2</sub> activity: their neurochemical effects and therapeutical importance for neurological disorders. *Brain Res Bull* 1999; 49: 139-53.
116. Algate DR, Beard DJ, Sacristán A, Ortiz AJ, Davies JE. Study on the effects of oral administration of CDP-choline on EEG changes and lethality induced by epidural compression in the anesthetized cat. *Arzneimittelforschung* 1983; 33/2: 1013-6.
117. Hayaishi O, Ozawa K, Araki C, Ishii S, Kondo Y. Biochemical studies of head injury and brain edema. *Jpn J Med Prog* 1961; 48: 519-39.
118. Kondo Y. Experimental study of the therapeutic use of cytidine nucleotids for brain injury. *Nihon Geka Hokan* 1963; 32: 489-505.
119. Tsuchida T, Nagai M, Hoshino T, Kamano S, Miyake H. Treatment of head injuries with intermediate substances of metabolic cycle of brain. II. Basic study on metabolism of cytidine diphosphate choline. *Brain Nerve* 1967; 19: 1041-5.
120. Boismare F, LePoncin M, Le François J, Hacpille L, Marchand JC. Étude des effets de l'administration de cytidinediphosphocholine sur les conséquences hémodynamiques, fonctionnelles et biochimiques du traumatisme crâniocervical chez le rat. *Thérapie* 1977; 32: 345-54.
121. Clendenon NR, Palayoor ST, Gordon WA. Influence of CDP-choline on ATPase activity in acute experimental spinal cord trauma. In Zappia V, Kennedy EP, Nilsson BI, Galletti P, eds. *Novel biochemical, pharmacological and clinical aspects of cytidinediphosphocholine*. Amsterdam: Elsevier Science Publishing; 1985. p. 275-84.
122. Cohadon F, Richer E, Poletto B. Étude d'un précurseur des phospholipides dans le traitement des comas traumatiques graves. *Neurochirurgie* 1982; 28: 287-90.
123. Lafuente JV, Cervós-Navarro J. Estudio por microgavimetría del efecto de la CDP-colina en el edema cerebral experimental inducido por radiaciones ultravioletas. *Med Clin (Barc)* 1986; 87 (Supl 1): 5-8.
124. Cervós-Navarro J, Lafuente JV. Effect of cytidine diphosphate choline on ultraviolet-induced brain edema. *Adv Neurol* 1990; 52: 421-9.
125. Majem X, Bidón-Chanal A, Vilá-Badó J. Estudio de los efectos del tratamiento oral con CDP-colina sobre los cambios inducidos por el edema encefálico experimental en el electroencefalograma de la rata no anestesiada. *Med Clin (Barc)* 1986; 87(Supl 1): 23-5.
126. Roda JE. Répartition macro et microscopique d'un oedème cérébral vasogénique expérimental. Symposium International: Souffrance cérébrale et précurseurs des phospholipides. Paris, Jan 18, 1980.
127. Schmidt K, Hernekamp JF, Doerr M, Zivkovic AR, Brenner T, Walther A, et al. Cytidine-5-diphosphocholine reduces microvascular permeability during experimental endotoxemia. *BMC Anesthesiol* 2015; 5: 114.
128. Hernekamp JF, Hu SX, Schmidt VJ, Vogelpohl J, Kneser U, Kremer T. Influence of CDP-choline administration on early burn edema in rats. *Ann Plast Surg* 2015; 75: 388-92.
129. Dixon CE, Ma X, Marion DW. Effects of CDP-choline treatment on neurobehavioral deficits after TBI and on hippocampal and neocortical acetylcholine release. *J Neurotrauma* 1997; 14: 161-9.
130. Plataras C, Taskiris S, Angelogianni P. Effect of CDP-choline on brain acetylcholinesterase and Na<sup>+</sup>/K<sup>+</sup>-ATPase in adult rats. *Clin Biochem* 2000; 33: 351-7.
131. Baskaya MK, Dogan A, Rao AM, Dempsey RJ. Neuroprotective effects of citicoline on brain edema and blood-brain barrier breakdown after traumatic brain injury. *J Neurosurg* 2000; 92: 448-52.
132. Dempsey RJ, Rao VLR. Cytidinediphosphocholine treatment to decrease traumatic brain injury-induced hippocampal neuronal death, cortical contusion volume, and neurological dysfunction in rats. *J Neurosurg* 2003; 98: 867-73.
133. Menku A, Ogden M, Saraymen R. The protective effects of propofol and citicoline combination in experimental head injury in rats. *Turk Neurosurg* 2010; 20: 57-62.
134. Jacotte-Simancas A, Costa-Miserachs D, Coll-Andreu M, Torras-García M, Borlongan C, Portell-Cortés I. Effects of voluntary physical exercise, citicoline, and combined treatment on object recognition memory, neurogenesis and neuroprotection after traumatic brain injury in rats. *J Neurotrauma* 2015; 32: 739-51.
135. Qian K, Gu Y, Zhao Y, Li Z, Sun M. Citicoline protects brain against closed head injury in rats through suppressing oxidative stress and calpain over-activation. *Neurochem Res* 2014; 39: 1206-18.
136. Abdolmaleki A, Moghimi A, Ghayour MB, Rassouli MB. Evaluation of neuroprotective, anticonvulsant, sedative and anxiolytic activity of citicoline in rats. *Eur J Pharmacol* 2016; 789: 275-9.
137. Cakir E, Usul H, Peksoylu B, Sayin OC, Alver A, Topbas M, et al. Effects of citicoline on experimental spinal cord injury. *J Clin Neurosci* 2005; 12: 924-7.
138. Yucel N, Cayli SR, Ates O, Karadag N, Firat S, Turkoz Y. Evaluation of the neuroprotective effects of citicoline after experimental spinal cord injury: improved behavioral and neuroanatomical recovery. *Neurochem Res* 2006; 31: 767-75.
139. Coskun C, Avci B, Ocak N, Yalcin M, Dirican M, Savci V. Effect of repeatedly given CDP-choline on cardiovascular and tissue injury in spinal shock conditions: investigation of the acute phase. *J Pharm Pharmacol* 2010; 62: 497-506.
140. Turkkan A, Alkan T, Goren B, Kocaeli H, Akar E, Korfali E. Citicoline and postconditioning provides neuroprotection in a rat model of ischemic spinal cord injury. *Acta Neurochir (Wien)* 2010; 152: 1033-42.
141. Schuettauf F, Rejdak R, Thaler S, Bolz S, Lehaci C, Mankowska A, et al. Citicoline and lithium rescue retinal

- ganglion cells following partial optic nerve crush in the rat. *Exp Eye Res* 2006; 83: 1128-34.
142. Ozay R, Bekar A, Kocaeli H, Karli N, Filiz G, Ulus IH. Citicoline improves functional recovery, promotes nerve regeneration, and reduces postoperative scarring after peripheral nerve surgery in rats. *Surg Neurol* 2007; 68 :615-22.
  143. Aslan E, Kocaeli H, Bekar A, Tolunay S, Ulus IH. CDP-choline and its endogenous metabolites, cytidine and choline, promote the nerve regeneration and improve the functional recovery of injured rat sciatic nerves. *Neurol Res* 2011; 33: 766-73.
  144. Caner B, Kafa MI, Bekar A, Kurt MA, Karli N, Cansev M, et al. Intraperitoneal administration of CDP-choline or a combination of cytidine plus choline improves nerve regeneration and functional recovery in a rat model of sciatic nerve injury. *Neurol Res* 2012; 34: 238-45.
  145. Kaplan T, Kafa IM, Cansev M, Bekar A, Karli N, Taskapilioglu MO, et al. Investigation of the dose-dependency of citicoline effects on nerve regeneration and functional recovery in a rat model of sciatic nerve injury. *Turk Neurosurg* 2014; 24: 54-62.
  146. Gundogdu EB, Bekar A, Turkyilmaz M, Gumus A, Kafa IM, Cansev M. CDP-choline modulates matrix metalloproteinases in rat sciatic injury. *J Surg Res* 2016; 200: 655-63.
  147. Emril DR, Wibowo S, Meliala L, Susilowati R. Cytidine 5'-diphosphocholine administration prevents peripheral neuropathic pain after sciatic nerve crush injury in rats. *J Pain Res* 2016; 9: 287-91.
  148. Savran M, Bekar A, Cansev M, Tolunay S, Ulus IH, Taskapilioglu MO. Prevention of epidural fibrosis in rats by local or systemic administration of citicoline. *Turk Neurosurg* 2012; 22: 634-40.
  149. Wang L, Rouleau DM, Beaumont E. Most effective adjuvant treatments after surgery in peripheral nerve laceration: systematic review of the literature on rodent models. *Restor Neurol Neurosci* 2013; 31: 253-62.
  150. Galletti P, De Rosa M, Coticelli MG, Morana A, Vaccaro R, Zappia V. Biochemical rationale for the use of CDP-choline in traumatic brain injury: pharmacokinetics of the orally administered drug. *J Neurol Sci* 1991; 103: 19-25.
  151. Cohen MM. Biochemistry of cerebral anoxia, hypoxia and ischemia. Monograph in Neural Sciences, vol. 1- Basel: Karger; 1973. p. 1-49.
  152. Siesjö BK. Cell damage in the brain caused by ischemia. An overview. In Krieglstein J, ed. *Pharmacology of cerebral ischemia*. Amsterdam: Elsevier Science Publishers; 1986. p. 3-11.
  153. Porcellati G, De Medio GE, Fini C, Floridi A, Goracci G, Horrocks LA, et al. Phospholipids and its metabolism in ischemia. *Proc Eur Soc Neurochem* 1978; 1: 285-302.
  154. Boismare F, Le Poncin-Lafitte M, Rapin JR. Effets hémodynamiques, fonctionnelles et biochimiques de l'hypoxie hypobare chez le rat traité par la cytidine diphosphocholine. *C R Soc Biol* 1978; 172: 651-8.
  155. Boismare F, Le Poncin-Lafitte M. Influence d'un traitement par la citidine sur les effets hémodynamiques de l'hypoxie normobare dans le chien. *C R Soc Biol* 1978; 172 :659-63.
  156. Boismare F, Le Poncin M, Lefrançois J, Lecordier JC. Action of cytidine diphosphocholine on functional and hemodynamic effects of cerebral ischemia in cats. *Pharmacology* 1978; 17: 15-20.
  157. Alberghina M, Viola M, Serra I, Mistretta A, Giuffrida AM. Effect of CDP-choline on the biosynthesis of phospholipids in brain regions during hypoxic treatment. *J Neurosci Res* 1981; 6: 421-33.
  158. Serra I, Alberghina M, Viola M, Mistretta A, Giuffrida AM. Effects of CDP-choline on the biosynthesis of nucleic acids and proteins in brain regions during hypoxia. *Neurochem Res* 1981; 6: 607-18.
  159. Horrocks LA, Dorman RV, Dabrowiecki Z, Goracci G, Porcellati G. CDP-choline and CDP-ethanolamine prevent the release of free fatty acids during brain ischemia. *Prog Lipid Res* 1981; 20: 531-4.
  160. Trovarelli G, De Medio GE, Dorman RV, Piccinin GL, Horrocks LA, Porcellati G. Effect of cytidine diphosphate choline (CDP-choline) on ischemia-induced alterations of brain lipid in the gerbil. *Neurochem Res* 1981; 6: 821-33.
  161. Trovarelli G, De Medio GE, Montanini I. The influence of CDP-choline on brain lipid metabolism during ischemia. *Il Farmaco* 1982; 37: 663-8.
  162. Dorman RV, Dabrowiecki Z, Horrocks LA. Effects of CDP-choline and CDP-ethanolamine on the alterations in rat brain lipid metabolism induced by global ischemia. *J Neurochem* 1983; 40: 276-9.
  163. Suno M, Nagaoka A. Effect of CDP-choline on cerebral lipid metabolism following complete ischemia in rats. *Yakuri to Chiryō* 1985; 13: 165-70.
  164. Murphy EJ, Horrocks LA. Mechanism of action of CDPcholine and CDPethanolamine on fatty acid release during ischemia of brain. In Bazan NG, ed. *New trends in lipid mediators research, vol. 4. Lipid mediators in ischemic brain damage and experimental epilepsy*. Basel: Karger; 1990. p. 67-84.
  165. Agut J, Ortiz JA. Effect of oral cytidine-(5')-diphosphocholine (CDP-choline) administration on the metabolism of phospholipids in rat brain during normobaric hypoxia. In Wurtman R, Corkin SH, Growdon JH, eds. *Alzheimer's disease: advances in basic research and therapies*. Cambridge: Center for Brain Sciences and Metabolism Charitable Trust; 1987. p. 327-32.
  166. D'Orlando KJ, Sandage BW. Citicoline (CDP-choline): mechanisms of action and effects in ischemic brain injury. *Neurol Res* 1995; 17: 281-4.
  167. López-Coviella I, Clark WM, Warach S, Sandage B, Agut J, Ortiz JA, et al. CDP-choline (citicoline): potential mechanism of action and preliminary results in human stroke. In Goldstein LB, ed. *Restorative neurology: advances in pharmacotherapy*. Armonk, NY: Futura Publishing; 1998. p. 195-212.
  168. Abad-Santos F, Gallego-Sandín S, Novalbos J, Gálvez-Múgica MA. Estado actual de la citicolina en la isquemia cerebral. *Rev Neurol* 2000; 30: 663-70.
  169. Rao AM, Hatcher JF, Dempsey RJ. CDP-choline: neuroprotection in transient forebrain ischemia of gerbils. *J Neurosci Res* 1999; 58: 697-705.
  170. Rao AM, Hatcher JF, Dempsey RJ. Lipid alterations in transient forebrain ischemia: Possible new mechanisms of CDP-choline neuroprotection. *J Neurochem* 2000; 75: 2528-35.
  171. Adibhatla RM, Hatcher JF, Dempsey RJ. Citicoline: neuroprotective mechanisms in cerebral ischemia. *J Neurochem* 2002; 80: 12-23.
  172. Adibhatla RM, Hatcher JF. Citicoline mechanisms and clinical efficacy in cerebral ischemia. *J Neurosci Res* 2002; 70: 133-9.
  173. Adibhatla RM, Hatcher JF. Citicoline decreases phospholipase A<sub>2</sub> stimulation and hydroxyl radical generation in transient cerebral ischemia. *J Neurosci Res* 2003; 73: 308-15.
  174. Adibhatla RM, Hatcher JF, Dempsey RJ. Phospholipase A<sub>2</sub>, hydroxyl radicals, and lipid peroxidation in transient cerebral ischemia. *Antioxid Redox Signal* 2003; 5: 647-54.
  175. Adibhatla RM, Hatcher JF. Cytidine 5'-diphosphocholine (CDP-choline) in stroke and other CNS disorders. *Neurochem Res* 2005; 30: 15-23.
  176. Adibhatla RM, Hatcher JF, Dempsey RJ. Cytidine-5'-diphosphocholine affects CTP-phosphocholine cytidyltransferase and lyso-phosphatidylcholine after transient brain ischemia. *J Neurosci Res* 2004; 76: 390-6.
  177. Adibhatla RM, Hatcher JF, Larsen EC, Chen X, Sun D, Tsao FHC. CDP-choline significantly restores the phosphatidylcholine levels by differentially affecting phospholipase A<sub>2</sub> and CTP-phosphocholine cytidyltransferase after stroke. *J Biol Chem* 2006; 281: 6718-25.

178. Adibhatla RM, Hatcher JF, Tureyen K. CDP-choline liposomes provide significant reduction in infarction over free CDP-choline in stroke. *Brain Res* 2005; 1058: 193-7.
179. Torno, ME, Sacristán A, Ortiz JA. Pharmacological study of CDP-choline. Protection against toxicity in a model of experimental hypoxia. *Arzneimittelforschung* 1983; 33: 1022-4.
180. Benzi G, Pastoris O, Villa RF. Pharmacobiological interventions of CDP-choline in hypoxia and aging of the brain. In Zappia V, Kennedy EP, Nilsson BI, Galletti P, eds.: *Novel biochemical, pharmacological and clinical aspects of cytidinediphosphocholine*. Amsterdam: Ellsevier Science Publishing; 1985. p. 239-49.
181. Villa RF, Curti D, Polgatti M, Benzi G. Synaptosomes and mitochondria from rat brain cerebral cortex: in vivo interference on some enzymatic activities by SAME and CDP-choline. *J Neurosci Res* 1982; 7: 341-7.
182. Narumi S, Nagaoka A. Effects of CDP-choline on the metabolism of monoamines in the brain of rats with experimental cerebral ischemia. *Jpn Pharmacol Ther* 1985; 13: 171-8.
183. Nagai Y, Nagaoka A. Effect of CDP-choline on glucose uptake into various brain regions in the cerebral ischemic rats. *Jpn Pharmacol Ther* 1985; 13: 235-9.
184. Hurtado O, Moro MA, Cárdenas A, Sánchez V, Fernández-Tomé P, Leza JC, et al. Neuroprotection afforded by prior citicoline administration in experimental brain ischemia: effects on glutamate transport. *Neurobiol Dis* 2005; 18: 336-45.
185. Hurtado O, Pradillo JM, Fernández-López D, Morales JR, Sobrino T, Castillo J, et al. Delayed post-ischemic administration of CDP-choline increases EAAT2 association to lipid rafts and affords neuroprotection in experimental stroke. *Neurobiol Dis* 2008; 29: 123-31.
186. Hurtado O, Cárdenas A, Pradillo JM, Morales JR, Ortega F, Sobrino T, et al. A chronic treatment with CDP-choline improves functional recovery and increases neuronal plasticity after experimental stroke. *Neurobiol Dis* 2007; 26: 105-11.
187. Zhao JJ, Liu Y, Chen XL, Liu JX, Tian YF, Zhang PB, et al. Effect of citicoline on spatial learning and memory of rats after focal cerebral ischemia. *J South Med Univ* 2006; 26: 174-6.
188. Kakhana M, Kato J, Narumi S, Nagaoka A. CDP-choline: distribution of radioactive CDP-choline and effect on glucose metabolism in the cerebral cortex of rats with 30-min cerebral ischemia. *Jpn Pharmacol Ther* 1985; 13: 241-53.
189. Kakhana M, Fukuda N, Suno M, Nagaoka A. Effects of CDP-choline on neurologic deficits and cerebral glucose metabolism in a rat model of cerebral ischemia. *Stroke* 1988; 19: 217-22.
190. Fukuda N, Ikeda K, Saji Y. Effects of CDP-choline in the rats with experimental cerebral ischemia. *Jpn Pharmacol Ther* 1985; 13: 219-27.
191. Nagaoka A. Effects of CDP-choline on neurological deficits in stroke-prone spontaneously hypertensive rats with experimental cerebral ischemia. *Jpn Pharmacol Ther* 1985; 13: 229-34.
192. Saligaut C, Boismare F. Tratamiento oral crónico con citidin-(5')-difosfololina de los efectos sobre el comportamiento y bioquímicos de una hipoxia. *Med Clin (Barc)* 1986; 87 (Supl 1): 19-22.
193. Barrachina M, Domínguez I, Ambrosio S, Secades J, Lozano R, Ferrer I. Neuroprotective effect of citicoline in 6-hydroxydopamine-lesioned rats and in 6-hydroxydopamine-treated SH-SY5Y human neuroblastoma cells. *J Neurol Sci* 2003; 215: 105-10.
194. Araki H, Karasawa Y, Nojiri M, Aihara H. Effect of various classes of drugs on complete ischemia induced by decapitation and cyanide intoxication in mice. *Methods Find Exp Clin Pharmacol* 1988; 10: 349-56.
195. Aronowski J, Strong R, Grotta JC. Citicoline for treatment of experimental focal ischemia: histologic and behavioral outcome. *Neurol Res* 1996; 18: 570-4.
196. Schäbitz WR, Weber J, Takano K, Sandage BW, Locke KW, Fisher M. The effects of prolonged treatment with citicoline in temporary experimental focal ischemia. *J Neurol Sci* 1996; 138: 21-5.
197. Andersen M, Overgaard K, Meden P, Boysen G, Choi SC. Effects of citicoline combined with thrombolytic therapy in a rat embolic stroke model. *Stroke* 1999; 30: 1464-71.
198. Díez-Tejedor E, Gutiérrez M, Carceller F, Roda JM, Alonso M. Treatment with reperfusion and neuroprotection with low and high dose of citicoline in an experimental model of focal cerebral ischemia. Which is the best? 5th WSC, Vancouver, Canada, 2004.
199. Alonso de Leciñana M, Gutiérrez M, Roda JM, Carceller F, Díez-Tejedor E. Effect of combined therapy with thrombolysis and citicoline in a rat model of embolic stroke. *J Neurol Sci* 2006; 247: 121-9.
200. Gutiérrez-Fernández M, Alonso de Leciñana M, Rodríguez-Frutos B, Ramos-Cejudo J, Roda JM, Díez-Tejedor E. CDP-choline at high doses is as effective as i.v. thrombolysis in experimental animal stroke. *Neurol Res* 2012; 34: 649-56.
201. Shuaib A, Yang Y, Li Q. Evaluating the efficacy of citicoline in embolic ischemic stroke in rats: neuroprotective effects when used alone or in combination with urokinase. *Exp Neurol* 2000; 161: 733-9.
202. Onal MZ, Li F, Tatlisumak T, Locke KW, Sandage BW, Fisher M. Synergistic effects of citicoline and MK-801 in temporary experimental focal ischemia in rats. *Stroke* 1997; 28: 1060-5.
203. Schäbitz WR, Li F, Irie K, Sandage BW, Locke KW, Fisher M. Synergistic effects of a combination of low-dose basic fibroblast growth factor and citicoline after temporary experimental focal ischemia. *Stroke* 1999; 30: 427-32.
204. Ataus SA, Onal MZ, Ozdem SS, Locke KW, Balkan S. The effects of citicoline and lamotrigine alone and in combination following permanent middle cerebral artery occlusion in rats. *Int J Neurosci* 2004; 114: 183-96.
205. Sobrado M, López MG, Carceller F, García AG, Roda JM. Combined nimodipine and citicoline reduce infarct size, attenuate apoptosis and increase Bcl-2 expression after focal cerebral ischemia. *Neuroscience* 2003; 118: 107-13.
206. Qin HZ, Wang JL, Li LH, Bai WS, Zhao ZW, Gao GD. Neuroprotective effect of the combination of nimodipine and citicoline on focal cerebral ischemia-reperfusion rats. *Chin J Cerebrovasc Dis* 2009; 6: 29-32.
207. Pramila B, Kalaivani P, Barathidasan R, Saravana Babu C. Combination of citicoline and L-NAME restores neurological functions, reverts biochemical alterations and reduces neuronal damage in transient focal cerebral ischemic rats. *Indian J Sci Technol* 2015; 8: 804-13.
208. Sahin S, Alkan T, Temel SG, Tureyen K, Tolunay S, Korfali E. Effects of citicoline used alone and in combination with mild hypothermia on apoptosis induced by focal cerebral ischemia in rats. *J Clin Neurosci* 2010; 17: 227-31.
209. González-Pacheco H, Méndez-Domínguez A, Hernández S, López-Marure R, Vázquez-Mellado MJ, Aguilar C, et al. Pre-conditioning with CDP-choline attenuates oxidative stress-induced cardiac myocyte death in a hypoxia/reperfusion model. *Sci World J* 2014; 2014: 187071.
210. Gutiérrez M, Rodríguez B, Álvarez J, Expósito M, Vallejo M, Merino J, et al. Effects of citicoline and mesenchymal stem cells in acute cerebral infarct. Experimental study in rats. European Stroke Conference. Barcelona (Spain), May 2010.
211. Gutiérrez-Fernández M, Rodríguez-Frutos B, Fuentes B, Vallejo-Cremades MT, Álvarez-Grech J, Expósito-Alcaide M, et al. CDP-choline treatment induces brain plasticity markers expression in experimental animal stroke. *Neurochem Int* 2011; 60: 310-7.
212. Diederich K, Frauenknecht K, Minnerup J, Schneider BK, Schmidt A, Altach E, et al. Citicoline enhances

- neuroregenerative processes after experimental stroke in rats. *Stroke* 2012; 43: 1931-40.
213. Krupinski J, Abudawood M, Matou-Nasri S, Al-Baradie R, Petcu E, Justicia C, et al. Citicoline induces angiogenesis improving survival of vascular/human brain microvessel endothelial cells through pathways involving ERK1/2 and insulin receptor substrate-1. *Vasc Cell* 2012; 4: 20.
  214. Bramanti V, Tomassoni D, Grasso S, Bronzi D, Napoli M, Campisi A, et al. Cholinergic precursors modulate the expression of heme oxygenase-1, p21 during astroglial cell proliferation and differentiation in culture. *Neurochem Res* 2012; 37: 2795-804.
  215. Fresta M, Puglisi G, Di Giacomo C, Russo A. Liposomes as in-vivo carriers for citicoline: effects on rat cerebral post-ischemic reperfusion. *J Pharm Pharmacol* 1994; 46: 974-81.
  216. Fresta M, Puglisi G. Biological effects of CDP-choline loaded long circulating liposomes on rat cerebral post-ischemic reperfusion. *Int J Pharm* 1996; 134: 89-97.
  217. Fresta M, Puglisi G. Survival rate improvement in a rat ischemia model by long circulating liposomes containing cytidine-5'-diphosphate choline. *Life Sci* 1997; 61: 1227-35.
  218. Fresta M, Puglisi G. Reduction of maturation phenomenon in cerebral ischemia with CDP-choline-loaded liposomes. *Pharm Res* 1999; 16: 1843-9.
  219. Ramos-Cabrer P, Agulla J, Argibay B, Pérez-Mato M, Castillo J. Serial MRI study of the enhanced therapeutic effects of liposome-encapsulated citicoline in cerebral ischemia. *Int J Pharm* 2011; 405: 228-33.
  220. Ghosh S, Das N, Mandal AK, Dungdung SR, Sarkar S. Mannosylated liposomal cytidine 5' diphosphocholine prevent age related global moderate cerebral ischemia reperfusion induced mitochondrial cytochrome c release in aged rat brain. *Neuroscience* 2010; 171: 1287-99.
  221. Liu H, Jablonska A, Li Y, Cao S, Liu D, Chen H, et al. Label-free CEST MRI detection of citicoline-liposome drug delivery in ischemic stroke. *Theranostics* 2016; 6: 1588-600.
  222. Xu F, Hongbin H, Yan J, Chen H, He Q, Xu W, et al. Greatly improved neuroprotective efficiency of citicoline by stereotactic delivery in treatment of ischemic injury. *Drug Deliv* 2011; 18: 461-7.
  223. Han H, Xia Z, Chen H, Hou C, Li W. Simple diffusion delivery via brain interstitial route for the treatment of cerebral ischemia. *Sci China Life Sci* 2011; 54: 235-9.
  224. Park CH, Kim YS, Noh HS, Cheon EW, Yang YA, Yoo JM, et al. Neuroprotective effect of citicoline against KA-induced neurotoxicity in the rat retina. *Exp Eye Res* 2005; 81: 350-8.
  225. Han YS, Chung IY, Park JM, Yu JM. Neuroprotective effect of citicoline on retinal cell damage induced by kainic acid in rats. *Korean J Ophthalmol* 2005; 19: 219-26.
  226. Park CH, Kim YS, Cheon EW, Noh HS, Cho CH, Chung IY, et al. Action of citicoline on rat retinal expression of extracellular-signal-regulated kinase (ERK1/2). *Brain Res* 2006; 1081: 203-10.
  227. Park CH, Kim YS, Lee HK, Kim YH, Choi MY, Jung DE, et al. Citicoline reduces upregulated clusterin following kainic acid injection in the rat retina. *Curr Eye Res* 2007; 32: 1055-63.
  228. Matteucci A, Varano M, Gaddini L, Mallozzi C, Villa M, Pricci F, et al. Neuroprotective effects of citicoline in vitro models of retinal neurodegeneration. *Int J Mol Sci* 2014; 15: 6286-97.
  229. Hamdorf G, Cervós-Navarro J. Study of the effects of oral administration of CDP-choline on open-field behaviour under conditions of chronic hypoxia. *Arzneimittelforschung* 1990; 40: 519-22.
  230. Hamdorf G, Cervós-Navarro J. Therapeutic effect of orally applied cytidine diphosphate choline in mild and severe degrees of normobaric and normocapnic degrees of hypoxia of rats. *Arzneimittelforschung* 1991; 41: 1206-10.
  231. Lee HJ, Kang JS, Kim YI. Citicoline protects against cognitive impairment in a rat model of chronic cerebral hyperperfusion. *J Clin Neurol* 2009; 5: 33-8.
  232. Ma X, Zhang H, Pan Q, Zhao Y, Chen J, Zhao B, et al. Hypoxia/aglycemia-induced endothelial barrier dysfunction and tight junction protein downregulation can be ameliorated by citicoline. *PLoS One* 2013; 8: e82604.
  233. Hernández-Esquivel L, Pavón N, Buelna-Chontal M, González-Pacheco H, Belmont J, Chávez E. Citicoline (CDP-choline) protects myocardium from ischemia/reperfusion injury via inhibiting mitochondrial permeability transition. *Life Sci* 2014; 96: 53-8.
  234. Hernández-Esquivel L, Pavón N, Buelna-Chontal M, González-Pacheco H, Belmont J, Chávez E. Cardioprotective properties of citicoline against hyperthyroidism-induced reperfusion damage in rat hearts. *Biochem Cell Biol* 2015; 93: 1-7.
  235. Yildirim T, Eylen A, Lule S, Erdener SE, Vural A, Karatas H, et al. Poloxamer-188 and citicoline provide neuronal membrane integrity and protect membrane stability in cortical spreading depression. *Int J Neurosci* 2015; 125: 941-6.
  236. Hurtado O, Hernández-Jiménez M, Zarruk JG, Cuartero MI, Ballesteros I, Camarero G, et al. Citicoline (CDP-choline) increases Sirtuin1 expression concomitant to neuroprotection in experimental stroke. *J Neurochem* 2013; 126: 819-26.
  237. Masi I, Giani E, Galli C. Effects of CDP-choline on platelet aggregation and the antiaggregatory activity of arterial wall in the rat. *Pharmacol Res Commun* 1986; 18: 273-81.
  238. Pinardi G, Pelissier T, Kramer V, Paeile C, Miranda HF. Effects of CDP-choline on acetylcholine-induced relaxation of the perfused carotid vascular beds of the rat. *Gen Pharmacol* 1994; 25: 635-8.
  239. Clark W, Gunion-Rinker L, Lessov N, Hazel K. Citicoline treatment for experimental intracerebral hemorrhage in mice. *Stroke* 1998; 29: 2136-40.
  240. Kermer P, Klocker N, Bahr M. Neuronal death after brain injury –models, mechanisms, and therapeutic strategies in vivo. *Cell Tissue Res* 1999; 298: 383-93.
  241. Banasiak KJ, Xia Y, Haddad GG. Mechanisms underlying hypoxia-induced neuronal apoptosis. *Prog Neurobiol* 2000; 62: 215-49.
  242. Kuschinsky W, Gillardon F. Apoptosis and cerebral ischemia. *Cerebrovasc Dis* 2000; 110: 165-9.
  243. Mattson MP, Culmsee C, Yu ZF. Apoptotic and antiapoptotic mechanisms in stroke. *Cell Tissue Res* 2000; 301: 173-87.
  244. Harrison DC, Davis RP, Bond BC, Campbell CA, James MF, Parsons AA, et al. Caspase mRNA expression in a rat model of focal cerebral ischemia. *Mol Brain Res* 2001; 89: 133-46.
  245. Love S, Barber R, Srinivasan A, Wilcock GK. Activation of caspase-3 in permanent and transient brain ischaemia in man. *Neuroreport* 2000; 11: 2495-9.
  246. Love S, Barber R, Wilcock GK. Neuronal death in brain infarcts in man. *Neuropathol Appl Neurobiol* 2000; 26: 55-66.
  247. Krupinski J, Ferrer I, Barrachina M, Secades JJ, Mercadal J, Lozano R. CDP-choline reduces pro-caspase and cleaved caspase-3 expression, nuclear DNA fragmentation, and specific PARP-cleaved products of caspase activation following middle cerebral artery occlusion in the rat. *Neuropharmacology* 2002; 42: 846-54.
  248. Pramila B, Kalaivani P, Barathidasan R, Saravana Babu C. Preischemic administration of citicoline exerts better neuroprotection and restores neurochemical and motor functions in MCAO/R rats. *Int J Pharm Bio Sci* 2015; 6: 1462-76.
  249. Krupinski J, Slevin M, Badimon L. Citicoline inhibits MAP kinase signalling pathways after focal cerebral ischaemia. *Neurochem Res* 2005; 30: 1067-73.
  250. Mir C, Clotet J, Aledo R, Durany N, Argemí J, Lozano R, et al. CDP-choline prevents glutamate-mediated cell death in cerebellar granule neurons. *J Mol Neurosci* 2003; 20: 53-9.
  251. Barrachina M, Secades J, Lozano R, Gómez-Santos C, Ambrosio S, Ferrer I. Citicoline increases glutathione redox ratio and reduces caspase-3 activation and cell death in

- staurosporine-treated SH-SY5Y human neuroblastoma cells. *Brain Res* 2002; 957: 84-90.
252. Oshitari T, Fujimoto N, Adachi-Usami E. Citicoline has a protective effect on damaged retinal ganglion cells in mouse culture retina. *Neuroreport* 2002; 13: 2109-11.
253. Matyja E, Taraszewska A, Naganska E, Grieb P, Rafalowska J. CDP-choline protects motor neurons against apoptotic changes in a model of chronic glutamate excitotoxicity in vitro. *Folia Neuropathol* 2008; 46: 139-48.
254. Oshitari T, Yoshida-Hata N, Yamamoto S. Effect of neurotrophic factors on neuronal apoptosis and neurite regeneration in cultured rat retinas exposed to high glucose. *Brain Res* 2010; 1346: 43-51.
255. Fiedorowicz M, Makarewicz D, Stanczak-Mrozek KI, Grieb P. CDP-choline (citicoline) attenuates brain damage in a rat model of birth asphyxia. *Acta Neurobiol Exp (Wars)* 2008; 68: 389-97.
256. Bustamante A, Giralt D, García-Bonilla L, Campos M, Rosell A, Montaner J. Citicoline in pre-clinical animal models of stroke: a meta-analysis shows the optimal neuroprotective profile and the missing steps for jumping into a stroke clinical trial. *J Neurochem* 2012; 123: 217-25.
257. Giralt D, García-Bonilla L, Campos M, Sosti V, Rosell A, Montaner J. Selecting the optimal dose of citicoline treatment in animal models of focal cerebral ischemia through a meta-analysis. *European Stroke Conference. Barcelona (Spain), May 2010.*
258. Drago F, Valerio C, D'Agata V, Spadaro F, Astuto C, Lauria N, et al. Razionale farmacologico dell'impiego della CDP-colina nelle cerebrovasculopatie croniche. *Ann Ital Med Int* 1989; 4: 261-7.
259. Qureshi I, Endres JR. Citicoline: a novel therapeutic agent with neuroprotective, neuromodulatory, and neuroregenerative properties. *Nat Med J* 2010; 2: 11-25.
260. Saver JL. Target brain: neuroprotection and neurorestoration in ischemic stroke. *Rev Neurol Dis* 2010; 7 (Suppl 1): s14-21.
261. Álvarez-Sabín J, Roman GC. The role of citicoline in neuroprotection and neurorepair in ischemic stroke. *Brain Sci* 2013; 3: 1395-414.
262. Jambou R, El-Assaad F, Combes V, Grau GE. Citicoline (CDP-choline): what role in the treatment of complications of infectious diseases. *Int J Biochem Cell Biol* 2009; 41: 1467-70.
263. El-Assaad F, Combes V, Grau GE, Jambou R. Potential efficacy of citicoline as adjunct therapy in the treatment of cerebral malaria. *Antimicrob Agents Chemother* 2013; 58: 602-5.
264. Martinet M, Fonlupt P, Pacheco H. Effects of cytidine-5' diphosphocholine on norepinephrine, dopamine and serotonin synthesis in various regions of the rat brain. *Arch Int Pharmacodyn* 1979; 239: 52-61.
265. Martinet M, Fonlupt P, Pacheco H. Interaction of CDP-choline with synaptosomal transport of biogenic amines and their precursors in vitro and in vivo in the rat corpus striatum. *Experientia* 1978; 34: 1197-9.
266. Martinet M, Fonlupt P, Pacheco H. Activation of soluble striatal tyrosine hydroxylase in the rat brain after CDP-choline administration. *Biochem Pharmacol* 1981; 30: 539-41.
267. Saligaut C, Daoust M, Moore N, Chretien P, Boismare F. Capture de dopamine striatale chez le rat: effets d'une hypoxie hypobare aigüe et/ou d'un traitement oral par la cytidine diphosphocholine. *Circ Metab Cerv* 1984; 2: 33-42.
268. Saligaut C, Daoust M, Chadelaud M, Moore N, Chretien P, Boismare F. Oxotremorine-induced cholinergic syndrome: modifications by levodopa and/or oral cytidine diphosphocholine. *Methods Find Exp Clin Pharmacol* 1985; 7: 5-8.
269. Saligaut C, Daoust M, Moore N, Boismare F. Effects of hypoxia and cytidine (5') diphosphocholine on the concentration of dopamine, norepinephrine and metabolites in rat hypothalamus and striatum. *Arch Int Pharmacodyn* 1987; 285: 25-33.
270. Saligaut C, Daoust M, Moore N, Boismare F. Circling behaviour in rats with unilateral lesions of the nigrostriatum induced by 6-hydroxydopamine: changes induced by oral administration of cytidine-5'-diphosphocholine. *Neuropharmacology* 1987; 26: 1315-9.
271. Cansev M, Ilcol YO, Yilmaz MS, Hamurtekin E, Ulus IH. Peripheral administration of CDP-choline, phosphocholine or choline increases plasma adrenaline and noradrenaline concentrations. *Auton Autacoid Pharmacol* 2008; 28: 41-58.
272. Tayebati SK, Tomassoni D, Nwankwo IE, Di Stefano A, Sozio P, Cerasa LS, et al. Modulation of monoaminergic transporters by choline-containing phospholipids in rat brain. *CNS Neurol Disord Drug Targets* 2013; 12: 94-103.
273. Tayebati SK, Tomassoni D, Di Stefano A, Sozio P, Cerasa LS, Amenta F. Effect of choline-containing phospholipids on brain cholinergic transporters in the rat. *J Neurol Sci* 2011; 302: 49-57.
274. Agut J, López González-Coviella I, Wurtman RJ. Cytidine(5')diphosphocholine enhances the ability of haloperidol to increase dopamine metabolites in the striatum of the rat and to diminish stereotyped behavior induced by apomorphine. *Neuropharmacology* 1984; 23: 1403-6.
275. Agut J, Font E, Saladrich JM, Sacristán A, Ortiz JA. Acción de la CDP-colina sobre los niveles de los ácidos homovanílico (HVA) y 3-4-dihidroxifenilacético (DOPAC) en estriado de rata. *Med Clin (Barc)* 1986; 87 (Supl 1): 9-10.
276. Agut J, Font E, Sacristán A, Ortiz JA. Acción de la CDP-colina sobre la hipotermia inducida por la apomorfina en ratas. *Med Clin (Barc)* 1986; 87 (Supl 1): 11-3.
277. Agut J, Font E, Saladrich JM, Sacristán A, Ortiz JA. Acción farmacológica de la CDP-colina oral en un modelo de discinesia tardía en rata. *Med Clin (Barc)* 1986; 87 (Supl 1): 14-8.
278. Agut J, Font E, Saladrich JM, Sacristán A, Ortiz JA. Effect of oral CDP-choline on acrylamide-induced lesion. *Arzneimittelforschung* 1983; 33: 1029-33.
279. Shibuya M, Kageyama N, Taniguchi T, Hidaka H, Fujiwara M. Effects of CDP-choline on striatal dopamine level and behavior in rats. *Jpn J Pharmacol* 1981; 31: 47-52.
280. Stanzani S. Morphological effects of cytidin-diphosphate-choline on rats with lesions of the substantia nigra: study using horse radish peroxidase method. *Boll Soc It Biol Sper* 1980; 57: 1830-4.
281. Porceddu ML, Concas A. Partial protection by CDP-choline against kainic acid-induced lesion in the rat caudate nucleus. *Il Farmaco* 1985; 40: 617-22.
282. Jiang XY, Jia XJ, Lu WT, Zhao HG, Wang ZC, Gong SL. Neuroprotective effects of citicoline on 6-hydroxydopamine-treated mesencephalic dopaminergic neurons in primary culture. *J Jilin Univ (Med Ed)* 2006; 32: 224-7.
283. Jia XJ, Gong SL, Jiang XY, Qu YQ, Wolf-Dieter R. Neuroprotective effect of citicoline on dopaminergic neuron injury induced by MPP+ in mouse mesencephalic dissociated culture. *J Jilin Univ (Med Ed)* 2008; 34: 53-6.
284. Radad K, Gille G, Xiaojing J, Durany N, Rausch WD. CDP-choline reduces dopaminergic cell loss induced by MPP(+) and glutamate in primary mesencephalic cell culture. *Int J Neurosci* 2007; 117: 985-98.
285. Miwa S, Taniguchi T, Fujiwara M, Kurahashi K, Fujiwara M. Pharmacological studies on CDP-choline with special reference to effects on striatal dopaminergic mechanisms. In Zappia V, Kennedy EP, Nilsson BI, Galletti P, eds. *Novel biochemical, pharmacological and clinical aspects of cytidinediphosphocholine*. Amsterdam: Elsevier Science Publishing; 1985. p. 179-94.
286. Giménez R, Raich J, Aguilar J. Changes in brain striatum dopamine and acetylcholine receptors induced by chronic CDP-choline treatment in aging mice. *Br J Pharmacol* 1991; 104: 575-8.

287. Petkov VD, Popova JS. Effects of the nootropic agents adafenoxate, meclofenoxate and the acetylcholine precursor citicholine on the brain muscarinic receptors (experiments on rats). *Acta Physiol Pharmacol Bulg* 1987; 13: 3-10.
288. Petkov VD, Stancheva SL, Tocuschieva L, Petkov VV. Changes in brain biogenic monoamines induced by the nootropic drugs adafenoxate and meclofenoxate and by citicholine (experiments on rats). *Gen Pharmacol* 1990; 21: 71-5.
289. Rejdak R, Toczolowski J, Solski J, Duma D, Grieb P. Citicoline treatment increases retinal dopamine content in rabbits. *Ophthalmic Res* 2002; 34: 146-9.
290. Mao J, Liu S, Fu C. Citicoline retards myopia progression following form deprivation in guinea pigs. *Exp Biol Med (Maywood)* 2016; 241: 1258-63.
291. López González-Coviella I, Agut J, Wurtman RJ. Effect of cytidine(5')diphosphocholine (CDP-choline) on the total urinary excretion of 3-methoxy-4-hydroxyphenylglycol (MHPG) by rats and humans. *J Neural Transm* 1986; 66: 129-34.
292. Agut J, Watkins C, Maher T, Ortiz JA, Wurtman RJ. Oral CDP-choline administration to rats increases glutamate and decreases GABA cortical brain levels. 27th Annual Meeting of the Society of Neuroscience. New Orleans, Oct 25-30, 1997.
293. Cavun S, Savci V, Ulus IH. Centrally injected CDP-choline increases plasma vasopressin levels by central cholinergic activation. *Fundam Clin Pharmacol* 2004; 18: 71-7.
294. Cavun S, Savci V. CDP-choline increases plasma ACTH and potentiates the stimulated release of GH, TSH and LH: the cholinergic involvement. *Fundam Clin Pharmacol* 2004; 18: 513-23.
295. Eyigor O, Coskun C, Cavun S, Savci V. Intravenous CDP-choline activates neurons in supraoptic and paraventricular nuclei and induces hormone secretion. *Brain Res Bull* 2012; 87: 286-94.
296. Savci V, Cavun S, Goktalay G, Ulus IH. Cardiovascular effects of intracerebroventricularly injected CDP-choline in normotensive and hypotensive animals: the involvement of cholinergic system. *Naunyn Schmiedebergs Arch Pharmacol* 2002; 365: 388-98.
297. Savci V, Goktalay G, Cansev M, Cavun S, Yilmaz MS, Ulus IH. Intravenously injected CDP-choline increases blood pressure and reverses hypotension in haemorrhagic shock: effect is mediated by central cholinergic activation. *Eur J Pharmacol* 2003; 468: 129-39.
298. Yilmaz MS, Yalcin M, Savci V. Cytidine 5'-diphosphocholine restores blood flow of superior mesenteric and renal arteries and prolongs survival time in haemorrhaged anaesthetized rats. *Clin Exp Pharmacol Physiol* 2006; 33: 415-20.
299. Jochem J, Savci V, Filiz N, Rybus-Kalinowska B, Fogel WA, Yalcin M. Involvement of the histaminergic system in cytidine 5'-diphosphocholine-induced reversal of critical haemorrhagic hypotension in rats. *J Physiol Pharmacol* 2010; 61: 37-43.
300. Cansev M, Yilmaz MS, Ilcol YO, Hamurtekin E, Ulus IH. Cardiovascular effects of CDP-choline and its metabolites: Involvement of peripheral autonomic nervous system. *Eur J Pharmacol* 2007; 577: 129-42.
301. Yilmaz MS, Coskun C, Yalcin M, Savci V. CDP-choline prevents cardiac arrhythmias and lethality induced by short-term myocardial ischemia-reperfusion injury in the rat: involvement of central muscarinic cholinergic mechanisms. *Naunyn Schmiedebergs Arch Pharmacol* 2008; 378: 293-301.
302. Isbil-Buyukcoskun N, Ilcol YO, Cansev M, Hamurtekin E, Ozluk K, Ulus IH. Central choline suppresses plasma renin response to graded haemorrhage in rats. *Clin Exp Pharmacol Physiol* 2008; 35: 1023-31.
303. Yu H, Qing H, Lei Z. Cytidine diphosphate choline improves the outcome of cardiac arrest vs epinephrine in rat model. *Am J Emerg Med* 2013; 31: 1022-8.
304. Ilcol YO, Cansev M, Yilmaz MS, Hamurtekin E, Ulus IH. Intraperitoneal administration of CDP-choline and its cholinergic and pyrimidineric metabolites induce hyperglycemia in rats: involvement of the sympathoadrenal system. *Arch Physiol Biochem* 2007; 113: 186-201.
305. Ilcol YO, Cansev M, Yilmaz MS, Hamurtekin E, Ulus IH. Peripheral administration of CDP-choline and its cholinergic metabolites increases serum insulin: muscarinic and nicotinic acetylcholine receptors are both involved in their actions. *Neurosci Lett* 2008; 431: 71-6.
306. Cansev M, Ilcol YO, Yilmaz MS, Hamurtekin E, Ulus IH. Choline, CDP-choline or phosphocholine increases plasma glucagon in rats: involvement of the peripheral autonomic nervous system. *Eur J Pharmacol* 2008; 589: 315-22.
307. Kiyici S, Basaran NF, Cavun S, Savci V. Central injection of CDP-choline suppresses serum ghrelin levels while increasing serum leptin levels in rats. *Eur J Pharmacol* 2015; 764: 264-70.
308. Villa RF, Ferrari F, Gorini A. Effect of CDP-choline on age-dependent modifications of energy- and glutamate-linked enzyme activities in synaptic and non-synaptic mitochondria from rat cerebral cortex. *Neurochem Int* 2012; 61: 1424-32.
309. Ilcol YO, Yilmaz Z, Cansev M, Ulus IH. Choline or CDP-choline alters serum lipid responses to endotoxin in dogs and rats: involvement of the peripheral nicotinic acetylcholine receptors. *Shock* 2009; 32: 286-94.
310. Uslu G, Savci V, Buyukyuksal LR, Goktalay G. CDP-choline attenuates scopolamine induced disruption of prepulse inhibition in rats: involvement of central nicotinic mechanism. *Neurosci Lett* 2014; 569: 153-7.
311. Yilmaz Z, Ozarda Y, Cansev M, Eralp O, Kocaturk M, Ulus IH. Choline or CDP-choline attenuates coagulation abnormalities and prevents the development of acute disseminated intravascular coagulation in dogs during endotoxemia. *Blood Coagul Fibrinolysis* 2010; 21: 339-48.
312. Hamurtekin E, Sibel Gurun M. The antinociceptive effects of centrally administered CDP-choline on acute pain models in rats: the involvement of cholinergic system. *Brain Res* 2006; 1117: 92-100.
313. Gurun MS, Parker R, Eisenach JC, Vincler M. The effect of peripherally administered CDP-choline in an acute inflammatory pain model: the role of alpha7 nicotinic acetylcholine receptor. *Anesth Analg* 2009; 108: 1680-7.
314. Kanat O, Bagdas D, Ozboluk HY, Gurun MS. Preclinical evidence for the antihyperalgesic activity of CDP-choline in oxaliplatin-induced neuropathic pain. *J BUON* 2013; 18: 1012-28.
315. Hamurtekin E, Bagdas D, Gurun MS. Possible involvement of supraspinal opioid and GABA receptors in CDP-choline-induced antinociception in acute pain models in rats. *Neurosci Lett* 2007; 420: 116-21.
316. Bagdas D, Sonat FA, Hamurtekin E, Sonal S, Gurun MS. The antihyperalgesic effect of cytidine-5'-diphosphate-choline in neuropathic and inflammatory pain models. *Behav Pharmacol* 2011; 22: 589-98.
317. Bagdas D, Yucel-Ozbuluk H, Orhan F, Kanat O, Isbil-Buyukcoskun N, Gurun MS. Role of central arginine vasopressin receptors in the analgesic effect of CDP-choline on acute and neuropathic pain. *Neuroreport* 2013; 24: 941-6.
318. Kamei J, Ohsawa M, Miyata S, Endo K, Hayakawa H. Effects of cytidine 5'-diphosphocholine (CDP-choline) on the thermal nociceptive threshold in streptozotocin-induced diabetic mice. *Eur J Pharmacol* 2008; 598: 32-6.
319. Ahmadi A, Mohitmafi S, Abarkar A. Effects of citicoline sodium on corneal reflex, anesthesia and analgesia duration after thiopental sodium injection in dogs – a preliminary report. *J Paramed Sci* 2014; 5: 7-11.
320. Ahmadi A, Mohitmafi S. Effects of citicholine on respiration rate, SpO<sub>2</sub>, heart rate and rectal temperature during thiopental intravenous anaesthesia in canine model. *J Paramedical Sci* 2013; 4: 87-91.
321. Hassan ES, Rasoul A, Khadim HA. Assessment of citicoline protection against seizure induced in the rabbits. *QMJ* 2010; 6: 81-93.



322. Karpova MN, Zin'kovskii KA, Kuznetsova LV, Klishina NV. Increase of the seizure threshold in C57BL/6 mice after citicoline administration. *Bull Exp Biol Med* 2015; 158: 315-7.
323. Karpova MN, Kuznetsova LV, Zin'kovskii KA, Klishina NV. Anticonvulsant effects of combined treatment with citicoline and valproate on the model of acute generalized convulsions induced by pentylenetetrazole in Wistar rats. *Bull Exp Biol Med* 2016; 160: 429-31.
324. Kim JH, Lee DW, Choi BY, Sohn M, Lee SH, Choi HC, et al. Cytidine 5'-diphosphocholine (CDP-choline) adversely effects on pilocarpine seizure-induced hippocampal neuronal death. *Brain Res* 2015; 1595: 156-65.
325. Giménez R, Aguilar J. Effects of CDP-choline administration on brain striatum platelet-activating factor in aging rats. *Eur J Pharmacol* 1998; 344: 149-52.
326. Giménez R, Aguilar J. Cytidine (5') diphosphocholine-induced decrease in cerebral platelet activating factor is due to inactivation of its synthesizing enzyme cholinephosphotransferase in aged rats. *Neurosci Lett* 2001; 299: 209-12.
327. Guldali O, Savci V, Buyukafsar K. CDP-choline-induced contractions in the mouse gastric fundus through purinoceptors and Rho/Rho-kinase signalling. *Life Sci* 2011; 88: 473-9.
328. Topuz BB, Altinbas B, Yilmaz MS, Saha S, Batten TF, Savci V, et al. The effect of centrally injected CDP-choline on respiratory system; involvement of phospholipase to thromboxane signaling pathway. *Respir Physiol Neurobiol* 2014; 195: 50-8.
329. Topuz BB, Altinbas B, Ilhan T, Yilmaz MS, Erdost H, Saha S, et al. Centrally administered CDP-choline induced cardiovascular responses are mediated by activation of the central phospholipase-prostaglandin signaling cascade. *Brain Res* 2014; 1563: 61-71.
330. Cetinkaya M, Cansev M, Cekmez F, Tayman C, Canpolat FE, Kafa IM, et al. CDP-choline reduces severity of intestinal injury in a neonatal rat model of necrotizing enterocolitis. *J Surg Res* 2013; 183: 119-28.
331. Cetinkaya M, Cansev M, Kafa IM, Tayman C, Cekmez F, Canpolat FE, et al. Cytidine 5'-diphosphocholine ameliorates hyperoxic lung injury in a neonatal rat model. *Pediatr Res* 2013; 74: 26-33.
332. Ek RO, Serter M, Ergin K, Cecen S, Unsal C, Yildiz Y, et al. Protective effects of citicoline on TNBS-induced experimental colitis in rats. *Int J Clin Exp Med* 2014; 7: 989-97.
333. Drago F, Mauceri F, Nardo L, Valerio C, Genazzani AA, Grass M. Effects of cytidine-diphosphocholine on acetylcholine-mediated behaviors in the rat. *Brain Res Bull* 1993; 31: 485-9.
334. Petkov VD, Mosharraf AH, Petkov VV. Comparative studies on the effects of nootropic drugs adafenoxate, meclofenoxate and piracetam and of citicholine on scopolamine-impaired memory, exploratory behavior and physical capabilities (experiments on rats and mice). *Acta Physiol Pharmacol Bulg* 1988; 14: 3-13.
335. Mosharraf AH, Petkov VD. Effects of citicholine and of the combination citicholine + piracetam on the memory (experiments on mice). *Acta Physiol Pharmacol Bulg* 1990; 16: 25-31.
336. Takasaki K, Mishima K, Morita M, Morishita K, Nogami A, Sakamoto Y, et al. Cytidine-5'-diphosphocholine ameliorates the impairment of spatial memory induced by scopolamine. *J Health Sci* 2011; 57: 432-5.
337. Petkov VD, Kehayov RA, Mosharraf AH, Petkov VV, Getova D, Lazarova MB, et al. Effects of cytidine diphosphate choline on rats with memory deficits. *Arzneimittelforschung* 1993; 43: 822-8.
338. Álvarez XA, Vecino B, Perea JE, Daniele D, Cacabelos R. Citicoline antagonizes bromazepam-induced amnesia in rats. *Human Psychopharmacol* 1997; 12: 547-56.
339. Bruhwiler J, Liegeois JF, Géczy J. Facilitatory effects of chronically administered citicoline on learning and memory processes in the dog. *Prog Neuropsychopharmacol Biol Psychiatry* 1998; 22: 115-28.
340. Teather LA, Wurtman RJ. Dietary cytidine (5')-diphosphocholine supplementation protects against development of memory deficits in aging rats. *Prog Neuropsychopharmacol Biol Psychiatry* 2003; 27: 711-7.
341. Teather LA, Wurtman RJ. Dietary CDP-choline supplementation prevents memory impairment caused by impoverished environmental conditions in rats. *Learn Mem* 2005; 12: 39-43.
342. De Bruin NM, Kiliaan AJ, De Wilde MC, Broersen LM. Combined uridine and choline administration improves cognitive deficits in spontaneously hypertensive rats. *Neurobiol Learn Mem* 2003; 80: 63-79.
343. De Medio GE, Trovarelli G, Piccinin GL, Porcellati G. The effect of cytidine-diphosphate choline (CDP-choline) on brain lipid changes during aging. *J Neurosci Res* 1984; 11: 49-58.
344. López González-Coviella I, Agut J, Ortiz JA, Wurtman RJ. Effects of orally administered cytidine 5'-diphosphate choline on brain phospholipid content. *J Nutr Biochem* 1992; 3: 313-5.
345. Wang CS, Lee RKK. Choline plus cytidine stimulate phospholipid production, and the expression and secretion of amyloid precursor protein in rat PC12 cells. *Neurosci Lett* 2000; 283: 25-8.
346. Plataras C, Angelogianni P, Tsakiris S. Effect of CDP-choline on hippocampal acetylcholinesterase and Na<sup>+</sup>,K<sup>+</sup>-ATPase in adult and aged rats. *Z Naturforsch* 2003; 58: 277-81.
347. Zhang LN, Sun YJ, Pan S, Li JX, Qu YE, Li Y, et al. Na(+)-K(+)-ATPase, a potent neuroprotective modulator against Alzheimer disease. *Fundam Clin Pharmacol* 2013; 27: 96-103.
348. Giménez R, Soler S, Aguilar J. Cytidine diphosphate choline administration activates brain cytidine triphosphate: phosphocholine cytidyltransferase in aged rats. *Neurosci Lett* 1999; 273: 163-6.
349. Giménez R, Aguilar J. Effects of cytidine 5'-diphosphocholine on plasma homocysteine levels in rat. *Comp Biochem Physiol B Biochem Mol Biol* 2003; 134: 271-6.
350. Giuffrida Stella AM, Alberghina M, Avola R, Condorelli DF, Ragusa N, Turpeenoja L, et al. Effetto della somministrazione cronica di CDP-colina sul metabolismo degli acidi nucleici e delle proteine in diverse aree cerebrali durante l'invecchiamento. *G Gerontol* 1988; 36: 331-40.
351. Avola R, Villa R, Condorelli DF, Magri G, Ingrao F, Turpeenoja L, et al. Age-dependent changes on nucleic acid and protein metabolism in different brain regions: effect of CDP-choline treatment. In De Vellis J, Pérez-Polo JR, Giuffrida Stella AM, eds. *Regulation of gene expression in the nervous system*. New York: Wiley-Liss; 1990. p. 399-401.
352. Villa RF, Ingrao F, Magri G, Gorini A, Reale S, Costa A, et al. Effect of CDP-choline treatment on mitochondrial and synaptosomal protein composition in different brain regions during aging. *Int J Dev Neurosci* 1993; 11: 83-93.
353. Deutsch SI, Rosse RB, Schwartz BL, Schooler NR, Gaskins BL, Long KD, et al. Effects of CDP-choline and the combination of CDP-choline and galantamine differ in an animal model of schizophrenia: Development of a selective alpha(7) nicotinic acetylcholine receptor agonist strategy. *Eur Neuropsychopharmacol* 2008; 18: 147-51.
354. Petkov VD, Milanov S, Petkov VV. Effects of CDP-choline and the nootropic drug meclofenoxate on age-related changes in the blood levels of prolactin and growth hormone. *C R Acad Bulg Sci* 1993; 46: 137-9.
355. Crespo D, Verduga R, Fernández-Viadero C, Megías M. Structural changes induced by cytidine-5'-diphosphate choline (CDP-choline) chronic treatment in neurosecretory

- neurons of the supraoptic nucleus of aged CFW-mice. *Mech Ageing Dev* 1995; 84: 183-93.
356. Crespo D, Megias M, Fernández-Viadero C, Verduga R. Chronic treatment with a precursor of cellular phosphatidylcholine ameliorates morphological and behavioral effects of aging in the rat hippocampus. *Ann NY Acad Sci* 2004; 1019: 41-3.
357. Miguel-Hidalgo JJ, Álvarez XA, Lagares R, Franco A, Fernández L, Cacabelos R. Brain neurotoxic lesions in rats: study of the neuroprotective effects of CDP-choline. 20th CINP Congress. Melbourne, June 1995.
358. Miguel-Hidalgo JJ, Álvarez XA, Lagares R, Franco A, Fernández L, Cacabelos R. Protective effects of CDP-choline against neurotoxic lesions in rat brain. 10th World Congress of Psychiatry. Madrid, Aug 23-28, 1996.
359. Abdel-Zaher AO, Hamdy MM, Abdel-Rahman MS, Abd El-Hamid DH. Protective effect of citicoline against aluminum-induced cognitive impairments in rats. *Toxicol Ind Health* 2016; May 13. [Epub ahead of print].
360. Zhiliuk VI, Mamchur VI, Pavlov SV. Role of functional state of neuronal mitochondria of cerebral cortex in mechanisms of nootropic activity of neuroprotectors in rats with alloxan hyperglycemia. *Eksp Klin Farmakol* 2015; 78: 10-4.
361. Amol G, Loc BP, Ramya YS. A comparative study of the effect of supplementing citicoline with fluoxetine and amitriptyline on learning and memory in albino rats. *Int J Basic Clin Pharmacol* 2015; 4: 884-7.
362. Miguel-Hidalgo JJ, Álvarez A, Cacabelos R. Plasticity of Congo red staining displayed by subpopulations of neurons within the rat central nervous system. *Cell Tissue Res* 1998; 293: 75-86.
363. Kenarova B, Vladimirova R, Hadjiivanova C, Petkov VD. Immunomodulating effects of cytidine diphosphate choline. *Biomed Lett* 1994; 49: 119-25.
364. Álvarez XA, Sampedro C, Lozano R, Cacabelos R. Citicoline protects hippocampal neurons against apoptosis induced by brain beta-amyloid deposits plus cerebral hypoperfusion in rats. *Methods Find Exp Clin Pharmacol* 1999; 21: 535-40.
365. Takasaki K, Uchida K, Fujikawa R, Nogami A, Nakamura K, Kawasaki C, et al. Neuroprotective effects of citidine-5-diphosphocholine on impaired spatial memory in a rat model of cerebrovascular dementia. *J Pharmacol Sci* 2011; 116: 232-7.
366. Mosharraf AH, Petkov VD, Petkov VV. Effects of meclofenoxate and citicholine on learning and memory in aged rats. *Acta Physiol Pharmacol Bulg* 1987; 13: 17-24.
367. Petkov VD, Mosharraf AH, Petkov VV, Kehayov RA. Age-related differences in memory and in the memory effects of nootropic drugs. *Acta Physiol Pharmacol Bulg* 1990; 16: 28-36.
368. Rema V, Bali KK, Ramachandra R, Chugh M, Darokhan Z, Chaudhary R. Cytidine-5-diphosphocholine supplement in early life induces stable increase in dendritic complexity of neurons in the somatosensory cortex of adult rats. *Neuroscience* 2008; 155: 556-64.
369. Bramanti V, Campisi A, Tomassoni D, Li Volti G, Caccamo D, Cannavò G, et al. Effect of acetylcholine precursors on proliferation and differentiation of astroglial cells in primary cultures. *Neurochem Res* 2008; 33: 2601-8.
370. Mieviss S, Levivier M, Vassart G, Brotchi J, Ledent C, Blum D. Citicoline is not protective in experimental models of Huntington's disease. *Neurobiol Aging* 2007; 28: 1944-6.
371. Knippenberg S, Skripuletz T, Rath KJ, Thau N, Gudi V, Pul R, et al. CDP-choline is not protective in the SOD1-G93A mouse model of ALS. *Amyotroph Lateral Scler Frontotemporal Degener* 2013; 14: 284-90.
372. Valdayo M. Tratamiento de las toxicomanías con citidín-difosfato de colina. *Phronesis* 1983; 5: 313-6.
373. Tornos ME, Sacristán A, Ortiz JA. Effect of oral CDP-choline on experimental withdrawal syndrome. *Arzneimittelforschung* 1983; 33: 1018-21.
374. Patt S, Cervós-Navarro J, Stoltenburg-Didinger, G, Schreiner, C. The effects of CDP-choline on newborn rat pups with experimental alcohol fetopathy. A Golgi study. *Histol Histopathol* 1989; 4: 429-34.
375. Wang G, Bieberich E. Prenatal alcohol exposure triggers ceramide-induced apoptosis in neural crest-derived tissues concurrent with defective cranial development. *Cell Death Dis* 2010; 1: e46.
376. Petkov VD, Konstantinova ER, Petkov VV, Vaglenova JV. Learning and memory in rats exposed pre- and postnatally to alcohol. An attempt at pharmacological control. *Meth Find Exp Clin Pharmacol* 1991; 13: 43-50.
377. Rosario P, Rubio I, De la Morena E. Effects of CDP-choline administration on in vivo release and biosynthesis of acetylcholine in hippocampus of ethanol-treated rats as studied by in vivo brain microdialysis. *J Neural Trans* 1996; 103: 46-7.
378. Rosario P, De la Morena E. CDP-choline reverses opiate receptor-induced decreases in hippocampal acetylcholine release during chronic ethanol consumption and suppresses the withdrawal syndrome. A microdialysis study. 4th Congress of the European Society for Clinical Neuropharmacology. Israel, 1997.
379. Grau T, Romero A, Sacristán A, Ortiz JA. Study on the protection of CDP-choline against nicotine intoxication. *Arzneimittelforschung* 1983; 33: 1025-6.
380. Sugianto P, Aulanni'am, Widodo MA, Machfoed MH. Neuroprotective effect of citicholine in mercury intoxication. *International Journal of Pharmaceutical Science Invention* 2013; 2: 38-44.
381. Grau T, Romero A, Sacristán A, Ortiz JA. CDP-choline: acute toxicity study. *Arzneimittelforschung* 1983; 33: 1033-4.
382. Matsuda Y, Toda N, Takaori S. Toxicidad aguda, subaguda y crónica de la CDP-colina en ratas y conejos. *Gendai no Rinsho* 1967; 1: 99-107.
383. Kanabayashi T, Shiota K, Mizuno M, Isaka H, Hoshino H. Toxicological studies on citicoline. Acute and subacute toxicity study in mice and rats. *Aso Yakuri* 1980; 20: 109-26.
384. Agut J, Font E, Sacristán A, Ortiz JA. Dissimilar effects in acute toxicity studies of CDP-choline and choline. *Arzneimittelforschung* 1983; 33: 1016-8.
385. Ciaceri G. Toxicological studies on CDP-choline. In Zappia V, Kennedy EP, Nilsson BI, Galletti P, eds. *Novel biochemical, pharmacological and clinical aspects of cytidinediphosphocholine*. Amsterdam: Elsevier Science Publishing; 1985. p. 159-67.
386. Schauss AG, Somfai-Relle S, Financsek I, Glavits R, Parent SC, Endres JR, et al. Single- and repeated-dose oral toxicity studies of citicoline free-base (choline cytidine 5'-pyrophosphate) in Sprague-Dawley rats. *Int J Toxicol* 2009; 28: 479-87.
387. Romero A, Grau T, Sacristán A, Ortiz JA. Study of subacute toxicity of CDP-choline after 30 days of oral administration to rats. *Arzneimittelforschung* 1983; 33: 1035-8.
388. Romero A, Grau T, Sacristán A, Ortiz JA. CDP-choline: 6-month study toxicity in dogs. *Arzneimittelforschung* 1983; 33: 1038-42.
389. Agut J, Font E, Sacristán A, Ortiz JA. Bioavailability of methyl-<sup>14</sup>C CDP-choline by oral route. *Arzneimittelforschung* 1983; 33: 1045-7.
390. López González-Coviella I, Agut J, Von Borstel R, Wurtman RJ. Metabolism of cytidine (5')-diphosphocholine (CDP-choline) following oral and intravenous administration to the human and the rat. *Neurochem Int* 1987; 11: 293-7.
391. López González-Coviella I, Agut J, Savci V, Ortiz JA, Wurtman RJ. Evidence that 5'-cytidinediphosphocholine can affect brain phospholipid composition by increasing choline and cytidine plasma levels. *J Neurochem* 1995; 65: 889-94.
392. Wurtman RJ, Regan M, Ulus I, Yu L. Effect of oral CDP-choline on plasma choline and uridine levels in humans. *Biochem Pharmacol* 2000; 60: 989-92.

393. Galletti P, De Rosa M, Nappi MA, Pontoni G, Del Piano L, Salluzzo A, et al. Transport and metabolism of double-labelled CDP-choline in mammalian tissues. *Biochem Pharmacol* 1985; 34: 4121-30.
394. De Rosa M, Galletti P, Romeo G, Nappi A, Pontoni G, Arrigoni E, et al. Pharmacokinetics and metabolism of double-labelled CDP-choline. In Zappia V, Kennedy EP, Nilsson BI, Galletti P, eds. *Novel biochemical, pharmacological and clinical aspects of cytidinediphosphocholine*. Amsterdam: Elsevier Science Publishing; 1985. p. 139-57.
395. Romero A, Serratos J, Sacristán A, Ortiz JA. High-resolution autoradiography in mouse brain 24 h after radiolabelled CDP-choline administration. *Arzneimittelforschung* 1983; 33: 1056-8.
396. Romero A, Serratos J, Sacristán A, Ortiz JA. High-resolution autoradiography in mouse brain and cerebellum 10 days after radiolabelled CDP-choline administration. *Arzneimittelforschung* 1983; 33: 1058-60.
397. Romero A, Serratos J, Sacristán A, Ortiz JA. Low-resolution autoradiography in rat brain after administering labelled CDP-choline. *Arzneimittelforschung* 1983; 33: 1054-6.
398. Agut J, Font E, Sacristán A, Ortiz JA. Radioactivity incorporation into different cerebral phospholipids after oral administration of <sup>14</sup>C methyl CDP-choline. *Arzneimittelforschung* 1983; 33: 1048-50.
399. Aguilar J, Giménez R, Bachs O, Enrich C, Agut J. Cerebral subcellular distribution of CDP-choline and/or its metabolites after oral administration of methyl-<sup>14</sup>C CDP-choline. *Arzneimittelforschung* 1983; 33: 1051-3.
400. Savci V, Wurtman RJ. Effect of cytidine on membrane phospholipid synthesis in rat striatal slices. *J Neurochem* 1995; 64: 378-84.
401. Knapp S, Wurtman RJ. Enhancement of free fatty acid incorporation into phospholipids by choline plus cytidine. *Brain Res* 1999; 822: 52-9.
402. Dinsdale JRM, Griffiths GK, Rowlands C, Castelló J, Ortiz JA, Maddock J, et al. Pharmacokinetics of <sup>14</sup>C CDP-choline. *Arzneimittelforschung* 1983; 33: 1066-70.
403. Moriyama M, Tsukumo T, Nakagawa Y. Effects of CDP-choline on head injury. *Gendai no Rinsho* 1967; 1: 114-20.
404. Ayuso JL, Saiz J. Efecto protector del citidín-5-difosfato de colina sobre el defecto mnésico post-electrochoque. *Munch Med Wochenschr* (ed. esp.) 1977; 119: 53-9.
405. De la Herrán J, Cortina C, Salazar J, Fernández F. Utilización del citidín difosfato de colina en lesiones encefálicas graves. *Actas Luso Esp Neurol Psiquiatr Ciencias Afines* 1978; 6: 3-12.
406. Carcasone M, LeTourneau JN. Étude en double insu du réxort en neurotraumatologie infantile. *Vie Médicale* 1979; 12: 1007.
407. Espagno J, Trémoulet M, Gigaud M, Espagno C. Étude de l'action de la CDP-choline dans les troubles de la vigilance post-traumatique. *Vie Médicale* 1979; 3: 195-6.
408. Richer E, Cohadon F. Essai thérapeutique d'un précurseur des phospholipides sur le traitement des comas traumatiques. *Symposium Internacional Souffrance Cérébrale et Précurseurs des Phospholipides*. Paris, Jan 18, 1980.
409. Lecuire J, Duplay J. Sperimentazione in doppio cieco della citicolina versus meclofenossato in pazienti colpiti da trauma cranico. *G Ital Ric Clin Ter* 1982; 3: 51-5.
410. Lecuire J, Duplay J. Sperimentazione della citicolina in un campione di 154 traumatizzati cranici. *G Ital Ric Clin Ter* 1982; 3: 61-7.
411. Lecuire J. Traumatismes crâniens: étude comparative piracetam-CDP-choline. *C R Ther Pharmacol Clin* 1985; 3: 3-7.
412. Cohadon F, Richer E. CDP-choline in severe traumatic coma: a double blind study. In Zappia V, Kennedy EP, Nilsson BI, Galletti P, eds. *Novel biochemical, pharmacological and clinical aspects of cytidinediphosphocholine*. Amsterdam: Elsevier Science Publishing; 1985. p. 299-303.
413. Deleuze R, Huguenard P, Laborit G, Roujas F. Effets de la CDP-choline sur le rapport lactates/pyruvates dans le LCR en cas de souffrance cérébrale grave. *C R Ther* 1985; 4: 11-8.
414. Ogasiwa M, Takeuchi K, Hara M, Tanaka Y, Okada J. Studies on the intrathecal pharmacotherapy. Part I: CDP-choline. *Int J Clin Pharmacol* 1975; 12: 327-35.
415. Ogasiwa M, Takeuchi K. Intrathecal pharmacotherapy in coma. *Acta Neurochir* 1976; 34: 37-44.
416. De Blas A, Martínez-Cubells J, Hernando C. Valoración de la efectividad de la citicolina en el tratamiento de los traumatismos craneoencefálicos. *Med Clin (Barc)* 1986; 87 (Supl 1): 41-4.
417. Ragueneau JL, Jarrige B. Enquête nationale sur les suites des traumatismes crâniens graves: analyse des 219 traumatismes traités par CDP-choline. *Agressologie* 1988; 29: 439-43.
418. Calatayud V, Calatayud JB, Aso J. Effects of CDP-choline on the recovery of patients with head injury. *J Neurol Sci* 1991; 103: S15-8.
419. Lozano R. CDP-choline in the treatment of cranio-encephalic trauma. *J Neurol Sci* 1991; 103: S43-7.
420. Levin HS. Treatment of postconcussional symptoms with CDP-choline. *J Neurol Sci* 1991; 103: S39-42.
421. Aniruddha TJ, Pillai S, Devi BI, Sampath S, Chandramouli BA. Role of citicolina in the management of mild head injury. *Indian J Neurotrauma* 2009; 6: 49-52.
422. Jotwani V, Harmon KG. Postconcussion syndrome in athletes. *Curr Sports Med Rep* 2010; 9: 21-6.
423. León-Carrión J, Domínguez-Roldán JM, Murillo-Cabeza F, Domínguez-Morales MR, Muñoz-Sánchez MA, Forastero P. Advances in the treatment of memory deficits after brain injury: the role of citicholine. 3rd World Congress on Brain Injury. Quebec, Jun 12-17, 1999.
424. León-Carrión J, Domínguez-Roldán JM, Murillo-Cabeza F, Domínguez-Morales MR, Muñoz-Sánchez MA. Normalization of memory-related cerebral blood flow in severe traumatic brain injury patients and improvements of memory induced by citicholine (CDP-choline): the role of a pro-cognitive drug. ICRAN'99. Taipei (Taiwan), November 1999.
425. León-Carrión J, Domínguez-Roldán JM, Murillo-Cabeza F, Domínguez-Morales MR, Muñoz-Sánchez MA. The role of citicholine in neuropsychological training after traumatic brain injury. *Neurorehabilitation* 2000; 14: 33-40.
426. Wortzel HS, Arciniegas DB. Treatment of post-traumatic cognitive impairments. *Curr Treat Options Neurol* 2012; 14: 493-508.
427. Spiers PA, Hochanadel G. Citicolina for traumatic brain injury: report of two cases, including my own. *J Int Neuropsychol Soc* 1999; 5: 260-4.
428. Chinnock P, Pokkunuri V. CDP-choline for acute traumatic brain injury. *Cochrane Database Syst Rev* 2005; 3: CD005402.
429. Zafonte R, Friedewald WT, Lee SM, Levin B, Díaz-Arrastia R, Ansel B, et al. The citicolina brain injury treatment (COBRIT) trial: design and methods. *J Neurotrauma* 2009; 26: 2207-16.
430. Zafonte RD, Bagiella E, Ansel BM, Novack TA, Friedewald WT, Hesdorffer DC, et al. Effect of citicolina on functional and cognitive status among patients with traumatic brain injury: Citicolina Brain Injury Treatment Trial (COBRIT). *JAMA* 2012; 308: 1993-2000.
431. Secades JJ. Citicolina for the treatment of head injury: a systematic review and meta-analysis of controlled clinical trials. *J Trauma Treat* 2014; 4: 227.
432. El Sayed I, Zaki A, Fayed AM, Shehata GM, Abdelmonem S. A meta-analysis of the effect of different neuroprotective drugs in management of patients with traumatic brain injury. *Neurosurg Rev* 2016; Aug 18. [Epub ahead of print].
433. El Reweny EM, Okasha A, Hafez A. The neuroprotective effect of citicholine (CDP choline) in patients with traumatic

- brain injury. 25th ESICM Annual Congress. Lisbon, Portugal, October 2012.
434. Salehpour F, Shokouhi G, Shakeri M, Shimia M, Maddkhah A, Baradaran A, et al. Neuroprotective effects of citicoline in diffuse axonal injuries. *Adv Biosci Clin Med* 2013; 1: 12-5.
  435. Salehpour F, Aghazade J, Mirzaee F, Mahdkhah A. Citicoline in patients with traumatic brain injuries. *EC Neurology* 2015; 2: 87-93.
  436. Shokouhi G, Haghjoo AG, Sattarnezhad N, Asghari M, Sattarnezhad A, Asghari A, et al. Effects of citicoline on level of consciousness, serum level of fetuin-A and matrix Gla-protein (MGP) in trauma patients with diffuse axonal injury (DAI) and GCS $\leq$ 8. *Ulus Travma Acil Cerrahi Derg* 2014; 20: 410-6.
  437. Janowitz T, Menon DK. Exploring new routes for neuroprotective drug development in traumatic brain injury. *Sci Transl Med* 2010; 2: 27rv1.
  438. Yadla S, Campbell PG, Jallo J. Traumatic brain injury: current management, controversies, and clinical trials. *Neurosurg Q* 2011; 21: 168-79.
  439. Brouns R, De Deyn PP. The complexity of neurobiological processes in acute ischemic stroke. *Clin Neurol Neurosurg* 2009; 111: 483-95.
  440. Rogalewski A, Schneider A, Ringelstein EB, Schabitz WR. Toward a multimodal neuroprotective treatment of stroke. *Stroke* 2006; 37: 1129-36.
  441. Minnerup J, Schabitz WR. Multifunctional actions of approved and candidate stroke drugs. *Neurotherapeutics* 2009; 6: 43-52.
  442. Zaleska MM, Mercado ML, Chavez J, Feuerstein GZ, Pangalos MN, Wood A. The development of stroke therapeutics: promising mechanisms and translational challenges. *Neuropharmacology* 2009; 56: 329-41.
  443. Chavez JC, Zaleska MM, Wang X, Wood A, Hurko O, Pangalos MN, et al. Multimodal magnetic resonance imaging for assessing evolution of ischemic penumbra: a key translational medicine strategy to manage the risk of developing novel therapies for acute ischemic stroke. *J Cereb Blood Flow Metab* 2009; 29: 217-9.
  444. Ducruet AF, Grobelny BT, Zacharia BE, Hickman ZL, Yeh ML, Connolly ES. Pharmacotherapy of cerebral ischemia. *Expert Opin Pharmacother* 2009; 10: 1895-906.
  445. Tuttolomondo A, Di Sciacca R, Di Raimondo D, Arnao V, Renda C, Pinto A, et al. Neuron protection as a therapeutic target in acute ischemic stroke. *Curr Top Med Chem* 2009; 9: 1317-34.
  446. Kellner CP, Connolly ES Jr. Neuroprotective strategies for intracerebral hemorrhage: trials and translation. *Stroke* 2010; 41 (Suppl 1): s99-102.
  447. Adeoye O, Broderick JP. Advances in the management of intracerebral hemorrhage. *Nat Rev Neurol* 2010; 6: 593-601.
  448. Sahota P, Savitz SI. Investigational therapies for ischemic stroke: neuroprotection and neurorecovery. *Neurotherapeutics* 2011; 8: 434-51.
  449. Goldstein LB. Poststroke pharmacotherapy: another ictus. *Stroke* 2012; 43: 3433-5.
  450. Matsuoka K, Uozumi T, Kano M, Yoshikawa I, Karita M, Toda T. Clinical study of the effect of cytidine diphosphate choline on sequelae of cerebral circulation disorders. *Gendai no Rinsho* 1967; 1: 184-9.
  451. Miyazaki M. Effects of CDP-choline on sequelae of cerebral apoplexy. *Gendai no Rinsho* 1967; 1: 169-71.
  452. Hazama T, Hasegawa T, Ueda S, Sakuma A. Evaluation of the effect of CDP-choline on poststroke hemiplegia employing a double-blind controlled trial: assessed by a new rating scale for recovery in hemiplegia. *Int J Neurosci* 1980; 11: 211-25.
  453. Goas JY, Bastard J, Missoune A. Bilan à 90 jours du traitement des accidents vasculaires cérébraux par la CDP-choline, à propos d'un essai en double insu. Symposium International: Souffrance Cérébrale et Précurseurs des Phospholipides. Paris, Jan 18, 1980.
  454. Boudouresques P, Alonzo B, Michel B. Conduite thérapeutique devant un accident vasculaire cérébral: place de la CDP-choline. Symposium International: Souffrance Cérébrale et Précurseurs des Phospholipides. Paris, Jan 18, 1980.
  455. Corso EA, Arena M, Ventimiglia A, Bizzarro G, Campo G, Rodolico F. La CDP-colina nelle vasculopatie cerebrali: valutazioni cliniche e di semiologia strumentale. *Clin Ter* 1982; 102: 379-86.
  456. Tazaki Y, Sakai F, Otomo E, Kutsuzawa T, Kameyama M, Omae T, et al. Treatment of acute cerebral infarction with a choline precursor in a multicenter double-blind placebo-controlled study. *Stroke* 1988; 19: 211-6.
  457. Schott B, Joyeux O. Valutazione dell'impiego della citicolina nella terapia di accidenti ischemici cerebrali. *G Ital Ric Clin Ter* 1982; 3: 56-60.
  458. Centrone G, Ragno G, Calicchio G. Uso della citicolina ad alti dosaggi nelle affezioni acute cerebro-vascolari. *Min Med* 1986; 77: 371-3.
  459. Dereux JE, Gallois P. Résultats comparatifs ACTH/citicoline dans la phase initiale des infarctus cérébraux. *Gazette Médicale* 1987; 94: 82-5.
  460. Franceschi M, Smirne S, Canal N. Treatment of clinical signs and EEG patterns in patients with 'organic brain syndrome'. Effects of citidin-diphosphocholine, citicholine. *Clin Trials J* 1982; 19: 74-84.
  461. Guillén F, Buendía C, Herrera JA. CDP-choline in the treatment of acute ischaemic stroke. 5th Meeting of the European Neurological Society. Munich, June 17-21, 1995.
  462. Bruhwylter J, Van Dorpe J, Géczy J. Multicentric open-label study of the efficacy and tolerability of citicoline in the treatment of acute cerebral infarction. *Curr Ther Res* 1997; 58: 309-16.
  463. Fridman EA, Ottaviano F, Fiol M, Javelier A, Perea JE, Ameriso SF. Neuroprotección en el ictus isquémico agudo. Factibilidad de un protocolo terapéutico. *Rev Neurol* 2001; 32: 818-21.
  464. Alviarez E, Gonzalez M. Efectividad y tolerabilidad de la citicolina en el ictus isquémico agudo, estudio aleatorizado, doble ciego comparado con placebo. *Archivos Venezolanos de Farmacología y Terapéutica* 2007; 26: 127-30.
  465. León-Jiménez C, Chiquete E, Cantú C, Miramontes-Saldaña MJ, Andrade-Ramos MA, Ruiz-Sandoval JL. Citicoline for acute ischemic stroke in Mexican hospitals: a retrospective postmarketing analysis. *Methods Find Exp Clin Pharmacol* 2010; 32: 325-30.
  466. Clark WM, Warach SJ, Pettigrew LC, Gammans RE, Sabounjian LA, for the Citicoline Study Group. A randomized dose-response trial of citicoline in acute ischemic stroke patients. *Neurology* 1997; 49: 671-8.
  467. Clark W, Williams BJ, Selzer KA, Zweifler RM, Sabounjian LA, Gammans RE. A randomized efficacy trial of citicoline in patients with acute ischemic stroke. *Stroke* 1999; 30: 2592-7.
  468. Clark WM, Wechsler LR, Sabounjian LA, Schwiderski UE. A phase III randomized efficacy trial of 2000 mg citicoline in acute ischemic stroke patients. *Neurology* 2001; 57: 1595-602.
  469. Tilley BC, Marler J, Geller NL, Lu M, Legler J, Brott T, et al. Use of a global test for multiple outcomes in stroke trials with application to the National Institute of Neurological Disorders and Stroke t-PA Stroke Trial. *Stroke* 1996; 27: 2136-42.
  470. Warach S, Benfield A, Schlaug G, Siewert B, Edelman RR. Reduction of lesion volume in human stroke by citicoline detected by diffusion weighted magnetic resonance imaging: a pilot study. *Ann Neurol* 1996; 40: 527-8.
  471. Warach S, Pettigrew LC, Dashe JE, Pullicino P, Lefkowitz DM, Sabounjian L, et al. Effect of citicoline on ischemic lesions as measured by diffusion-weighted magnetic resonance imaging. *Ann Neurol* 2000; 48: 713-22.
  472. Warach SJ, Sabounjian LA. ECCO 2000 study of citicoline for treatment of acute ischemic stroke: effects on infarct

- volumes measured by MRI. 25th International Stroke Conference. New Orleans, USA, February 2000.
473. Martínez-Vila E, Sieira PI. Current status and perspectives of neuroprotection in ischemic stroke treatment. *Cerebrovasc Dis* 2001; 11 (Suppl 1): 60-70.
  474. Dávalos A. Citicolina en el tratamiento del ictus isquémico agudo. Metaanálisis de los estudios clínicos y neuroimagen con citicolina en el ictus. Simposium Satélite, IX Curso en Español de la Academia Americana de Neurología. Miami, USA, 2000.
  475. Stewart LA, Clarke MJ. Practical methodology of meta-analyses (overviews) using updated individual patient data. *Cochrane Working Group. Stat Med* 1995; 14: 2057-79.
  476. Committee for Proprietary Medicinal Products. Points to consider on application with 1. Meta-analyses 2. One pivotal study. European Agency for the Evaluation of Medicinal Products. London, May 31, 2001.
  477. Dávalos A, Castillo J, Álvarez-Sabín J, Secades JJ, Mercadal J, López S, et al. Oral citicolina in acute ischemic stroke: an individual patient data pooling analysis of clinical trials. *Stroke* 2002; 33: 2850-7.
  478. Saver JL, Wilterdink J. Choline precursors in acute and subacute human stroke: a meta-analysis. *Stroke* 2002; 33: 353.
  479. Warach S, Harnett K. Dose dependent reduction in infarct growth with citicolina treatment: evidence of neuroprotection in human stroke? *Stroke* 2002; 33: 354.
  480. Casado A, Secades JJ, Ibarz R, Herdman M, Brosa M. Cost-effectiveness of citicolina versus conventional treatment in acute ischemic stroke. *Expert Rev Pharmacoeconomics Outcomes Res* 2008; 8: 151-7.
  481. Vorobyed P, Bezmelnitsyna L, Borisenko O. Cost-effectiveness of citicolina in patients with acute ischemic stroke in Russia. *Value in Health* 2011; 14: A41.
  482. Ryazhenov VV, Gorokhova SG. Pharmacoeconomic benefits of citicolina in the treatment of acute ischemic stroke in Russia. *Value in Health* 2013; 16: A519-20.
  483. Sobrino T, Rodríguez-González R, Blanco M, Brea D, Pérez-Mato M, Rodríguez-Yáñez M, et al. CDP-choline treatment increases circulating endothelial progenitor cells in acute ischemic stroke. *Neurol Res* 2011; 33: 572-7.
  484. Cho HJ, Kim YJ. Efficacy and safety of oral citicolina in acute ischemic stroke: drug surveillance study in 4191 cases. *Methods Find Exp Clin Pharmacol* 2009; 31: 171-6.
  485. Secades JJ, Álvarez-Sabín J, Rubio F, Lozano R, Dávalos A, Castillo J. Citicolina in intracerebral haemorrhage, a double-blind, randomized, placebo-controlled, multi-centre pilot study. *Cerebrovasc Dis* 2006; 21: 380-5.
  486. Eribal ME, Chua RH. Role of intravenous citicolina for supratentorial hemorrhage. *International Stroke Conference* 2007. San Francisco, USA.
  487. Iranmanesh F, Vakilian A. Efficiency of citicolina in increasing muscular strength of patients with nontraumatic cerebral hemorrhage: a double-blind randomized clinical trial. *J Stroke Cerebrovasc Dis* 2008; 17: 153-5.
  488. Secades JJ. Citicolina in the treatment of intracerebral hemorrhage. 4th Western China International Neuroscience Forum. Teng Chong (China), August 2010.
  489. Ali Mousavi S, Khorvash F, Hoseini T. The efficacy of citicolina in the treatment of ischemic stroke and primary hypertensive intracerebral hemorrhage: a review article. *ARYA Atheroscler* 2010; 6: 122-5.
  490. Toidze I, Aklavilli N, Lobjanidze N, Tsikarishvili L, Bakradze L, Janelidze M, et al. Use of citicolina (ceraxone) in treatment of secondary ischemic damage of subarachnoid hemorrhage after aneurysmal clipping. 8th World Stroke Conference. Brasilia (Brasil), October 10-12, 2012.
  491. Saver JL. Citicolina: update on a promising and widely available agent for neuroprotection and neurorepair. *Rev Neurol Dis* 2008; 5: 167-77.
  492. Lee M, Towfighi A, Saver JL. Choline precursors in acute and subacute ischemic and hemorrhagic stroke: an updated meta-analysis of randomized controlled trials. *Stroke* 2010; 41: e263.
  493. Martynov MI, Boiko AN, Kamchatnov PR, Kabanov AA, Iasmanova AN, Shchukin IA, et al. Neuroprotective treatment with citicolina (Ceraxon) in patients with ischemic stroke. *Zh Nevrol Psikhiatr Im S S Korsakova* 2012; 112: 21-6.
  494. Galkin AS, Koval'chuk VV, Gusev AO. Comparison of efficacy of different neurometabolic and vasoactive medicines in ischemic stroke patients' rehabilitation. *Zh Nevrol Psikhiatr Im S S Korsakova* 2011; 111 (Pt 1): 47-50.
  495. Piradov MA, Sergeev DV, Krotchenkova MV. Citicolina (Ceraxon) in acute stroke: assessment of clinical efficacy and effects on cerebral perfusion. *Ann Clin Exp Neurol* 2012; 6: 31-6.
  496. Mitta M, Goel D, Bansal KK, Puri P. Edaravone-citicolina comparative study in acute ischemic stroke (ECCS-AIS). *J Assoc Physicians India* 2012; 60: 36-8.
  497. Vaizova OE, Zautner NA, Alifirova VM, Vengerovski AI. Influence of neuroprotectors with choline-positive action on the level of brain-injury markers during acute ischemic stroke. *Eksp Klin Farmakol* 2012; 75: 7-9.
  498. Grewal N, Sharma G, Mohan G, Singh J. To study efficacy and safety of citicolina in acute ischemic stroke. *IJBCP* 2012; 1: 72-6.
  499. Martinov MI, Boiko AN, Kamchatnov PR, Kabanov AA, Yasamanova AN, Shchukin IA, et al. Neuroprotective therapy with citicolina (Ceraxon) in patients with ischemic stroke. *Neurosci Behav Physiol* 2013; 43: 706-11.
  500. Pushkarev K, Tsoy R. Neuroprotective therapy for lacunar stroke – which is better Ceraxon or Cerebrolysin? *Eur J Neurol* 2015; 22 (Suppl 1): 484-828.
  501. Ghosh S, Das SK, Nath T, Ghosh KC, Bhattacharyya R, Mondal GP. The effect of citicolina on stroke: a comparative study from the Eastern part of India. *Neurol India* 2015; 63: 697-701.
  502. Belova YA, Kotov SV, Chuksina YY, Shevelev SV, Yazdovskiy VV. Ceraxon (citicolina): likely impact on the angiogenesis process in patients with ischemic stroke. *Clin Gerontol* 2015; 21: 38-40.
  503. Umarova KY, Kazakov AY, Chugunov AV, Makeeva MM. Cerebrovascular diseases: the possibilities and efficiency of metabolic therapy. *Clinician* 2013; 2: 88-92.
  504. Shamalov NA, Stakhovskaia LV, Shetova IM, Efremova NM, Anisimov KV. Efficacy and safety of the combined therapy with citicolina and actovegin in the acute period of ischemic stroke. *Zh Nevrol Psikhiatr Im S S Korsakova* 2010; 110 (Pt 2): 13-7.
  505. Dávalos A. Protocol 06PRT/3005: ICTUS study: International Citicolina Trial on Acute Stroke (NCT00331890). Oral citicolina in acute ischemic stroke. *Lancet Protocol Reviews* 2007. URL: <http://www.thelancet.com/journals/lancet/misc/protocol/protocolreviews>.
  506. ICTUS Study: International Citicolina Trial on Acute Stroke. URL: <http://clinicaltrials.gov/ct2/show/NCT00331890?term=ictus&rank=1>.
  507. Bolland K, Whitehead J, Cobo E, Secades JJ. Evaluation of a sequential global test of improved recovery following stroke as applied to the ICTUS trial of citicolina. *Pharm Stat* 2008; 8: 136-49.
  508. Dávalos A, Álvarez-Sabín J, Castillo J, Díez-Tejedor E, Ferro J, Martínez-Vila E, et al. Citicolina in the treatment of acute ischaemic stroke: an international, randomised, multicentre, placebo-controlled study (ICTUS trial). *Lancet* 2012; 380: 349-57.
  509. Hankey GJ. How effective is citicolina for acute ischaemic stroke? *Lancet* 2012; 380: 318-9.
  510. Secades JJ, Álvarez-Sabín J, Castillo J, Díez-Tejedor E, Martínez-Vila E, Ríos J, et al. Citicolina for acute ischemic stroke: a systematic review and formal meta-analysis of randomized, double-blind, and placebo-controlled trials. *J Stroke Cerebrovasc Dis* 2016; 25: 1984-96.
  511. Shi PY, Zhou XC, Yin XX, Xu LL, Zhang XM, Bai HY. Early application of citicolina in the treatment of acute stroke: a

- meta-analysis of randomized controlled trials. *J Huazhong Univ Sci Technolog Med Sci* 2016; 36: 270-7.
512. Ueda S, Hasegawa T, Ando K, Okawa T, Chino N, Ogata H, et al. Evaluation of the pharmacological effect of CDP-choline injection in post-stroke hemiplegia. Double-blind comparative study using the Hemiplegia Function Test (12-grade evaluation method). *Strides of Medicine* 1994; 170: 297-314.
513. Galkin AS, Barantsevich ER, Gusev AO, Minnullin TI, Kovalchuck VV, Samus NL, et al. The possibilities of increase of efficacy of rehabilitation of stroke patients with neglect syndrome. *Zh Nevrol Psikhiatr Im S S Korsakova* 2014; 114: 30-4.
514. Secades JJ. Posible papel de la citicolina en la rehabilitación tras un ictus: revisión de la bibliografía. *Rev Neurol* 2012; 54: 173-9.
515. Krupinski J, Secades JJ, Shiraliyeva RK. Towards effective neurorehabilitation for stroke patients. *Int J Phys Med Rehabil* 2014; 2: 2.
516. Ovbiagele B, Kidwell CS, Starkman S, Saver JL. Potential role of neuroprotective agents in the treatment of patients with acute ischemic stroke. *Curr Treat Options Neurol* 2003; 5: 367-75.
517. Labiche LA, Grotta JC. Clinical trials for cytoprotection in stroke. *NeuroRx* 2004; 1: 46-70.
518. Alonso de Leciana M, Egidio JA, Casado I, Ribó M, Dávalos A, Masjuán J, et al. Guidelines for the treatment of acute ischaemic stroke. *Neurologia* 2014; 29: 102-22.
519. Muñoz-Collazos M. Avances en la terapéutica del ACV. *Revista de la Facultad de Ciencias de la Salud de la Universidad del Cauca* 2008; 6.
520. Davis S, Lees K, Donnan G. Treating the acute stroke patient as an emergency: current practices and future opportunities. *Int J Clin Pract* 2006; 60: 399-407.
521. Segura T, Calleja S, Jordán J. Recommendations and treatment strategies for the management of acute ischemic stroke. *Expert Opin Pharmacother* 2008; 9: 1071-85.
522. Jeyaseelan K, Lim KY, Armugam A. Neuroprotectants in stroke therapy. *Expert Opin Pharmacother* 2008; 9: 887-900.
523. Gupta SK, Gupta A, Gondhotra D, Gupta A, Gupta S. Role of citicolina in ischaemic stroke. *JK Science* 2008; 10: 160-2.
524. Schäbitz WR. CDP-cholin zur behandlung des schlaganfalls. *Psychopharmakotherapie* 2009; 16: 101-5.
525. Clark WM. Efficacy of citicolina as an acute stroke treatment. *Expert Opin Pharmacother* 2009; 10: 839-46.
526. Arenth PM, Russell KC, Ricker JH, Zafonte RD. CDP-choline as a biological supplement during neurorecovery: a focused review. *PM R* 2011; 3: s123-31.
527. Núñez-Coronado Y, Barrientos-Imán D. La era de la neuroprotección: citicolina en el infarto cerebral. *Rev Per Neurol* 2012; 13: 36-40.
528. Overgaard K. The effects of citicolina on acute ischemic stroke: a review. *J Stroke Cerebrovasc Dis* 2014; 23: 1764-9.
529. Martynov MY, Gusev EI. Current knowledge on the neuroprotective and neuroregenerative properties of citicolina in acute ischemic stroke. *J Exp Pharmacol* 2015; 7: 17-28.
530. Estrategia en Ictus del Sistema Nacional de Salud. Madrid: Ministerio de Sanidad y Consumo; 2008.
531. Management of patients with stroke or TIA: assessment, investigation, immediate management and secondary prevention. A national clinical guideline. Scottish Intercollegiate Guidelines Network. December 2008.
532. Wang J, Zhang HY, Tang XC. Cholinergic deficiency involved in vascular dementia: possible mechanism and strategy of treatment. *Acta Pharmacol Sin* 2009; 30: 879-88.
533. Fotuhi M, Hachinski V, Whitehouse PJ. Changing perspectives regarding late-life dementia. *Nat Rev Neurol* 2009; 5: 649-58.
534. Levine DA, Langa KM. Vascular cognitive impairment: disease mechanisms and therapeutic implications. *Neurotherapeutics* 2011; 8: 361-73.
535. Skrobot OA, Attems J, Esiri M, Hortobágyi T, Ironside JW, Kalara RN, et al. Vascular cognitive impairment neuropathology guidelines (VCING): the contribution of cerebrovascular pathology to cognitive impairment. *Brain* 2016; Sep 2. [Epub ahead of print].
536. García-Cobos R, Frank-García A, Gutiérrez-Fernández M, Díez-Tejedor E. Citicolina, use in cognitive decline: vascular and degenerative. *J Neurol Sci* 2010; 299: 188-92.
537. Babb SM, Appelmans KE, Renshaw PF, Wurtman RJ, Cohen BM. Differential effect of CDP-choline on brain cytosolic choline levels in younger and older subjects as measured by proton magnetic resonance spectroscopy. *Psychopharmacology* 1996; 127: 88-94.
538. Wald LL, Babb SM, Yurgelun-Todd DA, Cohen BM, Renshaw RF. CDP-choline decreases brain phosphomonoesters in normal elderly subjects. 6th Annual Meeting of the International Society for Magnetic Resonance in Medicine. Sydney (Australia), April 1998.
539. Babb SM, Wald LL, Cohen BM, Villafuerte RA, Gruber SA, Yurgelun-Todd DA, et al. Chronic citicolina increases phosphodiesterases in the brains of healthy older subjects: an in vivo phosphorus magnetic resonance spectroscopy study. *Psychopharmacology (Berl)* 2002; 161: 248-54.
540. Agarwal N, Sung YH, Jensen JE, DaCunha G, Harper D, Olson D, et al. Short-term administration of uridine increases brain membrane phospholipid precursors in healthy adults: a 31-phosphorus magnetic resonance spectroscopy study at 4T. *Bipolar Disord* 2010; 12: 825-33.
541. Silveri MM, Dikan J, Ross AJ, Jensen JE, Kamiya T, Kawada Y, et al. Citicolina enhances frontal lobe bioenergetics as measured by phosphorus magnetic resonance spectroscopy. *NMR Biomed* 2008; 21: 1066-75.
542. Renshaw PF, Babb SM, Yurgelun-Todd DA, Wald LL, Villafuerte RA, Cohen BM. Chronic citicolina (CDP-choline) administration alters brain phospholipid metabolites and improves cognitive performance in healthy, older adults. 37th ACNP Annual Meeting. Puerto Rico, Dec 14-18, 1998.
543. Spiers PA, Myers D, Hohanadel GS, Lieberman HR, Wurtman RJ. Citicolina improves verbal memory in aging. *Arch Neurol* 1996; 53: 441-8.
544. Álvarez XA, Laredo M, Corzo D, Fernández-Novoa L, Mouzo R, Perea JE, et al. Citicolina improves memory performance in elderly subjects. *Methods Find Exp Clin Pharmacol* 1997; 19: 201-10.
545. Sánchez S, García ME, Carrizalez Y, Chaves L, Rodríguez U, Cardenas J, et al. Efectividad y tolerabilidad de la citicolina (Somazina) en el tratamiento de pacientes con deterioro cognitivo tipo demencia. *Archivos Venezolanos de Farmacología y Terapéutica* 2006; 25: 101-3.
546. Bettini R, Gorini M. I tempi di reazione in corso di trattamento con citicolina. *Clin Ter* 2002; 153: 247-50.
547. McGlade E, Locatelli A, Hardy J, Kamiya T, Morita M, Morishita K, et al. Improved attentional performance following citicolina administration in healthy adult women. *Food and Nutrition Sciences* 2012; 3: 769-73.
548. McGlade E, Agoston AM, DiMuzio J, Kizaki M, Nakazaki E, Kamiya T, et al. The effect of citicolina supplementation on motor speed and attention in adolescent males. *J Atten Disord* 2015; Jul 15. [Epub ahead of print].
549. Bruce SE, Werner KB, Preston BF, Baker LM. Improvements in concentration, working memory and sustained attention following consumption of a natural citicolina-caffeine beverage. *Int J Food Sci Nutr* 2014; 65: 1003-7.
550. Knott V, De la Salle S, Choueiry J, Impney D, Smith D, Smith M, et al. Neurocognitive effects of acute choline supplementation in low, medium and high performer healthy volunteers. *Pharmacol Biochem Behav* 2015; 131: 119-29.
551. Bruce SE. Improvements in quantitative EEG following consumption of a natural citicolina-enhanced beverage. *Int J Food Sci Nutr* 2012; 63: 421-5.

552. Knott V, Smith D, De la Salle S, Impey D, Choueiry J, Beaudry E, et al. CDP-choline: effects of the procholine supplement on sensory gating and executive function in healthy volunteers stratified for low, medium and high P50 suppression. *J Psychopharmacol* 2014; 28: 1095-108.
553. Knott V, Salle S, Smith D, Choueiry J, Impey D, Smith M, et al. Effects of acute CDP-choline treatment on resting state brain oscillations in healthy volunteers. *Neurosci Lett* 2015; 591: 121-5.
554. Knott V, Impey D, Choueiry J, Smith D, De la Salle S, Saghir S, et al. An acute dose, randomized trial of the effects of CDP-Choline on mismatch negativity (MMN) in healthy volunteers stratified by deviance detection level. *Neuropsychiatr Electrophysiol* 2015; 1: 1.
555. Madariaga LM, Espina JM, Pascual A, Ortiz LG, Castro JM. Estudio doble ciego sobre un grupo de enfermas seniles tratadas con CDP-colina. *Rev Psiquiátr Psicol Med* 1978; 13: 331-42.
556. Fassio B, Fassio M, Pavesi G, Piantato E. La citicolina in psicogeriatría. *Clin Eur* 1982; 21: 635-46.
557. Lingetti M, Ciarimboli M, Rumiano C, Lingetti E, De Rosa A, Resciniti C, et al. Cerebropatie involutive senili gravi: trattamento con citicolina ad alto dosaggio. *Rass Int Clin Ter* 1982; 62: 704-14.
558. Stramba-Badiale M, Scillieri E. Attività della citicolina nel decadimento mentale senile. *Min Med* 1983; 74: 819-21.
559. Bonavita E, Chioma V, Dall'Oca P, Fini C, Michelini M, Ruggi MR, et al. Studio in doppio cieco sull'azione della citicolina nel cervello senile. *Min Psich* 1983; 24: 53-62.
560. Lozano R, Fernández MV, Balagué A. Alteraciones neuropsíquicas del anciano: evolución tras la administración de CDP-colina (citicolina). *Med Clin (Barc)* 1986; 87 (Supl 1): 30-3.
561. Palleschi M, Capobianco G. Invecchiamento cerebrale patologico. Osservazioni personali con l'impiego della citicolina. *Clin Ter* 1988; 125: 121-8.
562. Schergna E, Lupo L. La citicolina nella medicina di base: esperienza clinica multicentrica nell'area Veneto-Trentino Alto Adige-Friuli Venezia Giulia. *Giorn Geront* 1988; 36: 341-50.
563. Suryani LK, Adnjana TAK, Jensen GD. Citicoline treatment of memory deficits in elderly people. *Int J Geriatr Psychiatr* 1988; 3: 235-6.
564. Serra F, Diaspri GP, Gasbarrini A, Giancane S, Rimondi A, Tamè MR, et al. Effetto della CDP-colina sul decadimento mentale senile. Esperienza policentrica su 237 casi. *Min Med* 1990; 81: 465-70.
565. Lingetti M, Carimboli M, Porfido FA, De Paola P, Barlattani MP. Effetti della CDP-colina su alcuni parametri neuropsicologici in pazienti con involuzione cerebrale senile. *Riforma Med* 1990; 105: 11-6.
566. Di Trapani G, Fioravanti M. La citicolina nell trattamento dei disturbi cognitivi e comportamentali del decadimento senile patologico. *Clin Ter* 1991; 137: 403-13.
567. Matsuoka T, Kawanaka M, Nagai K. Effect of cytidine diphosphate choline on growth hormone and prolactin secretion in man. *Endocrinol Jpn* 1978; 25: 55-7.
568. Ceruso D, D'Andrea Petrelli L, Ciruolo O, Corica F, Petrelli RM. Effect of cytocholine on pituitary function in the elderly. *Acta Ther* 1983; 9: 41-4.
569. Ceda GP, Ceresini G, Magnani D, Marchini L, Valenti G, Hoffman AR. Effects of cytidine 5'-diphosphocholine administration on basal and growth hormone-releasing hormone-induced growth hormone secretion in elderly people. *Acta Endocrinol* 1991; 124: 516-20.
570. Fioravanti M, Buckley AE, Agnoli A, Nappi G, Arrigo A, Gerstenbrand F. Citicoline in CCVD patients: preliminary results of a multicenter study. *International Multidisciplinary Seminar on Cerebral Pathology in Old Age: Neuroradiological and Neurophysiological Correlations*. Pavia, Sep 27-28, 1982.
571. Falchi Delitalia G, Falchi Delitalia N, Casali R, Crescenzi GS, Attorri L, Lombardi R, et al. Studio a medio termine, in doppio cieco versus placebo, con CDP-colina nella insufficienza cerebrale senile. Aspetti psichici, endocrinologici, emoreologici e biochimico ematologici. *Gazz Med It* 1984; 143: 789-810.
572. Moglia A, Arrigo A, Bono G, Sinforiani E, Calabro G, Cinanni G, et al. Citicoline in patients with chronic cerebrovascular diseases (CCVD): quantitative EEG study. *Curr Ther Res* 1984; 36: 309-13.
573. Merchan C, Berchicci R, Cuzzoni G, Pecorini M. CDP-colina e insufficienza cerebrovascolare nell'anziano. Studio clinico di 40 pazienti in corso di trattamento prolungato. *Min Cardioang* 1985; 33: 145-8.
574. Agnoli A, Fioravanti M, Lechner H. Efficacy of CDP-choline in chronic cerebral vascular diseases (CCV). In Zappia V, Kennedy EP, Nilsson BI, Galletti P, eds. *Novel biochemical, pharmacological and clinical aspects of cytidinediphosphocholine*. Amsterdam: Elsevier Science Publishing; 1985. p. 305-15.
575. Sinforiani E, Trucco M, Pacchetti C, Gualtieri S. Valutazione degli effetti della citicolina nella malattia cerebro-vascolare cronica. *Min Med* 1986; 77: 51-7.
576. Motta L, Fichera G, Tiralosi G, Di Stefano A. La citicolina nel trattamento delle cerebrovasculopatie croniche. *Giorn Geront* 1986; 34: 149-58.
577. Rossi M, Zanardi M. Studio in aperto sull'efficacia clinica della citicolina in pazienti affetti da cerebrovasculopatia cronica. *Clin Ter* 1993; 142: 141-4.
578. Fioravanti M. La cerebropatie vascolari croniche: la terapia con CDP-colina. *Ann Ital Med Int* 1989; 4: 268-73.
579. Raji A, Winkler G. Treatment of cognitive impairment in small vessel stroke and white matter disease with CDP-choline. *European Stroke Conference*. Barcelona, May 2010.
580. Zapadnyuk BV, Kopchak OO. Features drug correction of vascular cognitive disorders in patients with discirculatory encephalopathy and metabolic syndrome. *ProNeuro* 2010; 4: 77-82.
581. Kopchak OO. Efficacy of citicoline in the treatment of patients with vascular cognitive impairment. *European Neurological Society Meeting*. Berlin, June 2010.
582. Kal'bus O, Shkolnyk V. Citicoline in correction of cognitive decline in patients with arterial hypertension (pilot study). *22nd European Meeting on Hypertension and Cardiovascular Protection*. London, April 2012.
583. Gavrilova SI, Fedorova IB, Gantman, Kalyn IB, Kolykhalov IV. Ceraxon (citicoline) in the treatment of the mild cognitive impairment syndrome. *Zh Nevrol Psikhiatr Im S S Korsakova* 2011; 111: 16-20.
584. Eberhardt R, Dehrr I. Eficacia y tolerancia de CDP-colina en pacientes geriátricos con insuficiencia cerebral senil. Estudio doble ciego cruzado. *Rev Esp Geriatr Gerontol* 1989; 24 (Supl 1): 73-81.
585. Chandra B. Treatment of multi-infarct dementia with citicholine. *J Stroke Cerebrovasc Dis* 1992; 2: 232-3.
586. Piccoli F, Battistini N, Carboni P, Dossi BC, Fiori L, La Bella V, et al. CDP-choline in the treatment of chronic cerebrovasculopathies. *Arch Gerontol Geriatr* 1994; 18: 161-8.
587. Capurso A, Capurso S, Panza F, Solfrizzi V, Mastroianni F, Giaquinto S, et al. Efficacy of cytidine diphosphate choline in patients affected by chronic cerebrovascular disease. *Clin Drug Invest* 1996; 12: 26-38.
588. Cohen RA, Brownndyke JN, Moser DJ, Paul RH, Gordon N, Sweet L. Long-term citicoline (cytidine diphosphate choline) use in patients with vascular dementia: neuroimaging and neuropsychological outcomes. *Cerebrovasc Dis* 2003; 16: 199-204.
589. Tanaka Y, Minematsu K, Hirano T, Hayashida K, Yamaguchi T. Effects of CDP-choline on dynamic changes in LCBF and cognitive function in demented subjects -an H<sub>2</sub><sup>15</sup>O-PET study. *Rinsho Shinkeigaku* 1994; 34: 877-81.

590. Lozano R. Estudio de la evolución del deterioro psicoorgánico en el anciano. Tratamiento con CDP-colina. *Rev Esp Geriatr Gerontol* 1989; 24 (Supl 1): 65-72.
591. Corona GI, Santagostino G, Frattini P, Cucchi ML, Zerbi F, Tosca P, et al. Preliminary data on monoamine metabolite levels in cerebrospinal fluid and in urine during therapy in dementia. *IRCS Med Sci* 1983; 11: 923-4.
592. Cacabelos R, Álvarez XA, Franco A, Fernández-Novoa L, Caamaño J, Del Valle-Inclán F. Therapeutic effects of CDP-choline in Alzheimer's disease and multi-infarct dementia: psychometric assessment and immune function. *Ann Psychiatr* 1992; 3: 233-45.
593. Caamaño J, Gómez MJ, Franco AM, Cacabelos R. Effects of CDP-choline on cognition and cerebral hemodynamics in patients with Alzheimer's disease. *Meth Find Exp Clin Pharmacol* 1994; 16: 211-8.
594. Fernández-Novoa L, Álvarez XA, Franco-Maside A, Caamaño J, Cacabelos R. CDP-choline-induced blood histamine changes in Alzheimer's disease. *Meth Find Exp Clin Pharmacol* 1994; 16: 279-84.
595. Cacabelos R, Caamaño J, Gómez MJ, Fernández-Novoa L, Franco-Maside A, Álvarez XA. Therapeutic effects of CDP-choline in Alzheimer's disease. Cognition, brain mapping, cerebrovascular hemodynamics, and immune factors. *Ann NY Acad Sci* 1996; 777: 399-403.
596. Álvarez XA, Mouzo R, Pichel V, Pérez P, Laredo M, Fernández-Novoa L, et al. Double-blind placebo-controlled study with citicoline in APOE genotyped Alzheimer's disease patients. Effects on cognitive performance, brain bioelectrical activity and cerebral perfusion. *Methods Find Exp Clin Pharmacol* 1999; 21: 633-44.
597. Soto A, Ruiz A, Medina C, Lonso A, Viaña JL. An evolutive study of the global impairment in patients diagnosed of senil and presenil primary degenerative dementia of the Alzheimer type and undergoing to medical treatment with citicoline, calcium antagonist and piracetam. In Beregi E, Gergely IA, Rajcz K, eds. *Recent advances in aging science*. Bologna: Monduzzi Editore; 1993. p. 723-9.
598. Cacabelos R, Álvarez A, Fernández-Novoa L, Lombardi VRM. A pharmacogenomic approach to Alzheimer's disease. *Acta Neurol Scand* 2000; Suppl 176: 12-9.
599. Zhuravin IA, Nalivaeva NN, Kozlova DI, Kochkina EG, Fedorova YB, Gavrilova SI. The activity of blood serum cholinesterases and neprilysin as potential biomarkers of mild-cognitive impairment and Alzheimer's disease. *Zh Nevrol Psikhiatr* 2015; 11: 77-85.
600. Fioravanti M, Yanagi M. Cytidinediphosphocholine (CDP-choline) for cognitive and behavioural disturbances associated with chronic cerebral disorders in the elderly. *Cochrane Database Syst Rev* 2005; 2: CD000269.
601. Deutsch SI, Schwartz BL, Schooler NR, Rosse RB, Mastropaolo J, Gaskins B. First administration of cytidine diphosphocholine and galantamine in schizophrenia: a sustained alpha7 nicotinic agonist strategy. *Clin Neuropharmacol* 2008; 31: 34-9.
602. Deutsch SI, Schwartz BL, Schooler NR, Brown CH, Rosse RB, Rosse SM. Targeting alpha-7 nicotinic neurotransmission in schizophrenia: a novel agonist strategy. *Schizophr Res* 2013; 148: 138-44.
603. Ovezov AM, Lobov MA, Nad'kina ED, Myatchin PS, Panteleeva MV, Knyazev AV. Citicoline in the prevention of postoperative cognitive dysfunction during total intravenous anesthesia. *Ann Clin Exp Neurol* 2013; 7: 27-34.
604. Shmelev VV, Neimark MI. The dynamics of the state of higher mental functions after surgical reconstruction of stenosed carotid arteries using different types of anesthesia. *Zh Nevrol Psikhiatr Im S S Korsakova* 2013; 13: 30-4.
605. Shestakova MV, Alekhin DI, Kokorishvili MA, Sinitskiy AI, Evseeva YD. Citicoline treatment in reconstructive operations of carotid arteries for prevention of reperfusion complications and cognitive disturbances in patients at risk. *Nevrologicheskii Zhurnal* 2014; 2: 47-53.
606. Li Z, Wang P, Yu Z, Sun H, Zhang J, Zhang J, et al. Effect of citicoline adjuvant therapy on mild cognitive impairment in Parkinson's disease. *J Clin Exp Med* 2016; 9: 4593-8.
607. Putignano S, Gareri P, Castagna A, Cerqua G, Cervera P, Cotroneo AM, et al. Retrospective and observational study to assess the efficacy of citicoline in elderly patients suffering from stupor related to complex geriatric syndrome. *Clin Interv Aging* 2012; 7: 113-8.
608. Cotroneo AM, Castagna A, Putignano S, Lacava R, Fantò F, Monteleone F, et al. Effectiveness and safety of citicoline in mild vascular cognitive impairment: the IDEALE study. *Clin Interv Aging* 2013; 8: 131-7.
609. Castagna A, Cotroneo AM, Ruotolo G, Gareri P. The CITIRIVAD Study: Citicoline plus Rivastigmine in Elderly Patients Affected with Dementia Study. *Clin Drug Investig* 2016; 36: 1059-65.
610. Lees R, Fearon P, Harrison JK, Broomfield NM, Quinn TJ. Cognitive and mood assessment in stroke research: focused review of contemporary studies. *Stroke* 2012; 43: 1678-80.
611. Jaillard A, Grand S, François Le Bas J, Hommel M. Predicting cognitive disfunctioning in nondemented patients early after stroke. *Cerebrovasc Dis* 2010; 29: 415-23.
612. Álvarez-Sabín J, Ortega G, Jacas C, Santamarina E, Maisterra O, Ribó M, et al. Long-term treatment with citicoline may improve poststroke vascular cognitive impairment. *Cerebrovasc Dis* 2013; 35: 146-54.
613. Álvarez-Sabín J, Santamarina E, Maisterra O, Jacas C, Molina C, Quintana M. Long-term treatment with citicoline prevents cognitive decline and predicts a better quality of life after a first ischemic stroke. *Int J Mol Sci* 2016; 17: 390.
614. Lobjanidze N, Dzagnidze A, Jeiranashvili A, Kukava M, Beridze M, Khachishvili M, et al. Long-term effects of the use of citicoline (Ceraxone) in the post-stroke cognitive-mood impairment. *Cerebrovasc Dis* 2010; 29 (Suppl 2).
615. Maslarov DB. Effects of citicoline on neuropsychological status after stroke. 18th World Congress of Psychobiology 2016.
616. Abad-Santos F, Novalbos-Reina J, Gallego-Sandín S, García AG. Tratamiento del deterioro cognitivo leve: utilidad de la citicolina. *Rev Neurol* 2002; 35: 675-82.
617. Fioravanti M, Buckley AE. Citicoline (Cognizin) in the treatment of cognitive impairment. *Clin Interv Aging* 2006; 1: 247-51.
618. Grieb P. Citicoline: a food that may improve memory. *Med Sci Rev* 2015; 2: 67-72.
619. Parnetti L, Mignini F, Tomassoni D, Traini E, Amenta F. Cholinergic precursors in the treatment of cognitive impairment of vascular origin: Ineffective approaches or need for re-evaluation? *J Neurol Sci* 2007; 257: 264-9.
620. Amenta F, Di Tullio MA, Tomassoni D. The cholinergic approach for the treatment of vascular dementia: evidence from pre-clinical and clinical studies. *Clin Exp Hypertens* 2002; 24: 697-713.
621. Gareri P, Castagna A, Cotroneo AM, Putignano S, De Sarro G, Bruni AC. The role of citicoline in cognitive impairment: pharmacological characteristics, possible advantages, and doubts for an old drug with new perspectives. *Clin Interv Aging* 2015; 10: 1421-9.
622. Shimamoto K, Hirano T, Aramaki Y. Therapeutic mechanism of cytidine diphosphate choline (CDP-choline) in parkinsonism. *J Takeda Res Lab* 1975; 34: 440-8.
623. Ruggieri S, Zamponi A, Casacchia M, Agnoli A. Effetti terapeutici della citicolina (citidin-difosfo-colina) nella sindrome parkinsoniana. *Clin Ter* 1976; 78: 515-25.
624. Agnoli A, Ruggieri S, Denaro A, Bruno G. New strategies in the management of Parkinson's disease: a biological approach using a phospholipid precursor (CDP-choline). *Neuropsychobiology* 1982; 8: 289-96.
625. Agnoli A, Ruggieri S, Baldassarre M, Stocchi F, Del Roscio S, Gallucci M, et al. Current concept in the treatment of Parkinson disease: use of citicoline. In Yahr MD, ed. *Current*



- concepts of Parkinson disease and related disorders. Amsterdam: Excerpta Medica; 1983. p. 124-40.
626. Eberhardt R, Gerstenbrand F, Klingler D, Birbamer G, Ransmayr G. Estudio sobre la eficacia de la combinación de CDP-colina y levodopa más un inhibidor de la descarboxilasa en pacientes con enfermedad de Parkinson. *Med Clin (Barc)* 1986; 87 (Supl 1): 34-40.
627. Poewe W, Gerstenbrand F. New trends in the therapy of Parkinson's disease. In Agnoli A, Bertolani G, eds. *Atti della 8. Riunione della Lega Italiana per la Lotta Contro il Morbo di Parkinson e le Malattie Extrapiramidali*. Roma: D. Guanella; 1982. p. 171-88.
628. Eberhardt R, Birbamer G, Gerstenbrand F, Rainer E, Traegner H. Citicoline in the treatment of Parkinson's disease. *Clin Ther* 1990; 12: 489-95.
629. Birbamer G, Gerstenbrand F, Rainer E, Eberhardt R. CDP-choline in the treatment of Parkinson syndrome. *New Trends Clin Neuropharmacol* 1990; 4: 29-34.
630. Loeb C, Albano C, Caraceni T, Caraffa T, Coppi R, Di Perri R, et al. CDP-choline in the treatment of Parkinson's disease: a multicenter controlled trial. In Zappia V, Kennedy EP, Nilsson BI, Galletti P, eds. *Novel biochemical, pharmacological and clinical aspects of cytidinediphosphocholine*. Amsterdam: Elsevier Science Publishing; 1985. p. 339-46.
631. Acosta J, Nombela M, Palao A, Pastor M, Recuero J. Multicentre trial: treatment of Parkinson's disease with CDP-choline (citicoline). In Bartko D, Turcáni P, Stern G, eds. *New trends in clinical neuropharmacology: calcium antagonists, acute neurology, headache and movement disorders*. London: John Libbey; 1988. p. 289-96.
632. Cubells JM, Hernando C. Clinical trial on the use of cytidine diphosphate choline in Parkinson's disease. *Clin Ther* 1988; 10: 664-71.
633. Martí-Massó JF, Urtasun M. Citicoline in the treatment of Parkinson's disease. *Clin Ther* 1991; 13: 239-42.
634. García-Más A, Rossiñol A, Roca M, Lozano R, Rosselló J, Llinás J. Efectos de la citicolina en la demencia subcortical asociada a la enfermedad de Parkinson valorada mediante electroencefalografía cuantificada. *Clin Ther* 1992; 14: 718-29.
635. Mubaidin A, Al-Dwairi AR, Nofal R, Wreikat A. Citicoline in the treatment of essential tremor. *JRMS* 2011; 18: 20-5.
636. Chinchilla A López-Ibor JJ, Vega M, Camarero M. CDP-colina en la evolución de las funciones mentales en el síndrome de abstinencia alcohólica. *Psiquiatr Biol* 1995; 2: 171-5.
637. Renshaw PF, Daniels S, Lundahl LH, Rogers V, Lukas SE. Short-term treatment with citicoline (CDP-choline) attenuates some measures of craving in cocaine-dependent subjects: a preliminary report. *Psychopharmacology* 1999; 142: 132-8.
638. Lukas SE, Kouri EM, Rhee C, Madrid A, McNeil J, Renshaw PF. Citicoline treatment for cocaine abuse: effects of acute cocaine challenge on subjective mood and cardiovascular responses in adult male and female volunteers. *Drug Alcohol Depend* 2001; 63 (Suppl 1): 94.
639. Lukas SE, Kouri EM, Rhee C, Madrid A, Renshaw PF. Effects of short-term citicoline treatment on acute cocaine intoxication and cardiovascular effects. *Psychopharmacology* 2001; 157: 163-7.
640. Bracken BK, Penetar DM, Rodolico J, Ryan ET, Lukas SE. Eight weeks of citicoline treatment does not perturb sleep/wake cycles in cocaine-dependent adults. *Pharmacol Biochem Behav* 2011; 98: 518-24.
641. Licata SC, Penetar DM, Ravichandran C, Rodolico J, Palmer C, Berko J, et al. Effects of daily treatment with citicoline: a double-blind, placebo-controlled study in cocaine-dependent volunteers. *J Addict Med* 2011; 5: 57-64.
642. Brown ES, Gorman AR, Hynan LS. A randomized, placebo-controlled trial of citicoline add-on therapy in outpatients with bipolar disorder and cocaine dependence. *J Clin Psychopharmacol* 2007; 27: 498-502.
643. Brown ES, Todd JP, Hu LT, Schmitz JM, Carmody TJ, Nakamura A, et al. A randomized, double-blind, placebo-controlled trial of citicoline for cocaine dependence in bipolar disorder. *Am J Psychiatry* 2015; 172: 1014-21.
644. Brown ES, Gabrielson B. A randomized, double-blind, placebo-controlled trial of citicoline for bipolar and unipolar depression and methamphetamine dependence. *J Affect Disord* 2012; 143: 257-60.
645. Gruber SA, Sagar KA, Dahlgren MK, Gonenç A, Conn N, Winer JP, et al. Citicoline treatment improves measures of impulsivity and task performance in chronic marijuana smokers: a pilot BOLD fMRI study. *Int J Neurol Neurother* 2015; 2: 1-8.
646. Ross BM, Moszczynska A, Peretti FJ, Adams V, Schmunk GA, Kalasinsky KS, et al. Decreased activity of brain phospholipid metabolic enzymes in human users of cocaine and methamphetamine. *Drug Alcohol Depend* 2002; 67: 73-9.
647. Yoon SJ, Lyoo IK, Kim HJ, Kim TS, Sung YH, Kim N, et al. Neurochemical alterations in methamphetamine-dependent patients treated with cytidine-5'-diphosphate choline: a longitudinal proton magnetic resonance spectroscopy study. *Neuropsychopharmacology* 2010; 35: 1165-73.
648. Lukas SE. New perspectives on using brain imaging to study CNS stimulants. *Neuropharmacology* 2014; 87: 104-14.
649. Killgore WD, Ross AJ, Kamiya T, Kawada Y, Renshaw PF, Yurgelun-Todd DA. Citicoline affects appetite and cortico-limbic responses to images of high-calorie foods. *Int J Eat Disord* 2010; 43: 6-13.
650. Wignall ND, Brown ES. Citicoline in addictive disorders: a review of the literature. *Am J Drug Alcohol Abuse* 2014; 40: 262-8.
651. Campos EC, Schiavi C, Benedetti P, Bolzani R, Porciatti V. Effect of citicoline on visual acuity in amblyopia: preliminary results. *Graefes Arch Clin Exp Ophthalmol* 1995; 233: 307-12.
652. Campos EC, Bolzani R, Schiavi C, Baldi A, Porciatti V. Cytidine-5'-diphosphocholine enhances the effect of part-time occlusion in amblyopia. *Doc Ophthalmol* 1997; 93: 247-63.
653. Campos EC. Future directions in the treatment of amblyopia. *Lancet* 1997; 349: 1190.
654. Porciatti V, Schiavi C, Benedetti P, Baldi A, Campos EC. Cytidine-5'-diphosphocholine improves visual acuity, contrast sensitivity and visually-evoked potentials of amblyopic subjects. *Curr Eye Res* 1998; 17: 141-8.
655. Simons K. Amblyopia characterization, treatment, and prophylaxis. *Surv Ophthalmol* 2005; 50: 123-66.
656. Campos EC, Fresina M. Medical treatment of amblyopia: present state and perspectives. *Strabismus* 2006; 14: 71-3.
657. Fresina M, Dickmann A, Salerni A, De Gregorio F, Campos EC. Effect of oral CDP-choline on visual function in young amblyopic patients. *Graefes Arch Clin Exp Ophthalmol* 2008; 246: 143-50.
658. Roberti G, Tanga L, Michelessi M, Quaranta L, Parisi V, Manni G, et al. Cytidine 5'-diphosphocholine (citicoline) in glaucoma: rationale of its use, current evidence and future perspectives. *Int J Mol Sci* 2015; 16: 28401-17.
659. Pawar PV, Mumbare SS, Patil MS, Ramakrishnan S. Effectiveness of the addition of citicoline to patching in the treatment of amblyopia around visual maturity: a randomized controlled trial. *Indian J Ophthalmol* 2014; 62: 124-9.
660. Furtado de Mendonça RH, Ferreira EL. Visual evoked potentials (VEP) and visual acuity improvement after cytidine 5'-diphosphocholine (CDP-choline) therapy in amblyopic patient. *Rev Bra Oftalmol* 2012; 71: 328-30.
661. Gore C, Wu C. Medical therapies of amblyopia: translational research to expand our treatment armamentarium. *Semin Ophthalmol* 2016; 31: 155-8.
662. Parisi V, Manni G, Colacino G, Bucci MG. Cytidine-5'-diphosphocholine (citicoline) improves retinal and cortical responses in patients with glaucoma. *Ophthalmology* 1999; 106: 1126-34.

663. Parisi V. Electrophysiological assessment of glaucomatous visual dysfunction during treatment with cytidine-5'-diphosphocholine (citicoline): a study of 8 years of follow-up. *Doc Ophthalmol* 2005; 110: 91-102.
664. Virno M, Pecori-Giraldi J, Liguori A, De Gregorio F. The protective effect of citicoline on the progression of the perimetric defects in glaucomatous patients (perimetric study with a 10-year follow-up). *Acta Ophthalmol Scand* 2000; 78: 56-7.
665. Grieb P, Rejdak R. Pharmacodynamics of citicoline relevant to the treatment of glaucoma. *J Neurosci Res* 2002; 67: 143-8.
666. Rejdak R, Toczolowski J, Kurkowski J, Kaminski ML, Rejdak K, Stelmasiak Z, et al. Oral citicoline treatment improves visual pathway function in glaucoma. *Med Sci Monit* 2003; 9: P124-8.
667. Parisi V, Coppola G, Centofanti M, Oddone F, Angrisani AM, Ziccardi L, et al. Evidence of the neuroprotective role of citicoline in glaucoma patients. *Prog Brain Res* 2008; 173: 541-54.
668. Bagnis A, Papadia M, Scotto R, Traverso CE. Current and emerging medical therapies in the treatment of glaucoma. *Expert Opin Emerg Drugs* 2011; 16: 293-307.
669. Slepova OS, Frolov MA, Morozova NS, Frolov AM, Lopache DN. Markers of Fas-mediated apoptosis in primary open-angle glaucoma and opportunities of their pharmacological correction. *Vestn Oftalmol* 2012; 128: 27-31.
670. Ottobelli L, Manni GL, Centofanti M, Iester M, Allevena F, Rossetti L. Citicoline oral solution in glaucoma: is there a role in slowing disease progression? *Ophthalmologica* 2013; 229: 219-26.
671. Roberti G, Tanga L, Parisi V, Sampalmieri M, Centofanti M, Manni G. A preliminary study of the neuroprotective role of citicoline eye drops in glaucomatous optic neuropathy. *Indian J Ophthalmol* 2014; 62: 549-53.
672. Roberti G, Tanga L, Michelessi M, Quaranta L, Parisi V, Manni G, et al. Cytidine 5'-diphosphocholine (citicoline) in glaucoma: rationale of its use, current evidence and future perspectives. *Int J Mol Sci* 2015; 16: 28401-17.
673. Parisi V, Coppola G, Ziccardi L, Gallinaro G, Falsini B. Cytidine-5'-diphosphocholine (citicoline): a pilot study in patients with non-arteritic ischaemic optic neuropathy. *Eur J Neurol* 2008; 15: 465-74.
674. Yao W, Li TM. Clinical observation on citicoline sodium tablets treating facial neuritis. *Med J West China* 2010; 22: 1053-4.
675. Carrascosa-Romero MC, Suela J, Alfaro-Ponce B, Cepillo-Boluda AJ. Ictiosis ligada al cromosoma X asociada a epilepsia, hiperactividad, autismo y retraso mental, por microdelección Xp22.31. *Rev Neurol* 2012; 54: 241-8.
676. Lay-Son Rivas L, Trujillo-Godoy O, Alvarado-Pastenes M. Encefalopatía tardía por monóxido de carbono de curso reversible en un paciente tratado con citicolina. *Neurología* 2015; 30: 453-5.
677. Zinkovsky AE, Musina LO, Zinkovsky KA, Moroseeva EA. Dynamics of change of infrared spectrum of blood serum of women with varying degrees of progression of epilepsy before and after ceraxon treatment. *Modern Problems of Science and Education* 2012; 2: 1-7.
678. Petrova D, Maslarov D, Angelov I, Zekin D. Analysis of therapeutic efficacy of citicoline in patients with vertigo of central origin and vascular aetiology. *Am J Neuroprotec Neuroregen* 2012; 4: 1-8.
679. Skripuletz T, Manzel A, Gropengiesser K, Schäfer N, Gudi V, Singh V, et al. Pivotal role of choline metabolites in remyelination. *Brain* 2015; 138 (Pt 2): 398-413.
680. Grieb P. Beneficial effects of exogenous CDP-choline (citicoline) in EAE. *Brain* 2015; 138 (Pt 11): e388.
681. Skripuletz T, Gudi V, Baumgärtner W, Linker RA, Stangel M. Reply: Beneficial effects of exogenous CDP-choline (citicoline) in EAE. *Brain* 2015; 138 (Pt 11): e389.
682. Skripuletz T, Linker RA, Stangel M. The choline pathway as a strategy to promote central nervous system (CNS) remyelination. *Neural Regen Res* 2015; 10: 1369-70.
683. Nasiri J, Kargar M. Combination of citicoline and physiotherapy in children with cerebral palsy. *Int J Prev Med* 2014; 5: 1308-13.
684. Yevtushenko SK, Yanovskaya NV, Yevtushenko OS, Lisovsky YV. Ceraxon as effective neuroprotector in treatment of children of the first year of the life with organic threatens of CNS. *Int J Neurol* 2007; 3: 21-5.
685. Warsiki E. CDP choline therapy on some cases of children with organic brain syndrome. *Folia Medica Indonesiana* 2004; 40: 43-7.
686. Issayeva R, Pushkarev K. CDP-choline (Ceraxon) treatment with hypoxia in the newborn infant. *J Neurol Sci* 2013; 333: e537-8.
687. Wang XL, Yu SL, Yu T, Li JH, Guo P, Liang HT. Treatment of neonatal hypoxic-ischaemic encephalopathy (HIE) with compound *Salvia miltiorrhizae* and citicoline: a comparative study in China. *Singapore Pediatr J* 1997; 39: 120-3.
688. Siddiqui AP, Lennerstrand G, Pansell T, Rydberg A. Citicoline treatment of children with visual impairment; a pilot study. *Pak J Ophthalmol* 2012; 28: 172-8.
689. Díaz-Atienza J, Compam F, Blázquez P, Sánchez F. Neurophysiologic abnormalities in developmental dysphasias and response to CDP-choline. *Adv Ther* 1998; 15: 8-13.
690. Ley R. Ensayo clínico con CDP-colina en neuropsiquiatría infantil. *Rev Esp Pediatr* 1980; 36: 3-6.
691. Espadaler JM. Ensayo clínico en el tratamiento de los trastornos del aprendizaje del niño. *Med Clin (Barc)* 1978; 71: 357-61.
692. Dinsdale JRM, Griffiths GK, Castelló J, Maddock J, Ortiz JA, Aylward M. CDP-choline: repeated oral dose tolerance studies in adult healthy volunteers. *Arzneimittelforschung* 1983; 33: 1061-5.
693. Lozano R. Efficacy and safety of oral CDP-choline. *Drug surveillance study in 2817 cases. Arzneimittelforschung* 1983; 33: 1073-80.
694. Milani M. Citicoline as coadjuvant treatment of cognitive impairment in chronic degenerative central nervous system diseases and in ischemic stroke: a review of available data. *Online Journal of Medicine and Medical Science Research* 2013; 2: 13-8.
695. Rajguru M, Agrawal A, Sampath Kumar NS, Anil Kumar T. An overview of clinical and therapeutic implications of citicoline. *Narayana Med J* 2014; 3: 54-60.

### Citicolina: revisión farmacológica y clínica, actualización 2016

**Resumen.** Esta revisión se basa en la publicada en 2010 –Secades JJ. *Citicolina: revisión farmacológica y clínica, actualización 2010*. *Rev Neurol* 2011; 52 (Supl 2): S1-62– e incorpora 183 nuevas referencias aparecidas desde entonces, con lo que se organiza toda la información disponible para facilitar el acceso a dicha información en un único documento. La revisión se centra en las principales indicaciones del fármaco, como son los accidentes cerebrovasculares agudos y sus secuelas, incluyendo el deterioro cognitivo, y los traumatismos craneoencefálicos y sus secuelas. Se recogen los principales aspectos experimentales y clínicos en estas indicaciones.

**Palabras clave.** Alcoholismo. Ampliopía. Apoptosis. CDP-colina. Citicolina. Demencia senil. Drogodependencia. Edema cerebral. Enfermedad de Alzheimer. Enfermedad de Parkinson. Fosfatidilcolina. Fosfolipasa. Fosfolípidos estructurales. Glaucoma. Ictus. Isquemia cerebral. Lesión cerebral traumática. Membrana neuronal. Memoria. Neuroplasticidad. Neuroprotección. Neurorreparación. Neurotransmisión. Remielinización. Trastorno cognitivo. Traumatismo craneoencefálico.